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Summary 
The PhD thesis presented here summarizes the work and the scientific effort done in the research group of 
Prof. Dr. Ward at the University of Basel during the years 2013 – 2017. The Ward group has a long-term 
knowledge in the design and evolution of artificial metalloenzymes capable of catalyzing reactions including 
transfer hydrogenation, ring-closing metathesis, C-H activation, Suzuki-coupling and many more. Artificial 
metalloenzymes are formed by the incorporation of a catalytically active transition-metal complex into a host 
protein. This allows combining the advantageous features of both homogeneous catalysis and enzyme 
catalysis. The protein forms a defined reaction environment (i.e. a second coordination sphere) around the 
metal cofactor. Thus, artificial metalloenzymes can be evolved by chemical modification of the metal cofactor 
or by genetic engineering of the host protein. In the Ward group often the biotin-streptavidin technology is 
applied to generate artificial metalloenzymes. This system relies on the ultra-high affinity of the protein 
streptavidin for the small molecule biotin. Attachment of a biotin-anchor to a transition-metal complex 
ensures its incorporation into the streptavidin scaffold.  
In this thesis the design, expression and evolution of an artificial allylic deallocase based on the biotin-
streptavidin technology is described. A biotinylated ruthenium complex was synthesized, incorporated into 
streptavidin and a crystal structure of the resulting artificial metalloenzyme was determined. The activity of 
the hybrid catalyst in a deallocation reaction was investigated. An O-allyl carbamate caged pro-fluorescent 
coumarin derivative was deprotected in the presence of the artificial metalloenzyme. The in vitro 
performance of the artificial allylic deallocase was evolved by genetic modification of the host protein. In a 
next step, the artificial metalloenzyme was displayed on the surface of E. coli cells. The activity of the hybrid 
catalyst was further evolved by in vivo screening of several single-site saturation mutagenesis libraries. It was 
aimed to further increase the throughput of the screening assay by application of a microfluidic system in 
combination with fluorescence-activated droplet sorting. In a third step, a biogenetic switch based on O-allyl 
carbamate caged inducer molecules was designed. By the action of the artificial allylic deallocase, the caged 
inducer was deprotected and subsequently induced the expression of a green fluorescent protein (GFP)-
reporter. By substitution of the GFP with another natural protein, a cascade reaction can be envisioned. In 
parallel, a series of streptavidin mutants with lid-like amino acid structures on top of the biotin-binding 
vestibule was designed. This approach aimed gaining a better control of the second coordination sphere of 
the metal cofactor in order to increase the activity and selectivity of the artificial metalloenzyme.  
In summary, these efforts should allow a straightforward design, expression and evolution of new artificial 
metalloenzymes for in vivo applications. During the time in the Ward group a deeper knowledge on protein 
design and expression, molecular biology, synthesis of organometallic cofactors, in vivo catalysis and high-
throughput screening based on microfluidics was garnered.  
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1 Introduction 
1.1 Artificial metalloenzymes 
Artificial metalloenzymes are formed by incorporation of a catalytically active metal cofactor into a host 
protein.1-9 This strategy was first introduced by Whitesides et al.10 and Kaiser et al.11 in the 1970’s. They 
designed hybrid catalysts by the modification of avidin with a biotinylated diphosphine rhodium (I) moiety 
and by the exchange of a Zn(II) with a Cu(II) in carboxypeptidase A, respectively. The concept of hybrid 
catalysts allows combining the advantageous features of both homogeneous catalysis and enzyme catalysis.12 
Homogeneous catalysts typically reveal a wide substrate scope, can contain a variety of different transition 
metals and show a high tolerance towards organic solvents. The activity and selectivity of these catalysts can 
be optimized by chemical modification of the ligand. However, their performance (i.e. the turnover number) 
is often limited. On the other hand, enzymes typically reveal high activities and selectivities. At the same 
time, the substrate scope of natural enzymes is often narrow and reactions are mostly limited to water as 
solvent. In artificial metalloenzymes, the high selectivity of natural enzymes and the wide substrate scope of 
homogeneous catalysts can be combined and new-to-nature reactions can be implemented.13-14 Embedding 
of an abiotic metal cofactor into a host protein creates a new reaction environment (i.e. a second 
coordination sphere)6 around the active metal center. It allows the installation of a catalytic acid/base or a 
coordinating residue at the correct spatial place, or the creation of a hydrophobic pocket – features which 
are often difficult to provide with small molecule ligands. In this way, the activity and especially the selectivity 
of the artificial metalloenzyme can be engineered by genetic modification of the host protein. In combination 
with the tools of directed evolution15-17, highly active and selective hydrid catalysts can be created. Artificial 
metalloenzymes with kinetics and catalytic efficiencies (i.e. high kcat/KM values and high turnover numbers) 
similar to native enzymes have been created, as reported by Hartwig et al. for a reconstituted cytochrome 
P450 performing C-H insertion reactions18 or by Baker et al. for an artificial hydrolase.19 In addition to natural 
proteins, also DNA and small peptides have been utilized as hosts for transition metal catalysts.20-21 
Furthermore, a variety of de novo proteins have been designed for the creation of artificial metalloenzymes.22 
This was done, amongst others, by Tezcan et al. for an artificial β-lactamase23, by De Grado and Kaplan as 
well as by Lombardi et al. for an artificial phenol oxidase based on the due ferri protein family24-25 and by 
Pecoraro et al. for an artificial hydrolase based on the TRI peptide family.26 The incorporation of unnatural 
amino acids27 into the host proteins completes the toolbox for the design of artificial metalloenzymes. Schultz 
et al. introduced the metal-chelating unnatural amino acid (2,2’-bipyridin-5-yl)alanine (Bpy-Ala) into the E. 
coli catabolite activator protein (CAP) and upon binding of Fe(II) or Cu(II) DNA-cleavage activity was 
observed.28  
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Incorporation of the abiotic metal cofactor into the host protein can be performed in four different ways, 
incliding (i) covalent linkage, (ii) supramolecular anchoring, (iii) dative anchoring, or (iv) metal substitution 
(Figure 1).29 The metal cofactor can be covalently linked to the host protein by selective reaction of a 
nucleophilic residue of the host protein (e.g. serine, lysine or cysteine) with an electrophilic moiety in the 
cofactor (e.g. maleimide or α-halocarbonyl). Covalent linkage can also be achieved by formation of a disulfide 
bond or by a “click reaction” involving an unnatural alkyne or azide residue.30 The supramolecular assembly 
relies on a high affinity between the host protein and an anchoring moiety attached to the metal cofactor 
(e.g. biotin-streptavidin; see chapter 1.2). This high affinity may be realized by an extended hydrogen-bond 
network between the host protein and the anchor and/or strong hydrophobic interactions. The dative 
anchoring involves direct coordination of a residue of the host protein (e.g. histidine, serine, aspartate, 
glutamate or cysteine) to the metal center of the abiotic cofactor. Finally, the metal center of a natural 
metalloenzyme (e.g. iron or zinc) can be exchanged for other transition metals (e.g. copper, iridium or 
rhodium).31-33  
 
 
Figure 1: Anchoring strategies of abiotic metal cofactors for the creation of artificial metalloenzymes.  
The four anchoring strategies include: a) covalent linkage, b) supramolecular anchoring, c) dative anchoring, d) metal substitution. 
The host protein is illustrated as blue cartoon shape. Natural residues/cofactors in blue. Artificial metal in black. Ligand and linkers in 
green. Supramolecular anchor in orange. Possible mutation sites in close proximity of the metal cofactor are displayed as red stars.  
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1.2 The biotin-streptavidin technology 
The biotin-streptavidin technology is a supramolecular anchoring strategy relying on the ultra-high affinity of 
the protein streptavidin for the small molecule biotin (aslo known as vitamin H).34 With a dissociation 
constant Kd of approximately 10-13 M, it is one of the strongest non-covalent interactions known in nature.35 
Streptavidin is a homotetrameric β-barrel protein (dimer of dimers with a D2-symmetry) with an approximate 
molecular weight of 65 kDa.36-37 Every monomer consists of eight antiparallel β-sheets with seven 
interconnecting loops (Figure 2b; see also chapter 2.5 and Figure 26a). Streptavidin is derived from the 
bacterium Streptomyces avidinii and is closely related to the protein avidin from chicken egg white (32% 
sequence homology).38 The thight biotin binding of streptavidin originates from an extended hydrogen bond 
network and several hydrophobic interactions. This includes hydrogen bonds between the urea moiety of 
biotin and the residues Asn23, Ser27, Tyr43, Ser45 and Asp128 as well as a hydrogen bond between the thioether 
and Thr90 and hydrogen bonds between the valeric acid of biotin and the residues Asn49 (backbone NH) and 
Ser88 (Figure 2a). The residues Trp79, Trp92, Trp108, and Trp120 (from the adjacent monomer) form a 
hydrophobic binding pocket. 36, 39-41 Furthermore, the loop 3,4 (Ser45…Arg53) adopts a closed position when 
biotin is bound.42-43 In terms of tetramer stability, residues in the subunit interfaces (including Val55, Thr76, 
Thr90, Leu109, Trp120, Val125, His127 and Asp128) play a critical role.44-47 In addition, there is an important inter-
subunit salt-bridge between Asp61 and His87 (at physiological pH).48 Overall, streptavidin is stable at a wide 
pH-range (pH 3 - 11), at elevated temperatures (up to 110 °C), in mixtures with organic solvents (e.g. DMSO 
or ethanol) and in the presence of chaotropic agents (e.g. sodium dodecyl sulfate) or high concentrations of 
guanidinium hydrochloride (6 M) or urea (8 M).49-52 The stability of streptavidin, in terms of melting 
temperature Tm, increases from 75°C to 112°C upon binding of biotin.53 Building on this robustness, 
streptavidin is an ideal template for the creation of artificial metalloenzymes. Streptavidin can bind up to 
four molecules of biotin, in which each β-barrel of the tetramer hosts one guest in its center. Thereby, non-
cooperativity was observed for individual binding events.54 The core of biotin is deeply buried inside of the 
β-barrel, whereas the valeric acid side chain points towards a half-open vestibule (Figure 2b). 
Functionalization of the carboxylic acid of biotin (e.g. formation of an amide) allows to covalently attach a 
metal cofactor. Due to the D2-symmetric structure of the streptavidin tetramer, two metal cofactors are 
located in close proximity to each other, which can potentially cause steric clashes (see chapters 2.1 and 
2.1.4).55 Furthermore, mutations within the binding site of one monomer are reflected by symmetry in the 
adjacent monomer. Streptavidin can be expressed in high yields in E. coli. Up to 35% of the total protein 
amount in the cells can be the protein of interest.56-57 Cells can be lysed and the streptavidin can be purified 
by affinity column chromatography (2-iminobiotin coated sepharose beads; see chapter 4.2.8). This allows a 
simple production of medium-sized streptavidin mutant libraries.  
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Various avidin and streptavidin variants have been created and genetically engineered.58 Some of them 
display very high stability towards harsh chemical conditions (e.g. high concentrations of methanol, ethanol, 
acetone or DMF).49 Engineered (strep)avidins were utilized in biotechnological applications, ranging from 
purification and labeling methods to drug targeting and formation of nanostructures.59 In the Ward research 
group, several artificial metalloenzymes based on the biotin-streptavidin technology have been designed. 
These hybrid catalysts are able to perform reactions such as transfer hydrogenation60-63, ring-closing 
metathesis64, C-H activation65, anion-π catalysis66, Suzuki-coupling67, dehydrogenation of olefins68 and 
more.69 Artificial metalloenzymes based on the biotin-streptavidin technology were also successfully applied 
in cascade reactions.70-71  
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Figure 2: Structure of streptavidin and interactions with biotin.  
a) Hydrogen bond interactions between biotin and streptavidin (residues Asn23, Ser27, Tyr43, Ser45, Asn49, Ser88, Thr90 and Asp128) as 
well as hydrophobic interactions including the residues Trp79, Trp92, Trp108 and Trp120 (from the adjacent monomer). Protein in grey, 
biotin in black, hydrogen bonds as dotted blue lines, tryptophane residues in orange. b) Structure of biotin-bound streptavidin (PDB 
ID 1STP).36 The streptavidin monomers are displayed as surface representation (green, red and yellow) or in cartoon style (blue). 
Biotin is displayed as sticks (atom color code: C = cyan, N = blue, O = red, N = blue, S = yellow).   
a) 
b) 
Loop 3,4 
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1.3 Transition metal-catalyzed allylic substitutions 
Transition metal-catalysed allylic substitution reactions are nowadays a common tool in organic synthesis 
and catalysis.72-77 Most often, palladium complexes are utilized to catalyse such reactions.73, 78 Beside 
palladium, also iridium79, ruthenium80, rhodium81, molybdenum82, nickel and tungsten83 complexes have 
been reported to catalyse nucleophilic allylic substitutions. The general mechanism of a palladium-catalyzed 
allylic substitution includes: 1) oxidative addition of the allylic substrate to form an η3-allyl palladium(II) 
complex with the simultaneous release of the leaving group (e.g. allyl carbonates release alkoxides, which 
can act as base to activate a nucleophile), 2) attack of the nucleophile (often carbanions) on one of the allyl-
termini to form an olefin-palladium(0) complex (attack on the central carbon has however also been 
reported84), and 3) release of the product, followed by the oxidative addition of another substrate molecule 
(Scheme 1).73 The η3-allyl palladium(II) complex is typically surrounded by two additional ligands (or one 
bidentate ligand) and adopts a square-planar coordination geometry. At this stage, the η3-allyl palladium(II) 
complex is highly dynamic and can undergo ligand dissociation-association processes or π-σ-π isomerization. 
In the later process, the η3-coordination of the allyl ligand is temporarely disrupted to form a short-lived η1-
intermediate. In this stage, a rotation along the C-C single bond of the allyl ligand is possible, which can result 
in different isomers. Furthmore, the stereoselectivity of the formed product is influenced by the (chiral) 
ligands.  
 
R R
PdII
L L
+
R R
Pd0
L L
Nu
X-
R R
X
R R
Nu
Nu- NuH
Base
 
Scheme 1: Mechanism of a palladium-catalyzed allylic substitution.73 
 
In this thesis, we focused on the deprotection of O-allyl carbamate-caged fluorophores (e.g. caged allyl-
coumarin 1; see Scheme 2 and chapter 2.2) and inducers (e.g. caged allyl-IPTG 58; see Figure 20 and chapter 
2.4). Since the used allyl moiety does not bear any substituents, an achiral allyl-transfer product results. It 
should be emphasized here that we are mainly interested in the liberated leaving group, rather than in the 
allylic substitution product.  
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The formation of an artificial allylic deallocase and its in vivo application requires that the incorporated metal 
cofactor is stable under air in aqueous solutions and maintains activity in a cellular environment (e.g. in the 
presence of millimolar concentrations of thiols). A transition metal catalyst for allylic substitutions which 
fulfill these requirements is, amongst others, the ruthenium complex [CpRu(QA)(Allyl)]PF6 (5) (see Scheme 2 
and chapter 1.4). This complex was first described by Kitamura et al. for the allylation of alcohols, using a 1:1 
mixture of 2-propen-1-ol and the alcoholic substrate as solvent.85 The same complex was also applied for the 
deprotection of allyl ethers86 and the cleavage of allyl esters and allyl carbonates.87 The structure of such 
ruthenium complexes and the kinetics of the deallylation of allyl methyl carbonate were described by 
Bruneau and Waymouth.88-89 Most of these allylation/deallylation reactions were performed in organic 
solvents (often in methanol). The cleavage of allyl phenethyl carbonate however also proceeded with high 
yields in a 1:1 mixture of methanol/water.87 Kitamura et al. subsequently anchored the ruthenium complex 
5 onto magnetic particles (Fe3O4@SiO2) to construct a heterogenoues catalysts, which can be easily separated 
after completion of the reaction.90 With the ruthenium complex [CpRu(QA)(Allyl)]PF6 (5), as well as with the 
related complex [Cp*Ru(cod)Cl] (13), also allylation of thiols was performed.91-92  
The research group of Meggers applied such ruthenium complexes in the deprotection of O-allyl carbamates 
(e.g. caged pro-fluorescent coumarin derivative 1; Scheme 2 and Table 1).93-95 The reactions were performed 
in water and in the presence of thiols. Furthermore, activity of these complexes in HeLa cells was observed 
(see chapter 1.4).  
Meggers et al. tested a variety of Cp/Cp*-ruthenium complexes for the deprotection of the O-allyl carbamate 
caged coumarin 1. Complexes bearing acetonitrile, 2,2’-bipyridine or 1,5-cyclooctadiene ligands only 
revealed moderate activities (Table 1, entries 1-4). 2-quinolinecarboxylate (QA) or 2-pyridinecarboxylate (PA) 
ligands increased to activity of the corresponding ruthenium complexes (Table 1, entries 5-8). However, 
ruthenium complexes bearing a Cp*-ligand performed slower than their corresponding Cp analogues. 
Complexes bearing electron donating groups at the 4’-position of the QA-ligand revealed elevated activities: 
H < OMe < NMe2 (Table 1, entries 9-11). In contrast, the opposite trend for the allylation of alcohols and the 
cleavage of allyl ethers with the ruthenium complex [CpRu(PA-4’X)(Allyl)]PF6 was observed (-OMe < -H < -Cl 
< -CF3 < -NO2).96 Exchange of the 2-quinolinecarboxylate (QA) ligand by 8-hydroxyquinolinates (HQ) further 
increased the activity of the ruthenium complex (Table 1, entries 12-17).95  
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Scheme 2: Ruthenium-catalyzed deprotection of allyl-coumarin 1.94-95  
Reaction conditions: see Table 1.  
 
Table 1: Catalytic performance of ruthenium complexes in the cleavage of an O-allyl carbamate protected coumarin (1).94-95  
Entry Complex Catalyst loading Reaction time Yield [%] 
1a [CpRu(MeCN)3]PF6 5 mol% 4 h < 10 
2a [Cp*Ru(MeCN)3]PF6 5 mol% 4 h < 10 
3a [CpRu(bpy)(MeCN)]PF6 5 mol% 4 h ~20 
4a [Cp*Ru(cod)Cl] (13) 5 mol% 4 h ~20 
5a [CpRu(PA)(Allyl)]PF6 (3) 5 mol% 4 h 80 
6a [Cp*Ru(PA)(Allyl)]PF6 (4) 5 mol% 4 h 10 
7a [CpRu(QA)(Allyl)]PF6 (5) 5 mol% 4 h >99 
8a [Cp*Ru(QA)(Allyl)]PF6 (8) 5 mol% 4 h 38 
9a [CpRu(QA)(Allyl)]PF6 (5) 1 mol% 4 h 47 
10a [CpRu(QA-OMe)(Allyl)]PF6 (6) 1 mol% 4 h 79 
11a [CpRu(QA-NMe2)(Allyl)]PF6 (7) 1 mol% 4 h 91 
12b [Cp*Ru(cod)Cl] (13) 10 mol% 2 h 1 
13b [CpRu(QA-NMe2)(Allyl)]PF6 (7) 10 mol% 2 h 30 
14b [CpRu(HQ)(Allyl)]PF6 (9) 10 mol% 2 h 56 
15b [CpRu(HQ-Cl)(Allyl)]PF6 (10) 10 mol% 2 h 75 
16b [CpRu(HQ-NO2)(Allyl)]PF6 (11) 10 mol% 2 h 67 
17b [CpRu(HQ-CO2Me)(Allyl)]PF6 (12) 10 mol% 2 h 89 
Reaction conditions: a) Entries 1-11: Allyl-coumarin 1 (500 μM), ruthenium catalyst, glutathione (5 mM) in water/DMSO (200:1), room 
temperature, air. For [Cp*Ru(cod)Cl] thiophenol (2.5 mM) was added to the reaction mixture. Conversion determined by fluorescence 
intensity measurements. b) Entries 12-18: Allyl-coumarin 1 (50 μM), ruthenium catalyst, glutathione (5 mM) in potassium phosphate 
buffer (pH 7.4), room temperature, air. Conversion determined by HPLC analysis. Cp = η5-cyclopentadienyl, Cp* = η5-
pentamethylcyclopentadienyl, bpy = 2,2’-bipyridine, cod = η4-1,5-cyclooctadiene, PA = 2-pyridinecarboxylate, QA = 2-
quinolinecarboxylate, HQ = 8-hydroxyquinolinate.  
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The proposed mechanism of the ruthenium-catalyzed deallylation of O-allyl carbamates includes the same 
steps as the mechanism for palladium-catalyzed allylic substitutions (Scheme 1). First, the allyl moiety of the 
substrate coordinates to the ruthenium(II)-complex. Upon ionization of the allyl carbamate, decarboxylation 
and release of the leaving group, an η3-allyl ruthenium(IV) intermediate is formed. Attack of the nucleophile 
and decomplexation of the formed olefin-ruthenium(II)-complex finally releases the allylic product (Scheme 
3).97  
 
N
R
O
OH
RuII
L
PF6
N
R
O
OH
RuII
PF6
O
O
NHR'
N
R
O
O
RuIV
PF6
N
R
O
O
RuII
PF6
Nu
H2NR' + CO2HNu
Nu
L
O NHR'
O
L
 
Scheme 3: Proposed catalytic cycle for the ruthenium-catalyzed deprotection of allyl-coumarin 1.94  
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1.4 Ruthenium-catalyzed uncaging reactions in living cells 
Bioorthogonal bond cleavage reactions have developed into an important tool in biochemical applications.98-
99 One of these reactions is the deprotection of O-allyl carbamate caged compounds. The groups of 
Meggers93-94, Mascareñas100-101 and Rotello102 have demonstrated that such substrates can be deprotected 
inside of cells, applying different ruthenium complexes (Scheme 4).  
Meggers et al. deprotected an O-allyl carbamate caged rhodamine 110 derivative (14) inside of HeLa cells 
using the ruthenium complex [Cp*Ru(cod)Cl] (13).93 By the addition of thiophenol, a higher rhodamine 110 
fluorescence intensity was obtained. The ruthenium catalyst was subsequently further optimized. Complex 
[CpRu(QA)(Allyl)]PF6 (5) revealed a highly increased activity for the same reaction.94 The performance of the 
catalyst could even be further increased by an exchange of the substituent at the 4’-position of the quinoline 
carboxylate ligand (complexes 6 and 7). The same trend was observed for the in vitro deprotection of the 
caged coumarin 1 (see Table 1, entries 9-11). Recently, Meggers et al. have further increased the catalytic 
activity of their ruthenium complex by substitution of the 2-quinolinecarboxylate ligand with an 8-
hydroxyquinolinate ligand (see Table 1, entries 12-17).95 Both optimized ruthenium catalysts, complex 
[CpRu(QA-NMe2)(Allyl)]PF6 (7) and complex [CpRu(HQ-CO2Me)(Allyl)]PF6 (12), were able to deprotect a caged 
doxorubicin derivative (16) in HeLa cell cultures. The released active drug then decimated the number of 
living HeLa cells. Thus, ruthenium complexes in combination with caged drugs might also be applied in anti-
cancer treatment. Furthermore, the catalysis rate of the ruthenium complex [CpRu(QA)(Allyl)]PF6 (5) is 
independent of the glutathione concentration (tested between 0 – 10 mM).94 As shown by Ward et al., 
artificial metalloenzyme containing precious metal cofactors (e.g. artificial transfer hydrogenases containing 
piano-stool iridium complexes) were strongly inhibited by thiols (e.g. glutathione).103 Thus, the zero order 
rate dependency of the ruthenium complex [CpRu(QA)(Allyl)]PF6 (5) for glutathione represents an important 
feature for the design of potential artificial metalloenzymes for in vivo catalysis.  
Mascareñas et al. attached a phosphonium anchor to the ruthenium complex [CpRu(QA-NMe2)(Allyl)]PF6 (7). 
The resulting catalyst preferentially accumulated in the mitochondria of the HeLa cells.101 In addition, they 
demonstrated that a DNA-binding agent (15) can be uncaged inside of chicken embryo fibroblast cells, 
applying [Cp*Ru(cod)Cl] (13).100  
The research group of Rotello designed gold nanoparticles, in which they embedded the ruthenium complex 
[Cp*Ru(cod)Cl] (13).102 The intracellular catalytic activity of this construct towards the deprotection of caged 
rhodamine 110 (14) was controlled by the interaction with a supramolecular cucurbit[7]uril “gate-keeper”.  
Finally, Wender et al. implemented a cellular luciferase reporter system.104 A caged probe (O-allyl carbamate 
protected D-aminoluciferin) was deprotected by the ruthenium complex [CpRu(QA-OMe)(Allyl)]PF6 (6). The 
released luminophore (D-aminoluciferin) was then used up by the luciferase in order to produce an optical 
readout. However, studies varying the order of addition of catalyst and substrate as well as ICP-MS 
experiments suggested that the catalysis occurred extracellularly.  
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Scheme 4: In vivo deprotection of O-allyl carbamate caged substrates applying different ruthenium complexes.  
 
Beside the ruthenium mediated deprotection, also palladium(0)-microspheres105 and various palladium-salts 
(e.g. Allyl2Pd2Cl2)106 were successfully applied in the uncaging of O-allyl carbamate-protected species. In 
addition, Meggers et al. demonstrated that natural enzymes (e.g. cytochrome P450-BM3) are able to uncage 
allyl ether-protected compounds.107 However, the natural enzymes revealed higher activities for the 
corresponding propargyl-derivatives.  
Based on the high activity and the in vivo compatibility of the presented ruthenium complexes (see Scheme 
4 and Table 1), we envisioned the design of an artificial allylic deallocase based on the biotin-streptavidin 
technology. Therefore, we planned to attach a biotin anchor to the ruthenium complex [CpRu(QA-
NMe2)(Allyl)]PF6 (7) with subsequent incorporation of the cofactor into streptavidin (chapter 2.1). The 
designed artificial allylic deallocase can then potentially be evolved and applied in catalysis in the presence 
of E. coli cells (chapters 2.2 and 2.3). By the design of caged inducers (chapter 1.5), the expression of a protein 
of interest could be triggered with an artificial metalloenzyme (chapter 2.4).  
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1.5 Caged inducer systems 
Biogenetic switches allow the regulation of genes and the expression of proteins in cells. In bacteria, often 
systems depending on small molecule inducers such as isopropyl-β-D-thiogalactopyranoside (IPTG) or L-
arabinose are employed for this task. However, once one of these inducers has been added to the cell culture, 
the gene expression cannot be longer controlled by an external stimulus. This control can be gained back by 
attachment of a protecting group to the inducer. The protected inducer can then be added to the cell culture 
and later on be activated when desired. Often photo-labile protective groups are used to “cage” the active 
inducer.108 This was applied for the protection of IPTG and arabinose using photo-cleavable 6-nitropiperonyl 
caging groups.109-111 Another caged IPTG inducer was chemically released by an RNA-templated Staudinger 
reaction followed by a 1,6-elimination.112 Alternatively, not the inducer molecule itself but the required T7 
RNA polymerase can be caged.113  
In this thesis, we envisioned the design of an O-allyl carbamate/carbonate protected IPTG derivative, which 
can be uncaged by the action of our artificial allylic deallocase (chapter 2.4). The liberated IPTG can then 
induce the expression of a GFP reporter protein.  
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1.6 Aims of the thesis 
The Ward research group has designed a variety of different artificial metalloenzymes based on the biotin-
streptavidin technology. The performance of these hybrid catalysts has been optimized by chemical 
modification of the biotinylated metal cofactor or by genetic engineering of the host protein. The resulting 
active artificial metalloenzymes have then been successfully applied in catalytic transformations, including 
transfer hydrogenation, C-H activation, ring-closing metathesis, Suzuki-coupling, anion-π catalysis and many 
more (chapters 1.1 and 1.2). In parallel, highly active allyl transfer catalysts based on palladium, iridium and 
ruthenium complexes have been developed, and some of them have been successfully applied in in vivo 
catalysis (chapters 1.3 and 1.4). Based on this knowledge, the following aims were formulated for this PhD 
thesis: 
 
- Creation of an artificial allylic deallocase by incorporation of a biotinylated ruthenium cofactor into 
streptavidin isoforms.  
 
- Optimisation of the catalytic performance of the artificial allylic deallocase by genetic modification 
of the host protein.  
 
- Design of streptavidin variants containing a lid-like structure on top of the solvent exposed biotin 
binding vestibule, in order to increase the influence of the host protein on the metal cofactor. In this 
way, the catalytic activity and selectivity of the artificial metalloenzyme can be further evolved.  
 
- Application of the artificial allylic deallocase in an in vivo catalysis reaction in E. coli.  
 
- Design of an ultrahigh-throughput assay for the in vivo evolution of the artificial allylic deallocase.  
 
- Design of O-allyl carbamate protected inducer molecules (IPTG) for the creation of a biogenetic 
switch, which can be triggered by the action of the artificial allylic deallocase.  
  
 13 
2 Results and discussion 
2.1 Design of an artificial allylic deallocase 
Inspired by the previous results of Meggers et al.94 (chapters 1.3 and 1.4) and the knowledge of the Ward 
group on artificial metalloenzymes based on the biotin-streptavidin technology, a new artificial allylic 
deallocase was designed. Incorporation of the catalytically active transition metal complex into streptavidin 
required the covalent attachment of a biotin anchor to the ruthenium cofactor. This linkage could be done 
either (i) via the cyclopentadienyl (Cp) ligand or (ii) via the 2-quinolinecarboxylate (QA) ligand (Figure 3, b and 
c).  
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Figure 3: Designed biotinylated ruthenium complexes for the construction of an artificial allylic deallocase.  
a) Ruthenium complex [CpRu(QA-NMe2)(Allyl)]PF6 (7) reported by Meggers et al.94; b) Ruthenium complex [(Biot-Cp)Ru(QA-
NMe2)(Allyl)]PF6 (17) with a biotin anchor attached to the cyclopentadienyl ligand; c) Ruthenium complex [CpRu(QA-Biot)(Allyl)]PF6 
(18) with a biotin anchor attached to the 2-quinolinecarboxylate ligand.  
The first strategy, linkage via the cyclopentadienyl ligand (17), allows a simple and fast exchange of the 
second coordination partner.62 Thus, the chemical diversity of the system could be explored by testing a 
variety of ligands (e.g. substituted 2-quinolinecarboxylates, 2-pyridinecarboxylates or 8-hydroxyquinolinates; 
Scheme 2 and Table 1).94-95 However, ruthenium complexes bearing a Cp*-ligand perform slower in the 
catalytic cleavage of an O-allyl carbamate protected coumarin (1) than their corresponding Cp analogues 
(Table 1, entries 5-8; Scheme 2).94 It is believed that this is caused by the steric hindrance of the five methyl 
groups. Thus, attachment of a bulky biotin anchor might decrease the catalytic efficiency of the complex as 
well.  
In the second strategy, the biotin anchor is attached to the 2-quinolinecarboxylate ligand (18). An increased 
catalytic efficiency for ruthenium complexes [CpRu(QA-4`X)(Allyl)]PF6 bearing electron donating groups at 
the 4`-position was detected: -H < -OMe < -NMe2 (Table 1, entries 9-11; Scheme 2).94  
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The beneficial effect of the electron donating dimethylamino group on the catalytic activity should be kept 
when the biotin anchor is attached. To simultaneously increase the rigidity of the ligand, a piperazine linker 
was selected to connect the biotin anchor to the ligand (Figure 3, c). For both strategies a protein-ligand 
docking was performed using GOLD (Figure 4).  
 
 
 
Figure 4: Protein-ligand docking of [(Biot-Cp)Ru(QA-NMe2)(Allyl)] (17, top) and [CpRu(QA-Biot)(Allyl)] (18, bottom) in Sav-WT.  
A biotin anchor was modelled into a crystal structure of [CpRu(QA)(Allyl)]PF6 (5) (Cambridge Structural Database Refcode: NAJLUG)85 
and the complete ruthenium cofactor was docked into a crystal structure of streptavidin (Protein Database entry: 3PK2).60 The 
docking was performed with the dimer of streptavidin. Protein in surface representation (color code for the residues: white = apolar, 
green = polar, red = acidic, blue = basic), biotinylated ruthenium complex represented as sticks (elements: H = white, C = cyan, N = 
blue, O = red, S = yellow, Ru = orange ball). The docking procedure is described in details in chapter 4.2.1. Docking was done by MSc 
Maxime Barnet (University of Basel).  
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For both strategies the designed biotinylated ruthenium complexes would potentially fit into the host 
protein. The docking furthermore suggested that two adjacent biotin-binding sites provide only the required 
space to host one cofactor. Due to the promising catalysis results presented in Table 1 it was decided to 
proceed with the second strategy, the attachment of the biotin anchor to the 2-quinolinecarboxylate ligand.  
 
2.1.1 Synthesis of a biotinylated ruthenium cofactor 
Synthesis of the desired biotinylated ruthenium complex [CpRu(QA-Biot)(Allyl)]PF6 (18) required the covalent 
attachment of a piperazine linker and a biotin anchor to the 2-quinolinecarboxylate ligand (Scheme 5). The 
synthesis was started from the commercially available kynurenic acid (19). Esterification with sulfuric acid in 
refluxing methanol led to the formation of methyl ester 20, which was further brominated at the 4`-position 
to form compound 21. The tert-butyloxycarbonyl (Boc) protected piperazine linker was attached via a 
Buchwald-Hartwig amination using Pd2(dba)3 and racemic BINAP in refluxing 1,4-dioxane. Compound 22 was 
the starting point for a variety of synthetic routes. However, at this point, two central questions arose: (i) 
What type of biotin or biotin-analogue should be used as an anchor? (ii) At which step of the synthesis should 
this anchor be installed?  
Using D-biotin as an anchor might cause problems, since its thioether group could potentially interact with 
the ruthenium center. On the other hand, a part of the affinity for (strept)avidin is lost when D-biotin is 
exchanged for desthiobiotin or its sulfone analogue (Table 2).35 However, since the interactions with avidin 
remain high (Kd ~10-13 M), D-biotin, D-biotin sulfone and desthiobiotin anchors were tested for the synthesis 
of the ruthenium complex.  
Table 2: Affinities of biotin derivatives towards avidin.35 
Entry Biotin analogue Kd [M]a 
1 D-Biotin 10-15 
2 D-Biotin sulfone >10-13 
3 Desthiobiotin 5·10-13 
4 2`-Iminobiotin 3.5·10-11 
5 2`-Thiobiotin (pH 9) 5·10-13 
6 N-3`-methoxycarbonyl biotin methyl ester 10-8-10-9 
7 N-1`-methoxycarbonyl biotin methyl ester 4·10-7 
aDetermined in aqueous solution at pH 7.  
The biotin anchors were in general attached to the 2-qiunolinecarboxylate moiety prior to complexation with 
ruthenium. The conditions to remove the Boc protective group or the correspondingly formed secondary 
amine might not be compatible with the ruthenium complex. Nevertheless, the other strategy was attempted 
as well in case of the D-biotin anchor. All the synthetic strategies and their success are summarized in Scheme 
5.  
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Scheme 5: Synthetic strategies for the synthesis of a biotinylated ruthenium catalyst.  
Reaction conditions: a) H2SO4, MeOH (dry), reflux, 20 h; b) P2O5, Bu4NBr, toluene, 90°C, 1 h; c) N-Boc-piperazine, Pd2(dba)3 (6 mol%), 
rac. BINAP (6 mol%), Cs2CO3, 1,4-dioxane (dry), reflux, 15 h; d) 1.) 50% TFA in DCM, TIS, r.t., 1 h. 2.) Biotin-PFP (24), DIPEA, DMF, r.t., 
24 h; e) 1.) 50% TFA, TIS, DCM, r.t., 1 h. 2.) Biot-sulfone-PFP (37), DIPEA, DMF, r.t., 20 h; f) 1.) 50% TFA, TIS, DCM, r.t., 1 h. 2.) 
Desthiobiotin-PFP (32), DIPEA, DMF, r.t., 20 h; g) 1.) LiOH·H2O, MeOH, r.t., 48 h. 2.) Allyl bromide (2.0 eq.), NaHCO3, DMF, 50°C, 18 h; 
h) Allyl bromide (1.5 eq.), NaHCO3, DMF, 50°C, 15 h; i) LiOH·H2O, MeOH, r.t., 22 h; j) Ligand 39 + [CpRu(MeCN)3]PF6, test reactions 
with different dry solvents (acetone, DCM, MeCN), r.t., 15 min, glovebox (see also chapter 2.1.2); k) 1.) LiOH·H2O, MeOH, r.t., 24 h. 
2.) Allyl bromide (2.0 eq.), NaHCO3, DMF, 50°C, 18 h; l) 1.) Ligand 26/[CpRu(MeCN)3]PF6 (1:1), acetone (dry), r.t., 15 min, glovebox. 
2.) Allyl alcohol (1 eq.), r.t. 15 min, glovebox; m) 1.) [CpRu(MeCN)3]PF6 (1 eq.), acetone (dry), r.t., glovebox. 2.) Ligand 34 (1 eq.), r.t., 
45 min; n) [CpRu(MeCN)3]PF6 (1.0 eq.), DMF, r.t., 15 min, used for catalysis in situ; o) [CpRu(MeCN)3]PF6, acetone (dry), r.t., 45 min; 
p) HCl in 1,4-dioxane (10 eq.), 1,4-dioxane, r.t., 2.5 h; q) Ligand 29/[CpRu(MeCN)3]PF6 (1:1), MeOH (dry), r.t., 15 min, glovebox; r) 1.) 
HCl (gas), DCM, r.t., 3 h. 2.) DCM, r.t., stirring overnight. 3.) Biotin-PFP (24), NEt3, DMF, r.t., overnight; Biot = D-biotin; Desthiobiot = 
Desthiobiotin; Biot-sulfone = D-biotin sulfone; Boc = tert-butyloxycarbonyl.  
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In the first synthetic route (Scheme 5, orange arrows), quinoline 22 was trans-esterificated to the 
corresponding allyl ester 28, which was then mixed with [CpRu(MeCN)3]PF6 in dry acetone to form the 
ruthenium complex [CpRu(QA-Boc)(Allyl)]PF6 (30). This complex was treated with HCl(g) in DCM to remove 
the Boc protective group, followed by addition of an activated biotin ester (24) in DMF to install the biotin 
anchor. However, according to NMR and MS analysis, the desired biotinylated ruthenium complex [CpRu(QA-
Biot)(Allyl)]PF6 (18) was not formed. Alternatively, allyl ester 28 was deprotected first to form the 
corresponding piperazine hydrochloride salt (29). Due to its limited solubility (insoluble in acetone, MeCN, 
DCM, THF), MeOH was selected as solvent for complexation. NMR analysis of the ruthenium precursor 
[CpRu(MeCN)3]PF6 in methanol-d4 revealed that the Cp ligand had been displaced. Therefore, no 
complexation with the biotinylated ligand was attempted.  
The second synthetic route (Scheme 5, blue arrows) includes the use of a desthiobiotin anchor. Quinoline 22 
was deprotected and treated with pentafluorophenyl destiobiotin (32) to yield methyl ester 33. After 
transesterification to the corresponding allyl ester (34), complexation with [CpRu(MeCN)3]PF6 in dry acetone 
was attempted. However, according to NMR analysis, the desired biotinylated ruthenium complex [CpRu(QA-
Desthiobiot)(Allyl)]PF6 (35) was not formed.  
In the third synthetic route (Scheme 5, pink arrow) a D-biotin sulfone anchor was successfully attached to 
the quinoline frame. The formed product (38), however, had very limited solubility (product precipitated 
during the synthesis from DMF), which rendered its use in subsequent synthesis very challenging.  
In a final synthetic route (Scheme 5, black arrows), D-biotin was introduced as an anchor for streptavidin. 
Quinoline 22 was deprotected and biotinylated to afford methyl ester 25, which was saponified to yield 
carboxylate 26. This ligand was mixed with [CpRu(MeCN)3]PF6 in DMF (1:1 ratio) and the formed ruthenium 
complex [CpRu(QA-Biot)(Sol.)]PF6 (27) was used in situ for catalysis. Detailed structural analysis (NMR studies, 
crystal structure analysis) and its performance in catalysis are discussed in chapters 2.1.2, 2.1.4 and 2.2.  
Based on the proposed mechanism (Scheme 3), it should be independent at which step of the catalytic cycle 
the reaction starts. This means that bearing an allyl fragment is not a requirement for the initial ruthenium 
complex to act as an allyl transfer catalyst. Nevertheless, synthesis of the allylated ruthenium complex 
[CpRu(QA-Biot)(Allyl)]PF6 (18) was attempted in two different ways (Scheme 5, green arrows). Direct 
complexation of ligand 26 with [CpRu(MeCN)3]PF6 in dry acetone followed by the addition of allyl alcohol 
(formation of the allyl ligand) failed. Therefore, allyl ester 39 was prepared and subsequent complexation 
with [CpRu(MeCN)3]PF6 was attempted using different organic solvents (acetone, MeCN or DCM), different 
ligand:metal ratios and different orders of addition (see chapter 2.1.2). Complexation with a 1:1 mixture of 
ligand 39 and ruthenium precursor [CpRu(MeCN)3]PF6 in dry DCM resulted in the successful formation of the 
desired ruthenium complex [CpRu(QA-Biot)(Allyl)]PF6 (18) as revealed by HRMS analysis. However, the crude 
product contained a fraction of the initial ruthenium precursor [CpRu(MeCN)3]PF6.  
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Purification of this mixture by chromatography (reverse phase TLC) proved to be challenging. Based on the 
good catalysis results with [CpRu(QA-Biot)(Sol.)]PF6 (27) (chapter 2.2), the synthesis and isolation of the 
allylated analogue [CpRu(QA-Biot)(Allyl)]PF6 (18) was not further pursued.  
In summary, a biotinylated 2-qiunolinecarboxylate ligand (26) was synthesized in five steps (Scheme 5, black 
arrows), with a Buchwald-Hartwig amination as the key step. The synthesis started from the commercially 
available kynurenic acid (19). Moderate to good yields (29-84%) were obtained for the individual steps. The 
efficiency of the aromatic bromination and the Buchwald-Hartwig amination (Scheme 5, steps b and c) could 
be further increased. Synthetic transformations in presence of biotin derivatives proved to be challenging 
and the desired products could not always be obtained in pure form. However, an in situ mixture of the 
biotinylated ligand 26 with the ruthenium precursor [CpRu(MeCN)3]PF6 in DMF was successfully applied in 
catalysis (chapter 2.2).  
 
2.1.2 NMR studies of the designed ruthenium complexes 
[CpRu(QA-NMe2)(Allyl)]PF6 (7): Effect of DMSO on the allyl ligand 
Based on the catalytic performance of [CpRu(QA-NMe2)(Allyl)]PF6 (7) for the deprotection of the coumarin 
derivative 1 (Scheme 6, Table 4), in which significantly higher yields were obtained if the catalyst stock 
solution was prepared in DMSO compared to MeCN, a set of 2D-NMR spectra of the ruthenium complex in 
these solvents were investigated. Only a single species (complex [CpRu(QA-NMe2)(Allyl)]PF6 (7)) was detected 
in the 1H NMR spectrum using MeCN-d3 as solvent. Two species were detected in DMSO-d6 (Figure 5). In 
addition to the initial ruthenium complex [CpRu(QA-NMe2)(Allyl)]PF6 (7), the allyl ester 40, in which the η3-
coordinated allyl fragment was transferred to the carboxylate of the quinoline ligand, was detected. The 
signals at 5.91 ppm and at 5.19 + 5.02 ppm show typical chemicals shifts and coupling patterns for an allyl 
ester. There was no HMBC cross-peak between the 1’-carbon and the 12’-protons detectable. It is thus 
believed that there is a fast exchange between the two species 7 and 40. In the 1H NMR spectrum using 
DMSO-d6 as solvent, the two species were obtained in the ratio 7/40 = 1.5:1. In addition, a set of NOE cross-
peaks between the Cp ligand and the 2-qiunolinecarboxylate/allyl ligand was detected, which supports the 
proposed arrangement of the ligands around the metal center. Whether DMSO coordinates to the ruthenium 
center in complex 40 could not be clearly established in this NMR study. However, complex 40 contains a 
potentially free coordination site at the ruthenium center, which might explain the increased activity of the 
complex if DMSO is used as the co-solvent.  
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Figure 5: 1H NMR spectrum of [CpRu(QA-NMe2)(Allyl)]PF6 (7) in DMSO-d6.  
a) Structure of the ruthenium complex [CpRu(QA-NMe2)(Allyl)]PF6 (7). b) Proposed structure of its analogue bearing an allyl ester and 
a potentially free coordination site instead of an η3-coordinated allyl fragment. c) 1H NMR spectrum of complex [CpRu(QA-
NMe2)(Allyl)]PF6 (7) in DMSO-d6. The two species were obtained in the ratio 7/40 1.5:1. Dashed blue lines indicate the obtained NOE 
peaks. Complete assignment of the spectrum: 1H NMR (500 MHz, DMSO-d6 δ/ppm): 8.53 (dd, J = 8.7, 1.2 Hz, 1H, 5`), 8.29 – 8.24 (m, 
1H, 8), 8.15 (dd, J = 8.5, 1.3 Hz, 1H, 8`), 7.92 (ddd, J = 8.8, 6.9, 1.5 Hz, 1H, 6), 7.82 (ddd, J = 8.5, 6.8, 1.4 Hz, 1H, 6`), 7.73 – 7.71 (m, 1H, 
5), 7.70 – 7.68 (m, 1H, 7), 7.65 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H, 7`), 7.33 (s, 1H, 3`), 7.23 (s, 1H, 3), 6.39 (s, 5H, 15), 5.91 (ddt, J = 17.2, 
10.5, 4.7 Hz, 1H, 13`), 5.19 (dd, J = 17.2, 2.1 Hz, 1H, 14`), 5.02 (dd, J = 10.4, 2.1 Hz, 1H, 14`), 4.68 – 4.60 (m, 2H, (12 or 14) +13), 4.51 
(s, 5H, 15`), 4.38 (d, J = 10.4 Hz, 1H, 12 or 14), 4.14 (dd, J = 6.2, 2.7 Hz, 1H, 12 or 14), 3.97 – 3.87 (m, 2H, (12 or 14)+12`), 3.31 (s, 6H, 
11), 3.15 (s, 6H, 11`). Unknown species: 7.71, 4.81, 4.70, 3.55. Solvents: DMSO (2.50), acetone (2.08). Standard: TMS (0.00). The 
spectra were measured and assigned with the help of PD Dr. Daniel Häussinger (University of Basel).  
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Formation of [CpRu(QA-Biot)(Allyl)]PF6 (18): Effect of different solvents 
Formation of the complex [CpRu(QA-Biot)(Allyl)]PF6 (18) from [CpRu(MeCN)3]PF6 and biotinylated ligand 39 
(Scheme 5, green arrows) was tested in different solvents with different ligand:metal ratios and orders of 
addition. Synthesis of the non-biotinylated metal complexes [CpRu(QA-NMe2)(Allyl)]PF6 (7) and [CpRu(QA-
Boc)(Allyl)]PF6 (30) were performed in acetone.94 A summary of all experiments is collected in Table 3 and a 
comparison of the determined 1H NMR spectra is presented in Figure 6.  
Table 3: Formation of [CpRu(QA-Biot)(Allyl)]PF6 (18) from [CpRu(MeCN)3]PF6 and biotinylated ligand 39.a  
Entry Solvent Ligand:Metal Added first Obtained product 
1 Acetone (dry) 1:1 [CpRu(MeCN)3]PF6 Brownish solid 
2 MeCN (dry) 1:1 Ligand 39 Dark red-brown solid 
3 DCM (dry) 1:1 [CpRu(MeCN)3]PF6 Yellow-ochre solid 
4 DCM (dry) 2:1 [CpRu(MeCN)3]PF6 Yellow-orange solid 
5 DCM (dry) 1:1 Ligand 39 Yellow-orange solidb 
aReaction, stoichiometry and conditions: see Scheme 5. bHRMS analysis confirmed the presence of the desired ruthenium complex 
[CpRu(QA-Biot)(Allyl)]PF6 (18), annex spectrum on page 189.  
In the aromatic region of the spectra (Figure 6, a), the five reactions show peaks (and peak splitting) with very 
similar chemical shifts compared to the ruthenium complex bearing the Boc protected piperazine linker 
([CpRu(QA-Boc)(Allyl)]PF6 (30)). The peaks are clearly shifted compared to the ones from the free ligand (39), 
thus indicating a change in the chemical environment (i.e. coordination to the ruthenium). However, besides 
a singlet peak at 6.12 ppm, which is very close to the one arising from the Cp protons of [CpRu(QA-
Boc)(Allyl)]PF6 (30), all spectra also display a singlet at 4.27 ppm, which was detected for the Cp protons of 
the metal precursor [CpRu(MeCN)3]PF6 as well (Figure 6, b). This result suggested that all of the test reactions 
still contain a fraction of the initial metal precursor. The peaks at 6.12 ppm and 4.27 ppm were integrated. 
The reactions in DCM (Table 3, entries 3 – 5) revealed ratios 6.12/4.27 ppm > 0.8, whereas for the reactions 
in acetone (Table 3, entry 1) and MeCN (Table 3, entry 2) ratios of 0.6 and 0.4 were obtained, respectively. 
Formation of the complex [CpRu(QA-Biot)(Allyl)]PF6 (18) seems therefore to be slightly favored in DCM. 
Indeed, the presence of the desired complex [CpRu(QA-Biot)(Allyl)]PF6 (18) for the reaction in DCM (Table 3, 
entry 5) could be detected by HRMS analysis. However, no pure product was obtained using the conditions 
collected in Table 3.  
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Figure 6: Comparison of 1H NMR spectra for the reactions collected in Table 3.  
The three pictures display different parts of the spectra: a) 8.5 – 7.0 ppm, b) 6.3 – 4.0 ppm and c) 6.1 – 0.7 ppm. All spectra were 
determined in MeCN-d3. Intensities of the individual spectra were adjusted for better visibility.  
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In addition, DOSY spectra were determined for the reaction mixture in MeCN (Table 3, entry 2) as well as for 
the metal precursor and the free biotinylated ligand. With DOSY NMR measurements, the diffusion 
coefficient (D) of a molecule in the considered solvent can be determined, which allows to estimate the 
molecular weight (MW) of the compound.114 Often the Einstein-Stokes equation (D = k·T/(6·π·η·Rh) with k: 
Boltzmann constant, T: absolute temperature, η: solvent viscosity, Rh: hydrodynamic radius) or an empirically 
derived power law (D = K·MWα with K: molecule dependent constant, α: coefficient depending on the shape 
of the particle) are applied.115 Approximating the molecules as spherical objects, the diffusion coefficient 
depends on the molecular weight as follows: 1/MW ∝ D3. For the metal precursor [CpRu(MeCN)3]PF6 a 
diffusion coefficient of 1.92·10-9 m2/s and for the ligand 39 a diffusion coefficient of 1.26·10-9 m2/s were 
determined. For the reaction mixture a smaller diffusion coefficient of 1.15·10-9 m2/s was determined, 
suggesting that this species has a larger hydrodynamic radius, and therefore in a first approximation, a larger 
molecular weight. The ratio of the cubed diffusion coefficients (Dligand/Dreaction)3 with a value of 1.315 is in good 
agreement with the ratio of the molecular weights MWcomplex/MWligand = 1.317. Thus, the DOSY NMR 
experiments strongly indicate that a complexation of the biotinylated ligand 39 with the metal precursor 
[CpRu(MeCN)3]PF6 has taken place.  
 
Analysis of [CpRu(QA-Biot)(Sol.)]PF6 (27) in DMF 
Formation of the complex [CpRu(QA-Biot)(Sol.)]PF6 (27) in DMF from a 1:1 mixture of metal precursor 
[CpRu(MeCN)3]PF6 and biotinylated ligand 26 (Scheme 5, black arrows) was followed by DOSY NMR analysis. 
From the spectra, the following diffusion coefficients were extracted: Dmetal precursor = 4.35·10-10 m2/s, Dligand = 
3.00·10-10 m2/s and Dreaction = 2.70·10-10 m2/s. Again here, a smaller diffusion coefficient was obtained for the 
reaction mixture compared to the free biotinylated ligand, indicating an increase in molecular weight. The 
ratio of the cubed diffusion coefficients (Dligand/Dreaction)3 with a value of 1.372 is in proximity of the ratio of 
the molecular weights MWcomplex/MWligand = 1.509, keeping in mind that these molecules are not spherical. A 
complexation of the ligand 26 with the metal precursor [CpRu(MeCN)3]PF6 most likely took place, although 
no unique ruthenium complex was formed as highlighted by 1H-NMR analysis (Figure 7). However, when this 
mixture was applied to an aqueous solution of streptavidin, a crystal structure of the defined complex 
[CpRu(QA-Biot)(H2O)]·Sav S112M-K121A was determined (chapter 2.1.4).  
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Figure 7: Comparison of the 1H NMR spectra of [CpRu(MeCN)3]PF6 (red), ligand 26 (green) and a 1:1 mixture of both (blue).  
All spectra were determined in DMF-d7. Intensities of the individual spectra were adjusted for better visibility. The spectra were 
measured with the help of PD Dr. Daniel Häussinger (University of Basel).  
 
2.1.3 Assembly of the artificial allylic deallocase 
In a next step, the catalytically active artificial allylic deallocase was assembled by incorporation of the 
ruthenium complex [CpRu(QA-Biot)(Sol.)]PF6 (27) in wild-type streptavidin. Binding of the biotinylated 
cofactor to streptavidin was highlighted by HABA-titration. In this titration assay 2-(4'-
hydroxybenzeneazo)benzoic acid (HABA), a small streptavidin-binding molecule (Kd ≈ 10-4 M)39, 116, is 
displaced by the biotinylated ruthenium cofactor with a higher affinity. This process is accompanied by a 
color change from red (HABA bound to avidin, λabs., max = 496 nm) to yellow (HABA free in solution, λabs., max = 
439 nm)117, which leads to a decrease in absorption at 506 nm. Titration curves were determined for D-biotin, 
the biotinylated ligand (26) and the biotinylated ruthenium complex [CpRu(QA-Biot)(Sol.)]PF6 (27). All results 
are summarized in Figure 8.  
 
[CpRu(MeCN)3]PF6 
 
 
 
Ligand 26 
 
 
 
1:1 mixture 
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Figure 8: HABA-titration for a designed artificial allylic deallocase.  
Conditions: 7.1 μM streptavidin wild-type (tetramer), 1.1 mM HABA in phosphate buffer (20 mM, pH 7.4). Absorption determined at 
506 nm.  
For all compounds tested (D-biotin, ligand 26, and complex 27) a linear decrease in absorption was obtained 
upon titration, indicating that these molecules are able to displace HABA and bind to streptavidin. Thus, the 
affinities of these compounds for streptavidin are significantly higher than HABA (Kd < 10-4 M). The titration 
curves for D-biotin and the biotinylated ligand 26 (Figure 8, blue and red curves) stay at the same absorption 
level as soon as all streptavidin-bound HABA molecules are released. In case of complex 27 (Figure 8, green 
curve), a small increase in absorption was determined after the addition of more than 4.7 eq. of the 
biotinylated species. This is caused by the complex 27 itself, which has an absorption band around 506 nm. 
For D-biotin, the equivalence point was reached at 3.5 eq. of biotinylated species per streptavidin tetramer, 
which is in good agreement with the B4F-assay (3.4 biotin binding sites per tetramer; see chapter 4.2.8). 
Ligand 26 and complex 27 revealed equivalence points at 4.2 and 4.7 eq. of biotinylated species, respectively. 
These too high values are potentially caused by impurities (e.g. traces of water) in those samples, leading to 
a smaller concentration of the active biotinylated species than actually calculated. In general, concentrations 
of solutions should be directly determined by photospectrometric methods rather than by weighing and 
dissolving a certain amount of the compound. However, the binding of the biotinylated ruthenium complex 
[CpRu(QA-Biot)(Sol.)]PF6 (27) was established by determination of its streptavidin-bound X-ray crystal 
structure (see chapter 2.1.4).  
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2.1.4 Crystal structure determination 
A crystal structure of the streptavidin mutant S112M-K121A with the bound biotinylated ruthenium cofactor 
[CpRu(QA-Biot)(H2O)]PF6 (27) was determined (Figure 9, PDB entry 6FH8)118. The protein as well as the 
biotinylated 2-quinolinecarboxylate ligand are clearly resolved in the crystal structure and there is a unique 
electron density for the ruthenium ion. The cyclopentadienyl ligand however can adopt two positions, 
indicated by the smeared electron density. The crystal structure revealed that two biotinylated ruthenium 
cofactors fit well into two adjacent binding sites. The methionine residue at position 112 is oriented on top 
of the aromatic rings of the 2-quinolinecarboxylate ligand. Thus, potentially a C-H···π interaction is formed 
which could stabilize the ruthenium complex. Replacement of the lysine residue at position 121 by an alanine 
removes a positive charge and generates more space in the biotin binding vestibule (i.e. the substrate 
coordinated to the ruthenium cofactor might better fit). The observed higher catalytic activity of the artificial 
allylic deallocase bearing the mutations S112M and K121A might be explained by these two features. A more 
detailed analysis of the crystal structure is published elsewhere.118  
 
 
Figure 9: Crystal structure of the artificial allylic deallocase [CpRu(QA-Biot)(H2O)]PF6 (27) · Sav-S112M-K121A.118 
The four monomers of streptavidin are displayed in cartoon style with half-transparent surface (blue, red, brown, green). Mutations 
S112M and K121A are highlighted in yellow and pink, respectively. The electron density map of one cofactor is displayed as fine blue 
wires. The biotinylated ruthenium cofactors are displayed as stick (element color code: C = grey/orange, N = blue, O = red, S = yellow, 
Ru = turquoise ball). The crystal structure was determined by Dr. Tillmann Heinisch (Ward group, University of Basel) and deposited 
in the Protein Data Base (PDB entry 6FH8).118    
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2.2 In vitro catalysis with an artificial allylic deallocase 
2.2.1 Catalysis with a caged coumarin substrate 
The activity of the designed artificial allylic deallocase was tested for the cleavage of an O-allyl carbamate 
protected coumarin (1, Table 4). The substrate was synthesized according to literature procedures from 
Kanaoka et al.119, Ryckelynck et al.120 and Meggers et al.94 The catalytic activity of the ruthenium complex 
[CpRu(QA-NMe2)(Allyl)]PF6 (7) designed by Meggers et al.94 was tested for the uncaging of the O-allyl 
carbamate protected coumarin 1 (Scheme 6). Thereby, a catalyst concentration of 5 μM (= 1 mol%) was 
applied. High reactivity was obtained when this complex was prepared in DMSO (Table 4, entry 1). In sharp 
contrast, the activity dramatically dropped if other solvents such as MeCN, DMF or EtOH were used (Table 4, 
entries 2 - 4). However, the reactivity could be restored if DMSO was added to a solution of complex 7 in 
MeCN (Table 4, entry 5). This phenomenon is discussed in more details in chapter 2.1.2. Mixtures of the 
ruthenium precursor [CpRu(MeCN)3]PF6 with the biotinylated ligand 26 were tested (Table 4, entries 6 - 10). 
The best results were obtained with DMF as co-solvent, in which a 2.5-fold increase in conversion of the 
artificial metalloenzyme compared to the free cofactor was obtained (9% conv. with free cofactor vs. 25% 
conv. with Sav-WT). A biotinylated ligand containing an allyl ester group (39) and the non-biotinylated 
analogues (41 and 42) were tested as well, leading to no improvement in activity (Table 4, entries 11 - 13). 
Low yields and no protein acceleration were obtained. Finally, the catalytic activity of the individual 
components (ruthenium precursor and ligands) was investigated separately (Table 4, entries 14 - 19). The 
results unambiguously demonstrated that neither the ruthenium precursor [CpRu(MeCN)3]PF6 nor one of the 
(biotinylated) ligands alone is catalytically active. A 1:1 mixture of [CpRu(MeCN)3]PF6 and ligand 26 in DMF 
performed best. The 2.5-fold increase in activity in combination with Sav-WT vs. free ruthenium cofactor 
represented an ideal starting point for a screening campaign of different streptavidin isoforms.  
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Scheme 6: Deprotection of caged coumarin 1 catalyzed by artificial allylic deallocases (Table 4).  
 
Table 4: Catalytic performance of artificial allylic deallocases towards the deprotection of coumarin 1 (Scheme 6).a  
   Conversion [%]b 
Entry Catalyst (1 mol%) Co-solvent No protein Sav-WT 
1 7 DMSO 96 94 
2 7 MeCN 7 9 
3 7 DMF 9 9 
4 7 EtOH 3 3 
5 7 MeCN + DMSOc 87 n.d. 
6 [CpRu(MeCN)3]PF6 + 26 DMSO 5 3 
7 [CpRu(MeCN)3]PF6 + 26 MeCN 12 7 
8 [CpRu(MeCN)3]PF6 + 26 DMF 9 25 
9 [CpRu(MeCN)3]PF6 + 26 EtOH 3 8 
10 [CpRu(MeCN)3]PF6 + 26 Allyl alcohold 14 25 
11 [CpRu(MeCN)3]PF6 + 39 DMF 13 3 
12 [CpRu(MeCN)3]PF6 + 41 DMF 12 10 
13 [CpRu(MeCN)3]PF6 + 42 DMF 7 4 
14 [CpRu(MeCN)3]PF6 DMF 1 1 
15 [CpRu(MeCN)3]PF6 Allyl alcohold 1 1 
16 26 DMF 1 1 
17 39 DMF 1 1 
18 41 DMF 1 1 
19 42 DMF 1 1 
aReaction conditions: 500 μM substrate 1, 1 mol% catalyst, 0.5 mol% Sav-WT (tetramer), PBS-buffer (1x, pH 7.4), 0.5% co-solvent, 
25°C, 18 h. The catalyst was dissolved in the co-solvent and added to the aqueous buffer containing the protein and the substrate. 
bThe conversion was determined by fluorescence of the product 2 from single reactions. cComplex 7 was dissolved in MeCN followed 
by the addition of an equal amount of DMSO, resulting in a total co-solvent concentration of 1.0% in the reaction mixture. dReaction 
time = 29 h.  
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2.2.2 In vitro screening of streptavidin mutants 
In order to identify promising residues for mutagenesis, the optimized biotinylated ruthenium cofactor 
[CpRu(QA-Biot)(Sol.)]PF6 (27) was docked into streptavidin (Figure 10). The docking revealed that the 
catalytically active ruthenium center is most likely closely surrounded by the residues S112, K121 and L124. 
Other residues in close distance to the cofactor include, amongst others, the amino acids P64, A65, D67, R84, 
H87, T114, N118, H127 and D128 (see also chapters 2.3.2 and 2.5). In an initial screen, a nearly complete site-
saturation library at the positions S112 and K121 was tested (all mutants except S112I, K121I and K121T). For 
the other positions, a selection of mutants available within the Ward research group was tested. Finally, 
double and triple mutants as well as elongated loop constructs and combinations of loops with promising 
single mutants were tested. The results of this screening campaign are summarized in Figure 11.  
 
 
Figure 10: Protein-ligand docking of [CpRu(QA-Biot)(H2O)] (27) in Sav S112M-K121A (dimer).  
A biotin anchor was modelled into a crystal structure of [CpRu(QA)(Allyl)]PF6 (5) (Cambridge Structural Database Refcode: NAJLUG)85 
and the complete ruthenium cofactor (allyl ligand was replaced by a water molecule) was docked into a crystal structure of 
streptavidin (Protein Database entry: 3PK2).60 The docking was performed with the dimer of streptavidin. Protein in surface 
representation (color code for the residues: white = apolar, green = polar, red = acidic, blue = basic), biotinylated ruthenium complex 
represented as sticks (elements: H = white, C = cyan, N = blue, O = red, S = yellow, Ru = orange ball). Residues targeted for mutagenesis 
(see: Figure 11) are highlighted in yellow. For clarity, only residues from one of the two adjacent binding sites are labelled. For details 
of the docking procedure see chapter 4.2.1. Docking was done by Dr. Vincent Lebrun (University of Basel).  
Good catalytic activities were obtained for single mutants at the positions S112 (S112A, S112L, S112M), K121 
(K121A, K121L, K121R) and L124 (L124G). Especially the mutants S112M, K121R and L124G displayed 
significant increase in catalytic activity compared to Sav-WT or the free ruthenium cofactor.  
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 29 
However, no general trend for preferred side chains at the positions S112 and K121 was identified, except 
that negatively charged amino acids such as aspartate or glutamate as well as cysteine residues or structure 
breaking prolines performed poorly. Surprisingly, the mutant containing a methionine at position S112 
showed an increased catalytic activity (see also chapter 2.1.4). At position L124, small amino acids proved 
beneficial, which may be caused by the limited free space underneath the ruthenium cofactor (Figure 10).  
 
 
Figure 11: Screening of streptavidin mutants for the uncaging of coumarin 1.  
Activities of the mutants are displayed as “bubble chart”, in which the size of the bubbles corresponds to the determined fluorescence 
of the product. Reaction: see Scheme 6. The reaction conditions were adapted in the following way: 500 µM coumarin substrate 1, 2 
µM ruthenium cofactor 27 (in DMF), 4 µM streptavidin (free biotin binding sites), PBS-buffer (1x, pH 7.4), 0.5% DMF, 30°C, 300 rpm 
shaking, 18 h. Fluorescence of product 2 was determined at λex. = 395 nm and λem. = 460 nm from single reactions. List with all the 
numerical values: see Annexes, Table 15. The following proteins showed a reduced solubility in the used reaction buffer: N49Y, S112P, 
K121N-L124G, K121R-L124G, 66(GGS)2-K121R, 159TPR and 159TPR-K121R.  
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Having obtained these promising results for streptavidin single mutants, selected double mutants at positions 
S112X-K121X, N118X-K121X and K121X-L124X were tested (see also Table 9, entries 25-30). Thereby, a 
synergetic effect was obtained for the combinations of activated single mutants such as S112A, S112M, 
K121A and K121R. Especially the combination S112M-K121R revealed a highly increased catalytic activity. For 
the single mutant S112M a 2.9-fold and for the single mutant K121R a 3.7-fold higher fluorescence compared 
to streptavidin wild-type was obtained, respectively. The combined double mutant S112M-K121R exhibited 
a 7.1-fold higher overall fluorescence. Compared to the free cofactor, the double mutant S112M-K121R 
yielded a 16.3-fold higher fluorescence. The double mutant S112Y-K121R, displayed almost the same activity 
(15.6-fold increase in fluorescence compared to the free ruthenium cofactor). Inspired by these results, 
elongated streptavidin loop mutants including 66(GGS)2, 159TPR and Loop2 were tested (Table 9, entries 31-
35). Promising results were obtained for the 66(GGS)2-loop mutant, revealing a 1.3-fold higher conversion 
than Sav-WT. Combination with activated single mutants led again to a further increase in catalytic activity 
(66(GGS)2-S112M: 4.1-fold, 66(GGS)2-K121R: 4.7-fold). A selection of the best performing mutants was 
rescreened in triplicate to highlight the increased catalytic activity (Figure 12). The best performing double 
mutant, Sav-S112M-K121R, was finally combined with additional single mutations in an in vivo screen 
(chapter 2.3.2).  
 
 
Figure 12: Rescreening of the best streptavidin mutants for the uncaging of coumarin 1. 
Reaction: see Scheme 6. Reaction conditions: see Figure 11. Error bars = ± 1 standard deviation of a triplicate measurement.  
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2.3 Catalysis on the surface of E. coli cells 
Engineered E. coli cells, displaying selected proteins on their surface, are applied, amongst others, in whole-
cell bio-catalysis121-123, in the identification of enantioselective enzymes124 or in surface-tagging 
applications.125 In order to install the proteins of interest on the surface of E. coli cells, several outer 
membrane anchoring systems have been developed.126 Cell surface display brings along many advantages, in 
the evolution of enzyme catalysts and their practical application as well as in the development of cascade 
reactions. In the first one, it allows to screen large enzyme libraries since the individual members do not have 
to be extracted and purified in a time consuming process (e.g. fluorescence activated droplet sorting (FADS): 
see chapter 2.3.3). Issues along with the uptake of required cofactors and substrates into the cell as well as 
with the subsequent release of the product cannot occur (see chapter 3: catalysis in the periplasm). The 
product can be separated by filtration and the catalyst (E. coli cells) can potentially be recycled. Cell surface 
displayed non-natural enzymes can also be combined with natural enzymes to engineer cascade reactions. 
Furthermore, by having a compartmentalization between one enzyme outside (e.g. an artificial 
metalloenzyme) and a potential cascade partner inside the cell, also two incompatible (artificial) enzymes 
can be combined (see chapter 3: cascade reactions).  
 
2.3.1 Design of a surface displayed streptavidin construct 
Streptavidin surface display on E. coli cells, using the autotransporter domain AIDA-I (adhesin involved in 
diffuse adherence), was reported by Pyun et al.127 The presence of streptavidin on the surface of E. coli was 
confirmed by SDS-PAGE analysis of the outer membrane proteins as well as by flow cytometry analysis of 
cells labeled with a biotinylated fluorophore. The expression level was estimated to be ~1.6 · 105 
molecules/cell, which would correspond to a streptavidin concentration of ~0.26 μM at a cell density of OD600 
= 1, assuming that 1 ml of a cell solution at OD600 = 1 contains ~109 cells.128  
Herein, we designed a surface displayed streptavidin variant based on the Lpp-ompA anchoring system.129-
130 The used construct is based on the work of Georgiou et al.131 The empty pBAD33 plasmid (provided by 
Prof. Dehio, University of Basel), containing a Para promoter and an araO operon, was equipped with the 
gene-cassette Lpp-ompA-T7-Sav (Lpp-ompA provided by Dr. Pinheiro, University College London) to express 
and translocate the surface-displayed streptavidin (Figure 13). This cassette is composed of the Lpp signal 
peptide, followed by the first 9 amino acids of the E. coli lipoprotein Lpp and a truncated version (amino acids 
46 to 159) of the outer-membrane protein ompA. Via a glycine linker, the full-length streptavidin (amino 
acids 13 to 159; codon optimized DNA-sequence132) bearing an N-terminal T7 solubility tag is attached. The 
expression of this construct is induced by addition of L-arabinose (L-ara). The cloned plasmid was 
transformed into E. coli TOP10(DE3) cells for expression and catalysis. The presence of the designed 
streptavidin construct on the surface of E. coli cells was evaluated by i) labelling of the cells with a biotinylated 
fluorescent dye and ii) staining of the cells with a fluorescent streptavidin antibody system.  
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Figure 13: pBAD33 plasmid map and location of the Lpp-ompA-T7-Sav surface construct on the outer membrane of E. coli.  
a) Schematic map of the pBAD33 plasmid containing the Para promoter, the araO operon, the Lpp-ompA-T7-Sav gene cassette as 
well as an antibiotic resistance against chloramphenicol (Camres). The empty pBAD33 plasmid was provided by the research group of 
Prof. Dehio (University of Basel). The Lpp-ompA gene was provided by Dr. Vitor Bernardes Pinheiro (University College London). 
Cloning was carried out by Dipl.-Biol. Juliane Klehr and Dr. Tillmann Heinisch (Ward group, University of Basel). b) Location of the 
Lpp-ompA anchor in the outer membrane of E. coli with the T7-Sav pointing towards the medium.  
In the first method, cells expressing the surface streptavidin construct were incubated with a biotinylated 
Atto-dye (Atto-565-biotin), washed and analyzed by flow cytometry (Figure 14). Induced cells, both Sav-WT 
and mutant S112M-K121A, displayed a highly increased fluorescence compared to non-induced cells or cells 
containing an empty pBAD33 plasmid. This indicates that the Lpp-ompA-T7-Sav construct is indeed expressed 
and can bind to a biotinylated fluorophore. However, this finding did not completely establish the presence 
of the streptavidin construct on the surface of E. coli, since the applied fluorophore also tends to enter the 
periplasmic space.64 At this point, testing the integrity of the outer membrane is also crucial.129  
 
 
Figure 14: Atto-565-biotin staining of E. coli cells expressing surface-displayed streptavidin.  
Reaction steps: 1) Sav surface expression in E. coli TOP10(DE3) cells containing the pBAD33 plasmid (LB-medium, 30 °C, 4 h, induction 
with 0.2 % L-arabinose (ara)); 2) Incubation with Atto565-biotin (2 μM in PBS-buffer, pH 7.4) for 30 min; 3) 2x washing of cells with 
PBS-buffer (pH 7.4); 4) Fluorescence analysis of the cells by flow cytometry.  
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A staining of the cells with a streptavidin antibody, which itself is too big to enter the periplasm, was 
performed. Cells were first treated with a mouse-anti-streptavidin antibody, followed by labeling with a 
fluorescein isothiocyanate-tagged goat-anti-mouse antibody. The cells were then analyzed by flow cytometry 
and fluorescence microscopy (Figure 15). Three types of cells were investigated: cells expressing cytoplasmic 
streptavidin, cells expressing periplasmic streptavidin and cells containing the surface streptavidin construct. 
Both, cells with the cytoplasmic streptavidin construct as well as cells with the periplasmic streptavidin 
construct revealed only a low fluorescence, whereas cells containing the surface-displayed streptavidin were 
shifted to higher fluorescence intensities in the histogram of the flow cytometry analysis (Figure 15, a). The 
same result was obtained for the fluorescence microscopy analysis. Cells containing the surface displayed 
streptavidin glowed, whereas almost no fluorescence was obtained for the periplasmic streptavidin construct 
(Figure 15, b). These results clearly indicate that the designed Lpp-ompA-T7-Sav construct is expressed and 
located on the outer membrane of the E. coli cells, and that the streptavidin is pointing towards the medium. 
However, at this point it remains still unclear in which oligomeric state the surface displayed streptavidin is. 
In the Lpp-ompA-T7-Sav construct, streptavidin is expressed and displayed on the E. coli surface as monomer. 
It is assumed that four of these surface-displayed constructs can be combined to form a streptavidin 
tetramer. Monomeric streptavidin still shows a moderate affinity for biotin, but its thermal stability is 
significantly decreased compared to the tetramer (monomeric Sav-V55T-T76R-L109T-W120A-V125R: Kd = 
123 nM, Tm = 31°C).47 The thermal stability as well as the affinity for biotin of the monomeric streptavidin can 
be increased by introduction of additional stabilizing mutations47 or by combination with protein sequences 
from rhizavidin.133 Mutations, which interrupt the dimer-dimer interface in the tetrameric state (e.g. V55T, 
T76R, L109T or V125R)46 could be introduced into our surface-displayed streptavidin construct as well. 
Obtaining a lower fluorescence intensity in the Atto-565-biotin staining or different results in catalysis might 
indirectly confirm the hypothesis that the surface-displayed streptavidin construct forms a tetramer. In a 
different approach, the surface-displayed streptavidin constructs can be crosslinked using 
bis[sulfosuccinimidyl] suberate134, assuming that they are present on the E. coli surface as a tetramer. After 
cell lysis, the oligomeric state of the (crosslinked) surface-displayed constructs can be investigated by SDS-
PAGE or Western Blot.135-136 Alternatively, the proposed tetrameric nature of the surface-displayed 
streptavidin construct might be investigated by Förster resonance energy transfer (FRET).137-138  
Based on the positive results obtained in the Sav-antibody staining experiment, catalytic deprotection of the 
caged coumarin substrate 1, applying these surface-displayed streptavidin constructs, was tried next. Cells 
containing the pBAD33 plasmid were cultivated and loaded with the biotinylated ruthenium cofactor 
[CpRu(QA-Biot)(Sol.)]PF6 (27). Potentially residual cofactor was washed away, caged substrate was added 
and the cells were incubated overnight. The performance of the Sav-WT construct as well as the activity of 
the previously identified promising double mutant S112M-K121A (see also Figure 12) was investigated. 
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Figure 15: Sav-antibody staining of E. coli cells expressing surface-displayed streptavidin.  
a) Flow cytometry analysis of cytoplasmic, periplasmic and surface-displayed streptavidin in E. coli TOP10(DE3). Cells were labelled 
with a primary mouse-anti-streptavidin antibody in combination with a secondary fluorescein isothiocyanate-tagged goat-anti-mouse 
antibody. b) Fluorescence microscopy pictures of the cell cultures (merged white-light and fluorescence picture). Baumann and 
Kleanthous et al. found, that outer-membrane proteins tend to accumulate at the poles of the cells when they are expressed.139 
Antibody staining experiments and fluorescence analysis were performed by Dr. Tillmann Heinisch (Ward group, University of Basel) 
with the help of Dr. Rosario Vanella (group of Prof. Michael Nash, University of Basel) according to the protocol of Wittrup et.al.140  
Cells containing an empty pBAD33 vector and two samples containing purified ArMs were tested as controls 
(Figure 16). For cells containing an empty pBAD33 plasmid (i.e. they do not contain the Lpp-ompA-T7-Sav 
gene cassette) as well as for all non-induced samples (-ara; i.e. expression of the surface streptavidin 
construct is not switched on), only a minimal background fluorescence was observed. For the induced wild-
type construct (WT, +ara) a minor fluorescence was determined, whereas the double mutant (S112M-K121A, 
+ara) revealed a highly increased activity. 12-fold higher fluorescence intensity was determined for mutant 
S112M-K121A compared to the wild-type construct. Compared to the non-induced double mutant (S112M-
K121A, -ara), a >30-fold increase in fluorescence intensity was determined for the induced one (S112M-
K121A, +ara), which expressed the surface streptavidin.  
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The surface displayed double mutant S112M-K121A even exceeded the activity of 1 μM purified wild-type 
metalloenzyme (1 uM ArM-WT). The determined standard deviations for triplicate measurements are small 
(<15%), thus indicating a good reproducibility of the assay.  
 
 
Figure 16: Deprotection of caged coumarin 1, applying ArMs displayed on the surface of E. coli cells.  
Reaction steps: 1) Sav surface expression (see Figure 14); 2) Normalization of the cell density to OD600 = 2.0; 3) Exchange of the 
medium with PBS-buffer (pH 7.4) containing 2 μM ruthenium cofactor [CpRu(QA-Biot)(Sol.)]PF6 (27), incubation for 30 min on ice; 4) 
Exchange of the medium with PBS-buffer (pH 7.4) containing 500 µM allyl-coumarin substrate 1; 5) Catalysis: 16 h, 30 °C, 310 rpm 
shaking, followed by determination of the fluorescence (λex. = 395 nm, λem. = 460 nm). Displayed values are corrected for cell density 
(OD600). Error bars = ± 1 standard deviation of a triplicate measurement. ara = L-arabinose (inducer), WT = wild-type Sav, MA = mutant 
S112M-K121A. The screening was performed with the help of Dr. Tillmann Heinisch (Ward group, University of Basel).  
The results clearly demonstrated that: i) streptavidin can be expressed and displayed on the outer membrane 
of E. coli bacteria, ii) the surface-displayed streptavidin can bind a biotinylated fluorophore (Atto565-biotin) 
as well as a biotinylated ruthenium complex ([CpRu(QA-Biot)(Sol.)]PF6 (27)), and iii) the surface-displayed 
ArMs are functional and their activity can be optimized by mutagenesis. Surface-displayed streptavidin 
constructs are thus suitable for directed evolution of the performance of the designed artificial allylic 
deallocases. The mutants can be expressed and displayed on the surface of E. coli cells without time intensive 
extraction and purification of the individual streptavidin variants (see chapter 4.2.8). The cofactor and the 
substrate can be added to the cell cultures and the product formation can be monitored by determination of 
the fluorescence. This simple experimental setup allows for high-throughput screening in the 96-well plate 
format. Thus, a library of streptavidin variants containing mutations at several promising positions within the 
biotin binding vestibule can be examined.  
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2.3.2 Screening of surface-displayed streptavidin libraries 
In order to expand the mutant diversity for the deprotection of coumarin substrate 1 using the artificial allylic 
deallocase Sav · [CpRu(QA-Biot)(Sol.)]PF6, potentially promising positions in the biotin binding vestibule of 
streptavidin were scanned. Beside the previously identified residues S112 and K121 (chapter 2.2.2), especially 
the loops between the β-barrels of streptavidin were examined. As shown by Jeschek et al.64 and Hestericová 
et al.63, an increased loop flexibility in general resulted in a higher catalytic activity of the artificial 
metalloenzyme. A similar effect was reported by Tezcan et al. for an artificial β-lactamase.141 Crystal 
structures of catalytically highly active Sav mutants (PDB entries 5F2B64 and 6ESS63) revealed increased B-
factors for the loop regions. In order to increase the flexibility of those loops, hydrogen bond networks within 
the loops were targeted for deletion as well as removal of steric clashes (Figure 17).  
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Figure 17: Hydrogen bond network in the loop regions of streptavidin.  
Hydrogen bonds: dotted red lines, preserved waters: blue, protein backbone: grey, side chains: black, previously identified residues 
with mayor influence on catalysis (Ser112, Lys121): orange, biotinylated ruthenium cofactor: green, possible steric clashes: red curves.  
With these aims in mind, the following 7 residues were selected for mutagenesis: Val47 and Ala119 (minimizing 
steric clashes), Asn49 (interrupting hydrogen bond to Arg84), Thr114 and Asn118 (interrupting hydrogen bonds 
to Thr115), Ser122 (interrupting extended hydrogen bond network) and Leu124 (directly located underneath the 
ruthenium cofactor). Their location in the streptavidin binding vestibule is illustrated in Figure 18.  
Single site saturation mutagenesis libraries were created for these 7 residues. Each position was tested 
independently. The best performing mutants at each position were then combined, hoping for a synergetic 
effect, resulting in a highly evolved variant.  
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Alternatively, an iterative saturation mutagenesis approach could have been used, in which the best hit of 
the first single site library serves as a template for the next (iterative) mutagenesis round.142 In this strategy, 
propitious mutations can be identified in a straightforward way. However, this approach does not allow a 
time-saving parallel screening of the single site libraries.  
 
 
 
Figure 18: Selected mutagenesis sites in the artificial allylic deallocase [CpRu(QA-Biot)(H2O)]·Sav S112M-K121A.  
The biotinylated cofactor [CpRu(QA-Biot)(H2O)] (27) was docked into a crystal structure of streptavidin (Protein Database entry: 
3PK2).60 The docking was performed with the dimer of streptavidin (see chapter 4.2.1). Protein represented as grey cartoon. 
Biotinylated ruthenium complex represented as sticks (elements: H = white, C = cyan, N = blue, O = red, S = yellow, Ru = orange ball). 
Residues targeted for mutagenesis are highlighted as sticks (Val47, Asn49, Thr114, Asn118, Ala119, Ser122 and Leu124). Residues targeted 
in the in vitro screening are displayed as well (Ser112 and Lys121). For clarity, only residues from one of the two adjacent binding sites 
are displayed. Loop regions in close proximity to the ruthenium cofactor are highlighted as yellow tubes. These includes the following 
loops: loop 3,4: Ser45…Arg53, loop4,5: Asp61…Gly70 (located on the adjacent monomer), loop 5,6: Asn81…Arg84, loop 7,8: Gly113…Ser122. 
Protein-ligand docking was done by Dr. Vincent Lebrun (University of Basel).  
In order to generate the seven single site saturation mutagenesis libraries, PCR primers with degenerate 
codons were designed. The traditional NNK codon (32 codons/20 amino acids) requires an oversampling of 
94 clones to ensure 95% coverage.143 Alternatively, the so-called “22 codon trick” can be applied.144 In this 
method, a mixture of primers with degenerate codons (NDT, VHG and TGG) is used, which reduces the 
screening effort to 66 clones per single site library. The seven single site saturation mutagenesis libraries 
were created applying the latter method.  
Preparation of the libraries and screening was done by Dr. Tillmann Heinisch and BSc Brett Garabedian (Ward 
group, University of Basel). Based on the in vitro screening results (Figure 11 and Figure 12), the highly active 
double mutant S112M-K121R was selected as parent for the seven libraries. Thus, all members of these 
libraries are triple mutants (S112M-K121R + third single mutation).  
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The quality of each library was verified by analyzing the sequences of 13 randomly picked clones (e.g. analysis 
of the library S122X stated the following results: 4x wild-type, 8x unique mutant and 1x unclear sequencing 
result). Sequence analysis revealed a good quality for the libraries V47X, N49X, T114X, A119X, S122X and 
L124X. For the library at position N118 the PCR did not work satisfactorily. Thus, this library was not included 
in the screening. Overall, 6 single site saturation libraries with a total of 120 mutants were tested. The 
screening itself was performed in the 96-well plate format. 88 clones per library were picked, which led to a 
>95% statistical coverage of all possible mutants. The remaining 8 wells in the 96-well plate contained control 
samples including i) 2x pure medium to assure a sterile handling of the plates and to exclude any 
contamination, ii) 2x free biotinylated ruthenium cofactor, iii) 2x streptavidin wild-type, and iv) 2x mutant 
S112M-K121R. First, a complete 96-well plate only containing the mutant S112M-K121R was prepared. This 
was done to test the reliability of the screening protocol and to exclude any positional bias on the plate. Cell 
samples at the edges of a 96-well plate can potentially be better aerated and therefore show a faster 
proliferation or a higher protein expression. An equal distribution of cell growth and catalytic activity was 
obtained over the whole plate. A standard deviation of the fluorescence of the coumarin (2) of only 9% was 
determined. Afterwards, the libraries V47X, N49X, T114X, A119X, S122X and L124X were screened. For the 
library V47X, only clones with decreased activities compared to the S112M-K121R parent were found. The 
residue V47 is located in the biotin-binding loop and part of the interface between two adjacent monomers. 
Mutations replacing the valine seem not be tolerated at all. For the remaining 5 libraries (N49X, T114X, 
A119X, S122X and L124X), a selection of the best performing clones was rescreened. Clones, for which the 
increased activity compared to the S112M-K121R parent could be confirmed in the rescreening, were 
sequenced. The 7 best performing clones, displaying activities greater than the one from the parent plus two 
times the standard deviation, turned out to all contain the mutation S122N. This result clearly demonstrated 
the reliability of the assay to identify activated mutants. Compared to the parent S112M-K121R, the triple 
mutant S112M-K121R-S122N performed around 30% better in the in vivo screening. This triple mutant will 
be purified to determine whether the elevated activity is caused by the additional S122N mutation or is just 
an effect of different expression levels in the E. coli surface display. Combinations of this triple mutant with 
other single site libraries will be further investigated to evaluate any synergetic effects.118 In addition, crystal 
structure analysis of the triple mutant S112M-K121R-S122N would be of high interest, since the side chain of 
the residue at position 122 is pointing away from the biotin-binding site (compare Figure 18). A mutation 
from serine to asparagine might induce a rearrangement of the backbone of loop 7,8 and thus initiate a 
structural change of the biotin binding vestibule.  
With this screening assay in hand, medium-sized libraries can be investigated in reasonable times. Testing 
the seven single-site libraries, including preparation of the libraries and rescreening, took about 5 weeks. The 
working effort can be divided into i) preparation of the libraries including quality control (~2 weeks), ii) 
screening of the libraries (~2 weeks), and iii) rescreening and sequencing of the best hits (~1 week).  
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Since the complete assay was performed in 96-well plates (see chapter 4.2.4), it can be easily adapted for 
automated screening using robots. This would allow to screen up to 10`000 mutants per month. This number 
can be significantly increased if the screening is performed in micro-droplets in combination with 
fluorescence activated droplet sorting (FADS).  
 
2.3.3 Micro-droplet system for ultrahigh-throughput screening 
Fluorescence activated droplet sorting (FADS) is a very powerful tool for the directed evolution of enzymes. 
It combines compartmentalization, as given in microtiter plates, with the ultrahigh-throughput sorting 
capacity of conventional fluorescence activated cell sorting (FACS).145-146 The individual members of a library 
are separately encapsulated in water-in-oil emulsions, which ensures a genotype-phenotype linkage.147 The 
formed monodisperse droplets have diameters in the range of 5-120 μm, which corresponds to internal 
volumes of approximately 0.05-1000 pL.146 The droplets can then be sorted based on their fluorescence 
intensity with frequencies of up to 2000 s-1.145 This corresponds to a sorting capacity of up to 7.2 million 
droplets per hour. A "gedankenexperiment": an enzyme library with simultaneous site-saturation at five 
positions consists of 205 = 3.2 million members. This library could be sorted, including oversampling, in a few 
hours. This clearly demonstrates the potential of this method. FADS was applied, amongst others, in the 
directed evolution of artificial retro-aldolases148, arylsulfatases149 and horseradish peroxidases.150  
In this thesis, we aimed for the evolution of an artificial allylic deallocase ([CpRu(QA-Biot)(H2O)] (27) · Sav) 
for the deprotection of a caged coumarin substrate using droplet sorting. The formed fluorescent product, 
coumarin 2, showed a long residence time (>5 days) inside of the droplets.120 This is an indispensable 
requirement to avoid cross-contamination between different droplets. The microfluidic chip for the 
formation of the droplets was developed, produced and operated by MSc Philipp Rottmann (DBSSE, ETH 
Zürich), based on the work of Fischlechner and Hollfelder et al.151 E. coli TOP10(DE3) cells, expressing the 
surface-displayed Lpp-OmpA-T7-Sav construct, were incubated with the biotinylated ruthenium cofactor. 
The excess of non-bound ruthenium complex was washed away. The cells were then, on the microfluidic 
chip, mixed with a solution of the caged substrate (1) and encapsulated in water-in-oil emulsions (Figure 19, 
a-c). Monodisperse droplets with a diameter of ~21 μm and an internal volume of ~5 pL were formed at a 
rate of ~104 droplets per second. The E. coli cell solution that was used was diluted to an OD600 of 0.2, which 
resulted in a final concentration of ~0.33 cells/droplet, assuming that 1 ml of a cell solution at an optical 
density of OD600 = 1 contains ~109 cells.128  
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Figure 19: Production of water-in-oil droplets on a microfluidic device.  
a) Design of the microfluidic chip for the production of water-in-oil emulsions. The chip contains three inlets: i) cell suspension (flow 
rate = 60 μL/h), ii) substrate solution (flow rate = 120 μL/h), and iii) fluorinated oil (flow rate = 600 μL/h), as well as an outlet for the 
produced droplets. b) Enlargement of the double junction of the microfluidic chip. Cells get first mixed with the substrate solution 
(junction at the righthand side) before they are encapsulated in the fluorinated oil (junction at the lefthand side). c) Formation of 
water-in-oil droplets at the water/oil junction with a rate of ~104 droplets/second. The produced droplets are monodisperse with a 
diameter of ~21 μm and an internal volume of ~5 pL. d) Water-in-oil droplets right after the production. A part of the droplets contain 
E. coli cells (little black dots). The picture was taken under bright field. e) Fluorescence microscopy picture of droplets containing 500 
μM coumarin substrate 1 (no cells), 216 ms exposure time. f) Fluorescence microscopy picture of droplets containing 500 μM 
coumarin product 2 (no cells), 216 ms exposure time. g) Picture of encapsulated cells after overnight incubation. Proliferation of E. 
coli cells (white dots) was obtained. The picture was taken under bright field. h) Double emulsions (water-in-oil-in-water) with an 
approximate diameter of ~42 μm directly after the production in the microfluidic device. The microfluidic chip for the formation of 
the droplets was developed, produced and operated by MSc Philipp Rottmann (DBSSE, ETH Zürich), based on the work of Fischlechner 
and Hollfelder et al.151 
b) 
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Based on a Poisson distribution with λ = 0.33, 71.9% of the droplets should be empty, 23.7% should contain 
one cell, 3.9% should contain two cells and 0.4% should contain three or more cells (compare droplets in 
Figure 19 d). In order to avoid any false positives during the screening, every droplet should only contain one 
mutant. The cell solution should therefore be further diluted before encapsulation, although this means that 
a higher number of droplets have to be analyzed. However, the produced droplets were then incubated 
overnight and analyzed by fluorescence microscopy (Figure 19, e-g). A defined amount of droplets was 
treated with a surfactant to break the emulsions. The fluorescence intensity of the aqueous phase was then 
quantitatively determined (Table 5).  
Table 5: Uncaging of coumarin 1 applying E. coli surface-displayed artificial allylic deallocases in water-in-oil emulsions. 
Entry Protein Ru-cofactord Washing Normalized fluorescencef 
1 Buffer only - n.a. 0.67 
2 Cells onlyb - Yes 1.00 
3 Cells onlyb 2 μMe Yes 2.33 
4 WT 2 μMe Yes 4.17 
5 S112M-K121A 2 μMe Yes 6.50 
6 Spikedc 2 μM n.a. 49.46 
Reaction conditions: LB-medium (50 mM NaH2PO4/Na2HPO4, pH 7.4), 500 μM coumarin substrate 1, 25°C, 19 h. A detailed 
experimental procedure is given in chapter 4.2.5. aThis sample did not contain the coumarin substrate. bNon-induced cells containing 
the Sav-WT construct. cSample containing purified artificial metalloenzyme (4 μM Sav-S112M-K121A (free biotin binding sites) + 2 
μM Ru-cofactor). dRu-cofactor = [CpRu(QA-Biot)(H2O)] (27). eThe non-bound Ru-cofactor was washed away before encapsulation of 
the cells. fA defined amount of droplets was treated with a surfactant to break the emulsions. The fluorescence intensity of the 
aqueous phase was then analyzed with a plate reader (λex. = 395 nm, λem. = 460 nm). The determined fluorescence intensities were 
normalized to the cellular background (entry 2).  
Cells containing Sav-WT showed a 4.17-fold increase in fluorescence compared to the background, whereas 
the double mutant S112M-K121A revealed a 6.50-fold higher fluorescence intensity (Table 5, entries 4 and 
5). For non-induced cells loaded with the ruthenium cofactor, a 2.33-fold increase was determined, which 
suggests that some of the cofactor unspecifically binds to the cells (Table 5, entry 3). The LB-medium itself 
also showed a background fluorescence at 460 nm (Table 5, entry 1). Compared to the sample containing 
purified ArM, the surface-displayed double mutant is not very active (Table 5, entry 6 vs. entry 5). However, 
these results suggest that catalysis, applying an E.coli surface-displayed artificial allylic deallocase, can be 
performed in micro-droplets.  
Encapsulated single cells were able to proliferate inside of the droplets (see Figure 19, g), and thus potentially 
more surface-displayed streptavidin can be produced over time. Co-encapsulation of an excess of ruthenium 
cofactor at the beginning might therefore result in a higher concentration of the active artificial 
metalloenzyme accompanied by a potential increase in catalytic activity. The catalytic efficiency of the system 
could be improved, assuming that i) the non-bound cofactor is not catalytically very active and ii) the 
ruthenium cofactor is stable in LB-medium until a high amount of streptavidin is expressed. More important, 
the difference in the catalytic activity between droplets containing Sav-WT and droplets containing an 
improved mutant might be increased.  
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In the current system, the double mutant S112M-K121A led to a 1.6-fold higher fluorescence intensity 
compared to the wild-type (Table 5, entry 5 vs. entry 4). This difference decreased significantly compared 
with the catalysis in free solution (12.4-fold difference between Sav-WT and mutant S112M-K121A, see 
Figure 16). At this point, it should be taken into account that the catalysis in free solution was performed at 
a cell density of OD600 = 2.0, whereas one cell in a 5 pL droplet approximately corresponds to a density of 
OD600 = 0.07.  
With the applied microfluidic chip, in addition to single emulsions (water-in-oil), also double emulsions 
(water-in-oil-in-water) can be produced. First single emulsions are produced as described in Figure 19, a-c. 
The single emulsions are then re-injected (in the former inlet for cells) with a simultaneous swapping of the 
substrate and the oil channel (Figure 19, a-b; the former substrate channel contains now fluorinated oil and 
the former oil channel contains now water). In this way, double emulsions with an approximate diameter of 
42 μm can be produced (Figure 19, h). This potentially allows to sort the droplets (double emulsions) with a 
normal FACS setup, rather than sorting the single emulsions directly on the microfluidic chip (FADS).  
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2.4 Design of a caged inducer system 
In this thesis, IPTG was caged with an O-allyl carbamate protective group, which can be cleaved by our 
designed artificial allylic deallocase (chapter 2.4.3). In this way, the expression of a GFP reporter protein can 
be regulated by the action of an artificial metalloenzyme (chapter 2.4.4). A closer look at a crystal structure 
of the lactose operon repressor, the target protein of IPTG, revealed a tight ligand binding including hydrogen 
bonds between the repressor protein and the 2’, 3’, 4’ and 6’-hydroxy groups of IPTG (PDB ID 1LBH).152 
Attachment of an O-allyl carbamate protective group would therefore probably inactivate the function of 
IPTG. In this way, several caged IPTG derivatives were synthesized and tested in catalysis.  
 
2.4.1 Self-immolative linkers 
IPTG does not contain any primary amine group, thus no O-allyl carbamate protective group can be directly 
installed. Either one of the alcohol groups of the sugar frame is substituted by a primary amine (chapter 3: 
2’-Amino-IPTG substrate) or the allyl function is introduced in the form of an allyl ether or an allyl carbonate. 
The latter one is not stable in aqueous solutions (chapter 2.4.3) and therefore not suitable for catalysis in the 
presence of E. coli cells. Alternatively, a traceless linker between an alcohol group of IPTG and the O-allyl 
carbamate protective group can be introduced. This can be achieved with the concept of the so-called self-
immolative spacers.153-154 Upon removal of the protective group, an active nucleophilic species is formed, 
which spontaneously undergoes a self-immolation based on elimination via electronic delocalization or via 
intramolecular cyclization to liberate the leaving group (Scheme 7).  
Applying self-immolative linkers allows to combine a variety of different protective and leaving groups, also 
those which cannot be introduced directly, as highlighted for IPTG and O-allyl-carbamates. This makes the 
concept of self-immolative linkers to a very powerful tool in catalysis.  
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Scheme 7: Self-immolation based on a) 1,4-elimination, b) 1,6-elimination, c) 1,8-elimination or d) intramolecular cyclization.153  
PG = protective group (i.e. O-allyl carbamate); LG = leaving group (i.e. HO-IPTG); X = O, NH or S; Y = O, NH, NMe or S; Z = CH, O, N;  
n = 1 or 2.  
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Self-immolations are generally driven by an increase in entropy and/or the formation of thermodynamically 
stable products (release of CO2, formation of 5- or 6-membered rings). However, the reaction velocity of such 
self-immolations, after the activation step has taken place, depends on:  
 
(i) The substituents on the aromatic rings. The reaction is faster with electron-donating groups such 
as R = OMe or R = NHMe, whereas electron-withdrawing substituents such as R = NO2 or  
R = CO2Me decrease the reaction speed (Scheme 7 a, b).153, 155-157  
 
(ii) The electronic and steric structure of the aromatic linker. Elimination takes place for a coumarin 
derivative (Scheme 7 c), whereas no reaction was obtained for the analogous naphthalene and 
biphenyl derivatives. It is assumed that this is caused by a too high energy barrier to break 
aromaticity, and by a non-planar structure preventing electron delocalization, respectively.158  
 
(iii) The linker between the aromatic moiety and the leaving group. Carbonate- and carbamate-linked 
leaving groups were released faster (up to 103-fold shorter half-life times) than their analogues 
linked via an ether function (Scheme 7 a, b).153, 155, 159  
 
(iv) The acidity of the leaving group. Higher rates were obtained for phenolic leaving groups if their 
respective pKa values decreased (Scheme 7 b).157 The same effect was determined for self-
immolation by cyclization (Scheme 7 d).160  
 
(v) The pH value and the temperature. Higher rates were obtained at high pH and temperature for 
a self-immolation based on 1,4-elimination (Scheme 7 a).155  
 
(vi) The functional groups Y, Z and the substituent R’ (Scheme 7 d). An enhanced intramolecular 
cyclization rate was obtained for R’ = Me, OH or cyclopentyl compared to R’ = H in the formation 
of lactams (Y = NH, Z = CH)153, 161, which could be explained by the Thorpe-Ingold effect162 and/or 
the reactive rotamer effect.163-164 In addition, faster cyclizations were obtained for 5-membered 
rings (n = 1) compared to 6-membered rings (n = 2) in the formation of ureas (Y = NH, Z = N, R’ = 
H or Me).165  
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2.4.2 Design and synthesis of caged IPTG substrates 
Three substrates containing self-immolative linkers and one substrate with a directly attached O-allyl 
carbonate protective group were designed (Figure 20).  
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Figure 20: Designed O-allyl carbonate/carbamate protected substrates for an artificial allylic deallocase.  
 
Due to its increased nucleophilicity, the primary alcohol at the 6’-position of the IPTG sugar frame offers a 
suitable anchor for attachment of protective groups and/or self-immolative linkers. In a first version, the 
protective group was directly attached to this alcohol in the form of an O-allyl carbonate (substrate 46). This 
concept was then expanded by the installation of a self-immolative linker based on a 1,6-elimination 
(substrate 50). Unfortunately, these two carbonate based substrates were not hydrolytically stable in the 
aqueous reaction medium used (see chapter 2.4.3). Therefore, two substrates containing an ester-linkage 
were designed. These substrates either contain an aliphatic (substrate 54) or an aromatic (substrate 58) self-
immolative linker based on intramolecular cyclization. These two substrates displayed an increased stability 
towards hydrolysis (see chapter 2.4.3). However, to make the caged IPTG substrates even more resistant, the 
use of a stable carbamate linkage is favorable (see chapter 3).  
The synthesis of the two IPTG-carbonates and the two IPTG-esters is summarized in Scheme 8 and can be 
divided into three parts. First, the linkers were treated with allyl chloroformate or allyl alcohol under basic 
conditions to attach the O-allyl carbamate/carbonate protective groups (compounds 44, 48, 52 and 56). The 
protected linkers were then activated in the form of p-nitrophenyl carbonates (compounds 44 and 49) or 
pentafluorophenyl esters (compounds 53 and 57). Finally, linkage with IPTG was achieved by treatment with 
4-(dimethylamino)-pyridine in pyridine (compounds 50, 54 and 58). In this process, the secondary alcohols 
of IPTG were not protected beforehand, which probably led to a decrease in conversion (12% – 39% for the 
last step).  
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Scheme 8: Synthesis of IPTG substrates bearing a caging group at the 6’-OH.  
Reaction conditions: a) Allyl alcohol (1.0 eq.), NEt3, DCM (dry), -10°C to r.t., 16 h; b) IPTG (1.0 eq.), DMAP (1.0 eq.), Pyridine, r.t., 18 
h; c) Allyl chloroformate (1.1 eq.), Pyridine, DCM, r.t., 3 h; d) 4-nitrophenyl chloroformate (43, 1.5 eq.), DIPEA, THF, r.t., 16 h; e) Allyl 
chloroformate (1.5 eq.), NaOH, H2O, 0°C, 5 h; f) Pentafluorophenyl trifluoroacetate (1.5 eq.), NEt3, DMF, 0°C to r.t., 3 h. g) Allyl 
chloroformate (1.50 eq.), NaOH, H2O, 0°C to r.t., 4 h; h) Pentafluorophenyl trifluoroacetate (0.85 eq.), NEt3, DCM, 0°C to r.t., 4 h. 
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2.4.3 In vitro evaluation of the best IPTG substrate 
The stability of the O-allyl carbonate/carbamate-protected IPTG substrates in the reaction medium at 
different pH’s as well as the performance of different ruthenium complexes and artificial allylic deallocases 
was investigated (Table 6).  
Table 6: Stability of IPTG substrates and performance of ruthenium complexes/artificial allylic deallocases.a  
Entry Substrate Complex Sav pH Reaction time Yield [%] 
1 46 - - 7.4 16 h 54 
2 46 [CpRu(QA-NMe2)(Allyl)]PF6 (7) - 7.4 16 h 73 
3 46 [CpRu(QA-Biot)(Sol.)]PF6 (27) - 7.4 16 h 61 
4 46 [CpRu(QA-Biot)(Sol.)]PF6 (27) WT 7.4 16 h 68 
5 46 [CpRu(QA-Biot)(Sol.)]PF6 (27) S112Y-K121R 7.4 16 h 79 
6 50 - - 7.4 16 h 57 
7 50 [CpRu(QA-NMe2)(Allyl)]PF6 (7) - 7.4 16 h 76 
8 50 [CpRu(QA-Biot)(Sol.)]PF6 (27) - 7.4 16 h 76 
9 50 [CpRu(QA-Biot)(Sol.)]PF6 (27) WT 7.4 16 h 70 
10 50 [CpRu(QA-Biot)(Sol.)]PF6 (27) S112Y-K121R 7.4 16 h 79 
11 54 - - 7.4 16 h 4 
12 54 [CpRu(QA-NMe2)(Allyl)]PF6 (7) - 7.4 16 h 33 
13 54 [CpRu(QA-Biot)(Sol.)]PF6 (27) - 7.4 16 h 7 
14 54 [CpRu(QA-Biot)(Sol.)]PF6 (27) WT 7.4 16 h 8 
15 54 [CpRu(QA-Biot)(Sol.)]PF6 (27) S112Y-K121R 7.4 16 h 13 
16 54b [CpRu(QA-Biot)(Sol.)]PF6 (27) WT 7.4 22 h 11 
17 54b [CpRu(QA-Biot)(Sol.)]PF6 (27) S112M 7.4 22 h 12 
18 54b [CpRu(QA-Biot)(Sol.)]PF6 (27) K121A 7.4 22 h 26 
19 54b [CpRu(QA-Biot)(Sol.)]PF6 (27) K121F 7.4 22 h 32 
20 54b [CpRu(QA-Biot)(Sol.)]PF6 (27) L124G 7.4 22 h 27 
21 58c - - 7.0 5 h 24 
22 58c [CpRu(QA-Biot)(Sol.)]PF6 (27) - 7.0 5 h 22 
23 58c [CpRu(QA-Biot)(Sol.)]PF6 (27) WT 7.0 5 h 26 
24 58c [CpRu(QA-Biot)(Sol.)]PF6 (27) S112M 7.0 5 h 30 
25 58c [CpRu(QA-Biot)(Sol.)]PF6 (27) K121F 7.0 5 h 35 
26 58c [CpRu(QA-Biot)(Sol.)]PF6 (27) L124G 7.0 5 h 40 
27 58c [CpRu(QA-Biot)(Sol.)]PF6 (27) S112M-K121A 7.0 5 h 61 
aReaction conditions: Phosphate-buffer (50 mM NaH2PO4/Na2HPO4), 0.9% NaCl, 500 μM substrate, 5 μM ruthenium cofactor, 10 μM 
Sav (free biotin binding sites), 0.5% DMF (for [CpRu(QA-Biot)(Sol.)]PF6 (27)) or 0.5% DMSO (for [CpRu(QA-NMe2)(Allyl)]PF6 (7)), 25°C, 
shaking (1000 rpm). Yields (concentration of liberated IPTG) were determined by UPLC-MS (see chapter 4.2.3). bComplete screening 
with a variety of Sav mutants at the positions S112X, K121X and L124X: see Table 16. cPhosphate buffered LB-medium (50 mM 
NaH2PO4/Na2HPO4, pH 7.0) was used for the catalysis with substrate 58.  
The two IPTG substrates bearing carbonate functions (substrate 46 and 50) turned out not to be hydrolytically 
stable in the reaction buffer at pH 7.4. High yields were determined also in the absence of any ruthenium 
cofactor (Table 6, entries 1 and 6; 54% and 57% yield, respectively). In contrast, substrate 54 bearing an 
aliphatic ester linker revealed high stability in the reaction buffer (Table 6, entry 11; 4% background 
hydrolysis). For the non-biotinylated ruthenium cofactor [CpRu(QA-NMe2)(Allyl)]PF6 (7) a 33% yield was 
obtained, whereas the biotinylated ruthenium cofactor [CpRu(QA-Biot)(Sol.)]PF6 (27) led to a conversion of 
7% (Table 6, entries 12 and 13).  
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Incorporated into streptavidin isoforms and upon prolonged reaction times (22 h instead of 16 h), 
conversions of up to 32% for the mutant K121F were obtained (Table 6, entries 14 – 20; for an extended 
mutant screening at positions S112X, K121X and L124X: see Table 16). However, the artificial allylic 
deallocases did not reveal high performances (only 32% yield in 22 h reaction time). Therefore, another 
substrate (58) bearing an aromatic ester linker was tested. This substrate is structurally related to the 
successfully applied coumarin derivative 1. Gratifyingly, with this IPTG substrate, higher conversions were 
obtained with shorter reaction times (5 h instead of 22 h). A set of promising streptavidin mutants from the 
former aliphatic substrate (54) was also applied for this aromatic substrate (58). Conversions of up to 61% 
for the double mutant S112M-K121A were obtained (Table 6, entries 21 - 27). However, this substrate 
revealed a high hydrolysis background in the reaction medium at pH 7.0 (Table 6, entry 21; 24% yield). 
Therefore, a pH screening was performed to potentially minimize this background (Table 7).  
Table 7: pH-screening for the deprotection of IPTG substrate 58.a 
Entry Complex Sav pH Yield [%] 
1 - - 6.0 5 
2 [CpRu(QA-Biot)(Sol.)]PF6 (27) - 6.0 8 
3 [CpRu(QA-Biot)(Sol.)]PF6 (27) WT 6.0 14 
4 - - 7.0 27 
5 [CpRu(QA-Biot)(Sol.)]PF6 (27) - 7.0 30 
6 [CpRu(QA-Biot)(Sol.)]PF6 (27) WT 7.0 32 
7 - - 8.0 71 
8 [CpRu(QA-Biot)(Sol.)]PF6 (27) - 8.0 71 
9 [CpRu(QA-Biot)(Sol.)]PF6 (27) WT 8.0 72 
Conversions for the substrate alone, the free ruthenium cofactor and the artificial wild type metalloenzyme were determined at 
different pH’s (6.0, 7.0 or 8.0) in phosphate buffer. aReaction conditions: Phosphate-buffer (50 mM NaH2PO4/Na2HPO4 at pH 6, 7 or 
8), 0.9% NaCl, 500 μM IPTG substrate 58, 5 μM ruthenium cofactor [CpRu(QA-Biot)(Sol.)]PF6 (27), 10 μM Sav (free biotin binding 
sites), 0.5% DMF, 30°C, shaking (300 rpm), 18 h. Yields (concentration of liberated IPTG) were determined by UPLC-MS analysis (see 
chapter 4.2.3). 
At pH 7.0 and 8.0 high hydrolysis backgrounds (27% and 71%, respectively) were obtained and no protein 
acceleration could be determined (Table 7, entries 4 – 9). Lowering the pH to 6.0 led to a decrease in 
background to 5% (Table 7, entry 1). Incorporation of the biotinylated ruthenium cofactor into wild-type 
streptavidin resulted in an elevated activity (Table 7, entries 2 and 3). Possessing a high stability and an initial 
activity with the wild-type metalloenzyme ([CpRu(QA-Biot)(Sol.)]PF6 (27)·Sav-WT), this IPTG substrate (58) 
offers an optimal starting point for further optimization. In this perspective, mutants at the positions S112X, 
K121X and combinations thereof were screened (Figure 21).  
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Figure 21: Screening of Sav isoforms for the deprotection of IPTG 58 using [CpRu(QA-Biot)(Sol.)]PF6 (27) · Sav.  
The substrate alone (sub. only), the free ruthenium cofactor 27 (free cof.) as well as a selection of artificial metalloenzymes were 
investigated. Aliphatic (alanine), Lewis base (methionine), charged (lysine and glutamate) and aromatic (tyrosine) mutations at 
positions S112 and K121 were tested. Reaction conditions: see Table 7. All reactions were performed at pH 6.0. Error bars = ± 1 
standard deviation of a triplicate measurement.  
A background reaction (hydrolysis of the substrate) of 4% was obtained, whereas the free ruthenium cofactor 
and the wild-type metalloenzyme yielded 9% and 18% conversion, respectively. The best mutations at both 
positions (S112M and K121A) were combined, leading to a positive synergetic effect. The double mutant 
S112M-K121A reached 96% conversion. This corresponded to a 5.5-fold increase in yield compared to the 
wild-type enzyme and a 10.8-fold increase compared to the free ruthenium cofactor. A crystal structure of 
the Sav mutant S112M-K121A bearing the ruthenium complex [CpRu(QA-Biot)(H2O)]PF6 is reported in 
chapter 2.1.4.  
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2.4.4 Catalysis in the presence of GFP reporter cells 
Inspired by the promising results obtained in the in vitro screening of streptavidin mutants for the uncaging 
of IPTG substrate 58 (Figure 21), the performance of the artificial metalloenzyme was tested in the presence 
of E. coli cells. A pCD353 plasmid (provided by the research group of Prof. Dehio, University of Basel)166 
containing a lac-operon167-168 followed by an GFP gene was transformed into E. coli cells (Figure 22).  
 
 
Figure 22: Schematic map of the pCD353-GFP plasmid.  
The pCD353 plasmid contains the Ptaclac promoter and the lacIq repressor, which binds to the lacO operon. The lacIq repressor is 
released from the lacO operon by binding of the IPTG inducer, which results in the expression of GFP. The plasmid furthermore 
contains a kanamycin antibiotic resistance (Kanres). The pCD353 plasmid was provided by the research group of Prof. Dehio, University 
of Basel. 166  
The designed system involves three steps: 1) Mixing of purified streptavidin (Sav) with biotinylated ruthenium 
cofactor ([CpRu(QA-Biot)(Sol.)]PF6 (27)) and subsequent formation of the artificial metalloenzyme (ArM), 
followed by the addition of the caged substrate and the GFP reporter cells. 2) Deallylation of substrate 58 by 
the ArM and subsequent release of IPTG via intramolecular cyclization. 3) Uptake of IPTG into the cytoplasm 
of the E. coli cells and expression of the GFP reporter (Scheme 9). The activity of the artificial metalloenzyme, 
represented in the amount of expressed GFP, can then be determined by fluorescence analysis of the cell 
culture.  
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Scheme 9: Catalysis in the presence of GFP reporter cells.  
Reaction steps: 1) Binding of the biotinylated ruthenium cofactor [CpRu(QA-Biot)(Sol.)]PF6 (27) to streptavidin (Sav) and formation 
of the artificial metalloenzyme (ArM). 2) Uncaging of the protected IPTG substrate 58 (reaction scheme on the right-hand side). 
Substrate 58 is deallylated by the ArM with a simultaneous loss of CO2. The primary amine spontaneously attacks the neighboring 
carbonyl to form a lactam and release a molecule of IPTG. 3) Uptake of IPTG into the cytoplasm of E. coli DH5α cell and induction of 
the GFP expression. Finally, the fluorescence of the cells can be determined photospectrometrically.  
 
Figure 23: GFP expression capacities of E. coli strains at different inducer concentrations and temperatures.  
Expression conditions: Studier-medium containing 50 μg/ml kanamycin (see chapter 4.2.4), 30°C or 37°C, 16 h, 96-well plate, 1 mL 
reaction volume, 280 rpm shaking. GFP-fluorescence determined at: λex. = 475 nm, λem. = 509 nm. The screening was performed by 
Dr. Tillmann Heinisch (Ward group, University of Basel).  
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Three E coli strains were tested for their capacity to express GFP at different inducer concentrations and 
reaction temperatures. It was aimed for a strain which i) expresses high amounts of GFP, ii) reveals a high 
sensitivity in terms of GFP expression at small IPTG concentrations, and iii) tolerates high amounts of IPTG 
until the GFP expression reaches saturation. TOP10(DE3), NEB® Turbo and DH5α E coli cells were tested at 
an IPTG concentration range from 0 – 2 mM and reaction temperatures of 30°C and 37°C, respectively (Figure 
23). The E coli strain DH5α, at an expression temperature of 30°C, fulfilled the criteria the best and was 
therefore selected for the proceeding experiments.  
The uncaging reaction using purified artificial allylic deallocases ([CpRu(QA-Biot)(Sol.)]PF6 (27) · Sav) was 
tested in the presence of E. coli DH5α reporter cells, applying the optimized reaction conditions (LB-medium, 
pH 6, 30°C). The background of the cells and the substrate alone, the activity of the free ruthenium cofactor 
as well as the performance of various streptavidin mutants was investigated (Figure 24). Thereby two 
different metal cofactor concentrations were tested: 1 μM and 5 μM.  
 
 
Figure 24: Performance of ArMs for the uncaging of IPTG substrate 58 in the presence of GFP reporter cells.  
Reaction conditions: Phosphate buffered LB-medium (50 mM Na2HPO4/NaH2PO4, pH 6.0), 500 μM IPTG substrate 58, 1 μM or 5 μM 
biotinylated ruthenium cofactor [CpRu(QA-Biot)(Sol.)]PF6 (27) in combination with 2 μM or 10 μM streptavidin isoforms (free biotin 
binding sites), 0.5% DMF, 30°C, reaction time = 15 h, E.coli DH5α reporter cells containing the pCD353-GFP plasmid at an initial cell 
density of OD600 = 0.7. GFP-fluorescence determined at: λex. = 475 nm, λem. = 509 nm. The values displayed are corrected for cell 
density (OD600). Error bars = ± 1 standard deviation of a triplicate measurement. The screening was performed with the help of Dr. 
Tillmann Heinisch (Ward group, University of Basel). 
The free biotinylated ruthenium cofactor [CpRu(QA-Biot)(Sol.)]PF6 (27) showed almost no activity above the 
cellular background, whereas in combination with Sav-WT, an increased fluorescence was observed. For 
mutants with improved activities in the in vitro screening (e.g. S112M, S112M-K121A; Figure 21) higher 
fluorescence intensities in the presence of GFP reporter cells were observed. This suggests that the catalytic 
activity of a streptavidin mutant correlates with the amount of expressed GFP.  
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With a low concentration of artificial metalloenzyme (1 μM ruthenium cofactor in combination with 2 μM 
streptavidin), mutant S112M-K121A led to a 2.3-fold higher fluorescence intensity compared with Sav-WT 
and to a 3.6–fold increased intensity compared to the free metal cofactor. With a higher cofactor 
concentration of 5 μM, the double mutant S112M-K121A reached full conversion, highlighted by a 
fluorescence intensity identical to the positive control containing 500 μM product (= IPTG).  
These experiments clearly demonstrate that i) an IPTG inducer can be protected with an O-allyl carbamate 
group in combination with a self-immolative linker, ii) the designed artificial allylic deallocases [CpRu(QA-
Biot)(Sol.)]PF6 (27) · Sav are active in vitro as well as in presence of E. coli cells, and iii) a biological event 
(expression of GFP) can be triggered with an artificial metalloenzyme.  
 
2.4.5 Design of a caged DmpR inducer system 
In order to extend the diversity of the caged inducer approach, beside the successfully applied caged 
IPTG/GFP expression system, also another inducer system based on the DmpR regulator was investigated. 
DmpR is a σ54-dependent regulator of the phenol catabolic pathway in Pseudomonas sp. Its function can be 
activated by the binding of phenols.169-170 A plasmid containing the DmpR regulator and an sfGFP reporter 
gene was designed and cloned by Dr. Tsvetan Kardashliev (Panke group, DBSSE ETH Zürich) based on the 
work from Shingler et al.171 The plasmid was subsequently transformed into E. coli DH5α cells for the 
evaluation of the induction capacity of different substituted anilines (Table 8). Assuming that these molecules 
are able to induce the GFP expression as well, they could be protected with an O-allyl carbamate function 
and serve as substrates for the artificial allylic deallocases.  
The methyl-, nitro-, chloro- or carboxylic acid-substituted aniline substrates showed no induction capacity 
(Table 8, entries 4-8). The unsubstituted aniline caused the expression of a small amount of GFP, whereas for 
the 4-hydroxy-substituted aniline substrate a high GFP fluorescence was obtained (Table 8, entries 3 and 9). 
Overall, a 76-fold increase in fluorescence intensity in presence of 4-hydroxyaniline compared to the negative 
control was determined (Table 8, entry 9 vs. entry 1). This represented a significant increase in the induction 
capacity, but did not completely reach the activity of the positive control (2-methylphenol; >350-fold 
increase; Table 8, entry 2 vs. entry 1). Based on the increased induction capacity of para-hydroxyaniline, the 
meta- and ortho-substituted analogues were investigated as well (Table 8, entries 10-13). The meta-
substituted hydroxyaniline was found to be the most active one, displaying a similar activity than the positive 
control (2-methylphenol; Table 8, entry 12 vs. entry 10). Therefore, an O-allyl carbamate protective group 
was attached to form the caged substrate 72.  
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Table 8: Induction capacity of various phenols and anilines for a designed DmpR regulator system.  
Entry Substrate Incubation time GFP fluorescence [AU] 
1 - 5 h 1100a 
2 2-Methylphenol 5 h 405545a 
3 Aniline 5 h 5158a 
4 2,4,6-Trimethylaniline 5 h 902a 
5 3-Methylaniline 5 h 1066a 
6 4-Nitroaniline 5 h 905a 
7 4-Chloroaniline 5 h 1047a 
8 4-Aminobenzoic acid 5 h 1119a 
9 4-Hydroxyaniline 5 h 83678a 
10 2-Methylphenol 6 h 6213b 
11 2-Hydroxyaniline 6 h 2650b 
12 3-Hydroxyaniline 6 h 6041b 
13 4-Hydroxyaniline 6 h 355b 
Reaction steps: 1) E.coli DH5α cells containing the DmpR/sfGFP reporter plasmid were cultivated in LB-medium at 30°C to a cell 
density of OD600 = 0.6. 2) Dilution of the cells to OD600 = 0.05-0.08, followed by the addition of 500 μM substrate. 3) Incubation at 
30°C, 200 rpm shaking. 4) Analysis of the fluorescence intensity. aFluorescence intensity determined with a TECAN plate reader (λex. 
= 485 nm, λem. = 510 nm). The GFP fluorescence intensity was normalized to the cell density (OD600). bFlow cytometry analysis of the 
cells (median value of the fluorescence intensity is listed). The screening was performed by Dr. Tsvetan Kardashliev (Panke group, 
DBSSE ETH Zürich).  
Based on these results, the activities of artificial allylic deallocases towards the deprotection of caged 
hydroxyaniline 72 in presence of the DmpR/GFP-reporter cells were investigated. The non-biotinylated 
ruthenium complex [CpRu(QA-NMe2)(Allyl)]PF6 (7), the free biotinylated ruthenium cofactor [CpRu(QA-
Biot)(Sol.)]PF6 (27) as well as a variety of artificial allylic deallocases ([CpRu(QA-Biot)(Sol.)]PF6 (27) · Sav) were 
tested. Thereby, streptavidin mutants which already revealed an elevated activity towards the uncaging of 
the coumarin and the IPTG substrate (Figure 12 and Figure 24) were selected. The result of this screening is 
presented in Figure 25. The free biotinylated ruthenium cofactor (27) showed almost no activity. 
Incoorporated in streptavidin isoforms, higher activities were obtained. Especially the double mutant S112M-
K121A performed well, revealing a 4.9-fold higher fluorescence intensity than the Sav-WT. Compared to the 
free cofactor (27), a 9.2-fold increase was observed. In terms of activity, the double mutant S112M-K121A 
compares with the non-biotinylated ruthenium complex (7), which reached full conversion in 9 h. However, 
the activity of the artificial allylic deallocase [CpRu(QA-Biot)(Sol.)]PF6 (27) · Sav-S112M-K121A can potentially 
be further increased by directed evolution.  
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Figure 25: Screening of artificial allylic deallocases for the deportection of aniline substrate 72.  
Preparation of DmpR/GFP reporter cells: see Table 8. Reaction conditions: 500 μM substrate 72, 5 μM ruthenium complex ([CpRu(QA-
NMe2)(Allyl)]PF6 (7) in DMSO or [CpRu(QA-Biot)(Sol.)]PF6 (27) in DMF), 10 μM streptavidin (free biotin binding sites), 30°C, 9 h, 200 
rpm shaking. Cells cultures were analyzed in a TECAN plate reader. The GFP fluorescence intensity was normalized to the cell density 
(OD600). The screening was performed by Dr. Tsvetan Kardashliev (Panke group, DBSSE ETH Zürich).  
These experiments clearly demonstrated that i) the DmpR regulator can be activated by the binding of 
hydroxyanilines, ii) the designed artificial allylic deallocases can catalyse the deallylation of a caged 
hydroxyaniline substrate (72) in the presence of E. coli DmpR/GFP reporter cells, and iii) the “caged inducer 
approach” can be transferred from an IPTG/lac to a hydroxyaniline/DmpR system.  
The unsubstituted aniline only showed a modest induction capacity. Thus, a cascade reaction, in which an O-
allyl carbamate protected aniline substrate gets first deallylated by an artificial metalloenzyme and then 
hydroxylated by an oxidase (e.g. cytochrome P450), can be envisioned (chapter 3: cascade reactions).172 
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2.5 Streptavidin loop mutants 
In the Ward research group several streptavidin single site libraries were designed132, resulting in artificial 
metalloenzymes capable of catalyzing a variety of different reactions (see chapter 1.2). To optimize these 
artificial metalloenzymes, mostly residues within the biotin-binding vestibule in close proximity to the metal 
cofactor were targeted (i.e. S112, K121 or L124). A look at a crystal structure of such an enzyme revealed that 
the biotinylated metal-cofactor is exposed to the reaction medium (see chapter 2.1.4). This suggests that one 
hemisphere of the catalytic reaction space is not influenced by the protein scaffold. This decreases the 
potential of genetic optimization of ArMs. To increase the control of the reaction environment (i.e. the 
second coordination sphere6), it would be desirable to partially close the biotin binding vestibule. Ideally, lids 
may be placed on top of the biotin binding site to create a defined reaction environment for the catalytic 
event. Simultaneously, these lids should be flexible enough to allow the biotinylated catalyst and the 
substrate to enter the binding pocket. These lids can be composed of unstructured loops (e.g. (GGX)n 
motif173), or of more defined secondary structure elements (e.g. antiparallel β-sheets174, helix-turn-helix 
motif175-177 or coiled coil178). The elements to build these streptavidin chimeras179 can be of natural origin or 
computationally designed (e.g. Foldit-player design180). In addition to fusion proteins, the streptavidin 
scaffold may also be post-translationally modified.30, 181 Due to the symmetric structure of the streptavidin 
tetramer, the introduced elements will appear on both sides of two adjacent binding sites. Thus, these lids 
may have a significant influence on the second coordination sphere around the biotinylated cofactor. By 
placing a cysteine residue in the middle of such a lid, a disulfide bond may be created holding two lids 
together on top of the metal cofactor. In this way, the active site might even be further shielded. However, 
first suitable positions in the streptavidin sequence for the introduction of these secondary structure 
elements needed to be identified.  
 
2.5.1 Design of streptavidin loop mutants 
Streptavidin is a homotetrameric β-barrel protein, in which every monomer consists of eight antiparallel β-
sheets with seven interconnecting loops (Figure 26 a; see also chapter 1.2). To ensure the stability of 
streptavidin, the β-sheets were not targeted for mutagenesis or introduction of the lid structures. From the 
seven interconnecting loops, five lie in proximity of the biotinylated metal cofactor. These are namely the 
loops 1,2 (Asn23…Ser27), 3,4 (Ser45…Arg53), 4,5 (Asp61…Gly70, adjacent monomer), 5,6 (Ala78…Ala89) and 7,8 
(Thr111…Ser122). These loops could potentially function as an anchoring point for introduction of the desired 
lid structures (Figure 26 a, b). However, there are a number of critical residues involved in biotin binding or 
tetramer stability, which should not be touched. The strong biotin binding (avidin-biotin complex: Kd ≈ 10-15 
M)35 includes several hydrogen bonds (Asn23, Ser27, Tyr43, Ser45, Asn49, Ser88, Thr90, Asp128) and hydrophobic 
interactions (Trp79, Trp92, Trp108, Trp120 (from the adjacent monomer)).36, 39-41 Furthermore, the loop 3,4 
(Ser45…Arg53) adopts a closed position if biotin is bound.42  
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Indeed, by two point mutations in this loop (Sav S52G-R53D = traptavidin) the off-rate of free biotin was 
lowered 10-fold.182 On the other hand, by engineering of the loop 7,8 (Thr111…Ser122), a streptavidin variant 
with a reversible biotin binding capability was designed.183 In terms of tetramer stability, residues in the 
subunit interfaces (including Val55, Thr76, Thr90, Leu109, Trp120, Val125, His127 and Asp128) play a critical role.44-47 
Furthermore, there is an important inter-subunit salt-bridge between Asp61 and His87 (at physiological pH).48 
 
    
Figure 26: Design of streptavidin loop mutants.  
a) Schematic representation of full-length streptavidin. β-sheets in dark blue, interconnecting loops in light blue and additional 
secondary structure elements in orange (here inserted in the loop 3,4 (Ser45…Arg53)). b) Crystal structure of [Cp*Ir(biot-p-L)Cl] · Sav 
S112A (PDB ID 3PK2)60. Protein in surface representation (monomers displayed in red, green, yellow and translucent grey). 
Biotinylated iridium cofactor represented as sticks (C = cyan, N = blue, O = red, S = yellow, Cl = green, Ir = orange ball). Loops for 
insertion of secondary structure elements displayed as grey tubes. These include loop 3,4 (Ser45…Arg53), loop 4,5 (Asp61…Gly70, red 
monomer), loop 5,6 (Ala78…Ala89) and loop 7,8 (Thr111…Ser122).  
With these limitations in mind, the following positions were selected to insert the secondary structure 
elements in-between: G48…N49, T66…D67, R84…N85 and A117…N118. Position G48…N49 was selected although it is 
located in the loop 3,4 (Ser45…Arg53), and might therefore influence the binding affinity of the biotinylated 
metal cofactor. The selected positions are all located in the middle of interconnecting loops in proximity of 
the biotinylated metal cofactor (Figure 26 b). Lid structures introduced at these positions might therefore 
effectively shield the biotinylated cofactor and influence the catalytic properties of the artificial 
metalloenzyme. A drawback of this strategy is the necessity that the introduced lids have to adopt a circular 
structure. The end point of one β-sheet and the starting residue of the next β-sheet are spatially close 
together. Distances between the Cα atoms are as follows: Ser45…Arg53: 7.92 Å, Asp61…Gly70: 9.68 Å, 
Ala78…Ala89: 4.24 Å and Thr111…Ser122: 5.46 Å (determined in the crystal structure of [Cp*Ir(biot-p-L)Cl] · Sav 
S112A (PDB ID 3PK2)60). This problem can be avoided by the introduction of a circular permutation into 
streptavidin. As demonstrated by Stayton and Stenkamp et al.184, core streptavidin can be circularly 
permutated at the positions 48/49 or 49/50 with simultaneous connection of the former N- and C-termini 
(Ala13 and Ser139, respectively) by a GGGS-linker.  
a) b) 
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Using such a circular permutated streptavidin widens the scope of secondary structure elements for the 
creation of artificial lids on top of the biotin binding vestibule. A further anchoring point for the attachment 
of such lid structures would be the C-terminus of streptavidin. In the Ward research group full-length 
streptavidin (159 amino acids) with an N-terminal T7-solubility tag (positions 1-12) is used.56 Inspection of a 
crystal structure of apo full-length streptavidin (PDB ID 2BC3)185 revealed that the C-terminus occupies the 
biotin-binding site and may therefore be in close proximity to the biotinylated metal cofactor.  
 
2.5.2 Expression of streptavidin loop mutants 
The tolerance of streptavidin towards the introduction of loop structures on top of the biotin binding site 
was examined by the insertion of the small and flexible (GGS)2-motif at the positions G48…N49, T66…D67, 
R84…N85 and A117…N118 (Table 9, entries 1-4). All four Sav variants were expressed as soluble tetramers. 
Modelling of their structures revealed that the biotin binding vestibule is narrowed, especially for the 
48(GGS)2 construct (Figure 27). In order to further shield the biotinylated metal cofactor, combinations of 
these Sav variants were created. These designs bore the (GGS)2-motif at two positions simultaneously (Table 
9, entries 5-10). The combinations at positions 48+66 and 48+84 could be successfully expressed and purified.  
In a next step, the inserted loop between the positions G48…N49 was modified. The designed constructs, 
bearing a (GGX)n-motif (n = 2-8), were elongated to contain up to 24 additional amino acids (Table 9, entries 
11-18). All constructs were expressed as soluble biotin-binding tetramers, demonstrating the compatibility 
of streptavidin with an elongated loop 3,4. The structure of Loop2 was modeled applying homology modeling 
and structure refinement with YASARA (Figure 28 a). This modelling revealed that the biotinylated metal 
cofactor is most likely not completely shielded when an unstructured (GGX)n-motif is applied. A well-defined 
secondary structure element might better act as a lid on top of the biotin binding vestibule.  
Therefore, a 30 amino acid long helix-turn-helix motif from an idealized tetratricopeptide repeat (TPR)175, 186 
was investigated. The TPR motif was inserted between the positions G48…N49, T66…D67, R84…N85 and A117…N118, 
as well as at the C-terminus of core streptavidin (139TPR) and at the C-terminus of full-length streptavidin 
(Table 9, entries 19-24). From these six constructs, only the variant bearing the TPR-motif at the C-terminus 
of the full-length Sav (159TPR) could be expressed and isolated as a soluble biotin-binding tetramer. 
However, the construct 48TPR, initially obtained as an insoluble tetramer after the expression, was 
successfully denatured and refolded. The YASARA-modelled structure however suggested that the α-helices 
are bent to the back instead than lying on top of the biotin binding site (Figure 28 b). Introduction of a cysteine 
residue in the middle of the motif, along with the formation of a disulfide bond between two adjacent TPR’s, 
might force the lids to be placed on top of the biotinylated metal cofactor.  
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Figure 27: Modelled structures of elongated Sav loop mutants with (GGS)2 inserts at the positions G48, T66, R84 or A117.  
Elongated loop structures were generated from an X-ray crystal structure of homotetrameric Sav S112A bearing the biotinylated 
iridium cofactor [Cp*Ir(biot-p-L)Cl] (PDB ID 3PK2)60, applying homology modeling and structure refinement with YASARA. Protein in 
surface representation (residues: white = apolar, green = polar, red = acidic, blue = basic), biotinylated iridium complex represented 
as sticks (elements: H = white, C = cyan, N = blue, O = red, S = yellow, Cl = green, Ir = orange ball). The (GGS)2 loops are highlighted as 
yellow surface. (GGS)2 loops were inserted between the residues a) G48…N49, b) T66…D67, c) R84…N85 or d) A117…N118 (see also: Table 
9, entries 1-4).  
Finally, circular permutated core streptavidin variants were investigated (Table 9, entries 36-40). The circular 
permutation was performed at the position 64/68 and the former termini were connected with a GGGS-
linker (see Table 9 footer for sequences).184 The new constructs contained a 53 amino acid helix-turn-helix 
motif designed by Dr. Christine Tinberg in the research group of Prof. David Baker (University of Washington, 
Seattle). Rosetta calculations sugested that two neighboring motifs can form a four-helix bundle lid on top of 
the biotin binding site and effectively shield the metal cofactor (Figure 28 c, d). However, these constructs 
could only be expressed as insoluble inclusion bodies, as before obtained by Stayton and Stenkamp et al.184 
for their circular permutated core streptavidin. Initial attempts to refold these Sav variants failed.184, 187-188 In 
the meanwhile, a denaturing and refolding procedure was developed and these constructs are applied in 
catalysis.179  
 
a) b) 
c) d) 
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Figure 28: Designed Sav loop mutants containing defined secondary structure elements.  
a) Elongated (GGX)5 loop at position G48…N49 (Table 9, entry 12: Loop2). b) Idealized tetratricopeptide repeat175, 186 at position G48…N49 
(Table 9, entry 19: 48TPR). c/d) Circular permutated Sav bearing a helix-turn-helix motif at position P64 (Table 9, entry 37: Cp1) 
displayed as cartoon (c) or surface model (d). Elongated loop structures in a) and b) were generated from an X-ray crystal structure 
of homotetrameric Sav S112A bearing the biotinylated iridium cofactor [Cp*Ir(biot-p-L)Cl] (PDB ID 3PK2)60, applying homology 
modeling and structure refinement with YASARA. The circular permutated streptavidin in c) and d) was designed by Dr. Christine 
Tinberg in the research group of Prof. David Baker (University of Washington, Seattle) using Rosetta. a), b), d): Protein in surface 
representation (residues: white = apolar, green = polar, red = acidic, blue = basic), biotinylated iridium complex represented as sticks 
(elements: H = white, C = cyan, N = blue, O = red, S = yellow, Cl = green, Ir = orange ball). The inserted secondary structure elements 
are highlighted in yellow. c): Protein in cartoon representation. The four monomers of streptavidin are highlighted in different colors 
(blue, grey, green, red).  
 
 
a) c) 
b) d) Biotin binding 
vestibule 
 61 
In summary, 40 streptavidin (loop) mutants were designed, from which 28 could be expressed as soluble 
biotin binding tetramers. 19 variants were purified and from one (mutant S112M-K121A) a crystal structure 
with the bound ruthenium cofactor [CpRu(QA-Biot)(H2O)]PF6 (27) could be determined (chapter 2.1.4). Some 
of the loop mutants, especially the 66(GGS)2 and the 159TPR variants were successfully applied in catalysis 
(Figure 11 and Figure 12). In general, streptavidin showed a high tolerance towards the introduction of 
elongated loops. Five positions, suitable for the introduction of lid structures, were identified. These include 
the positions G48…N49, T66…D67, R84…N85, A117…N118 as well as the C-terminus. Unstructured (small) 
loops were successfully introduced at those positions. Replacement of these loops with longer well-defined 
secondary structure elements (e.g. helix-turn-helix motifs)189-193 might result in the creation of lids on top of 
the biotin binding site. Thus, the second coordination sphere around the biotinylated metal cofactor can be 
modified from all sites, potentially resulting in elevated activities and selectivities.  
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Table 9: Overview of designed and expressed streptavidin (loop) mutants.  
Entry Name Position(s) Sequence of insert(s) Length of insert 
Expression 
hostj 
Solubility and 
oligomeric state 
Mass of monomerc [Da] CFE Purified protein 
Calculated Determinedd FBBS
h 
[nmol/mg] 
Yielde 
[mg/l] FBBS
i Yield
f 
[mg/l] 
1 48(GGS)2 G48…N49 GGSGGS 6 TOP10(DE3) Soluble tetramer 16827.3 16828.1 2.7 549.6 n.d. 13.8 
2 66(GGS)2 T66…D67 GGSGGS 6 TOP10(DE3) Soluble tetramer 16827.3 16827.7 2.7 557.0 n.d. 16.3 
3 84(GGS)2 R84…N85 GGSGGS 6 TOP10(DE3) Soluble tetramer 16827.3 16828.0 2.8 529.4 n.d. 13.0 
4 117(GGS)2 A117…N118 GGSGGS 6 TOP10(DE3) Soluble tetramer 16827.3 - 2.6 235.4 - - 
5 48+66(GGS)2 
G48…N49 
T66…D67 
GGSGGS 
GGSGGS 6+6 TOP10(DE3) Soluble tetramer 17229.7 
g 6.2 338.0 n.d. 1.5 
6 48+84(GGS)2 
G48…N49 
R84…N85 
GGSGGS 
GGSGGS 6+6 TOP10(DE3) Soluble tetramer 17229.7 
g 5.6 489.0 n.d. 0.9 
7 48+117(GGS)2 
G48…N49 
A117…N118 
GGSGGS 
GGSGGS 6+6 TOP10(DE3) Soluble tetramer 17229.7 - 0.2 363.0 - - 
8 66+84(GGS)2 
T66…D67 
R84…N85 
GGSGGS 
GGSGGS 6+6 TOP10(DE3) Insoluble monomer 17229.7 - - - - - 
9 66+117(GGS)2 
T66…D67 
A117…N118 
GGSGGS 
GGSGGS 6+6 TOP10(DE3) Soluble tetramer 17229.7 - 0.2 383.0 - - 
10 84+117(GGS)2 
R84…N85 
A117…N118 
GGSGGS 
GGSGGS 6+6 TOP10(DE3) Insoluble monomer 17229.7 - - - - - 
11 Loop 1 G48…N49 GGDGGNGGSGGLGGCGGS 18 BL21(DE3) Soluble tetramer 17729.2 - 19.4 678.0 - - 
12 Loop 2 G48…N49 GGNGGNGGGGGVGGS 15 BL21(DE3) Soluble tetramer 17466.9 17468.3 22.0 580.0 n.d. 55.0 
13 Loop 3 G48…N49 GGIGGSGGGGGHGGRGGGGGVGGS 24 BL21(DE3) Soluble tetramer 18131.6 - 12.3 619.0 - - 
14 Loop 4 G48…N49 GGNGGSGGGGGGGGSGGSGGS 21 BL21(DE3) Soluble tetramer 17800.2 - 12.3 596.0 - - 
15 Loop 5 G48…N49 GGRGGGGGHGGCGGVGGS 18 BL21(DE3) Soluble tetramer 17749.3 - 17.0 1039.0 - - 
16 Loop 7 G48…N49 GGDGGS 6 BL21(DE3) Soluble tetramer 16855.3 - 15.8 630.0 - - 
17 Loop 8 G48…N49 GGCGGSGGGGGGGGGGGCGGS 21 BL21(DE3) Soluble tetramer 17775.2 - 10.8 544.0 - - 
18 Loop 9 G48…N49 GGCGGIGGS 9 BL21(DE3) Soluble tetramer 17070.6 - 15.4 519.0 - - 
19 48TPR G48…N49 TPR motif 36 TOP10(DE3) Insolublea 20402.1 n.d. - - n.d. 26.4 
20 66TPR T66…D67 TPR motif 36 TOP10(DE3) Insoluble monomerb 20402.1 - - - - - 
21 84TPR R84…N85 TPR motif 36 TOP10(DE3) Insoluble monomer 20402.1 - - - - - 
22 117TPR A117…N118 TPR motif 36 BL21(DE3) Insoluble monomer 20402.1 - - - - - 
23 139TPR S139… TPR motif 36 BL21(DE3) Insoluble monomer 18396.9 - - - - - 
24 159TPR Q159… TPR motif 36 BL21(DE3) Soluble tetramer 20402.1 20402.0 - - n.d. 63.0 
25 S112M-K121A - - 0 BL21(DE3) Soluble tetramer 16411.9 16412.6 - - 3.6 121.2 
26 S112M-K121N - - 0 BL21(DE3) Soluble tetramer 16454.9 16455.6 - - 3.6 19.8 
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27 S112M-K121R - - 0 BL21(DE3) Soluble tetramer 16497.0 16497.7 - - 3.9 129.7 
28 K121A-L124G - - 0 BL21(DE3) Soluble tetramer 16311.7 16312.0 - - 2.0 6.7 
29 K121N-L124G - - 0 BL21(DE3) Soluble tetramer 16354.7 16355.4 - - 2.0 11.4 
30 K121R-L124G - - 0 BL21(DE3) Soluble tetramer 16396.8 16397.5 - - 2.2 10.8 
31 66(GGS)2-S112M T66…D67 GGSGGS 6 BL21(DE3) Soluble tetramer 16871.4 16872.2 - - 3.6 115.1 
32 66(GGS)2-K121R T66…D67 GGSGGS 6 BL21(DE3) Soluble tetramer 16855.3 16856.4 - - 1.6 115.9 
33 Loop2-S112M G48…N49 GGNGGNGGGGGVGGS 15 BL21(DE3) Soluble tetramer 17511.0 17513.3 - - 4.0 188.3 
34 Loop2-K121R G48…N49 GGNGGNGGGGGVGGS 15 BL21(DE3) Soluble tetramer 17494.9 17497.5 - - 3.5 100.4 
35 159TPR-K121R Q159 TPR motif 36 BL21(DE3) Soluble tetramer 20430.1 20431.8 - - 3.1 83.9 
36 CpSav - Circular permutation - BL21(DE3) Insoluble monomer 14191.5 - - - - - 
37 Cp1 P64 Helix-turn-helix motif 57 TOP10(DE3) Insoluble monomer 20’694.6 - - - - - 
38 Cp2 P64 Helix-turn-helix motif 58 TOP10(DE3) Insoluble monomer 20’821.9 - - - - - 
39 Cp3 P64 Helix-turn-helix motif 59 TOP10(DE3) Insoluble monomer 20’965.0 - - - - - 
40 Cp4 P64 Helix-turn-helix motif 59 TOP10(DE3) Insoluble monomer 20’835.9 - - - - - 
aMostly insoluble monomer with a small B4F-binding insoluble tetrameric fraction. Protein was successfully refolded from insoluble inclusion bodies (detailed procedure described in chapter 4.2.8). The 
refolded protein bound B4F on the SDS-PAGE. After purification on iminobiotin sepharose beads, the refolded protein precipitated. Thus, no mass spectrum was determined. bRefolding of the protein 
failed. cMass of the streptavidin monomer without the N-terminal methionine. dMass was only determined for purified proteins. eDried cell free extract (CFE) powder per 1 L culture. fIsolated purified 
protein per 1 L culture. gPeak corresponding to desired product mass could not be detected in the MS analysis. hAmount of free biotin binding sites per weight of dried CFE powder. iFree biotin binding 
sites (FBBS) per streptavidin tetramer. jExpression conditions: see chapter 4.2.8.  
(GGS)2 motif: 
Example sequence of a streptavidin loop mutant with the (GGS)2 motif between residues G48 and N49 (including T7-tag): 
H2N—ASMTGGQQMGRDQAGITGTWYNQLGSTFIVTAGADGALTGTYESAVG48GGSGGSN49AESRYVLTGRYDSAPATDGSGTALGWTVAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFT 
KVKPSAASIDAAKKAGVNNGNPLDAVQQ—CO2H 
 
TPR motif: 
This helix-turn-helix motif is derived from an idealized 30 amino acid tetratricopeptide repeat175, 186 and is flanked by two short GGS-linkers (example: TPR motif at position 48, including T7-tag): 
H2N—ASMTGGQQMGRDQAGITGTWYNQLGSTFIVTAGADGALTGTYESAVG48GGSAEAWYNLGNAYYKQGDYDEAIEYYQKALELSGGN49AESRYVLTGRYDSAPATDGSGTALGWTVAWKNNYRNAHSATTWSGQYVGGAE 
ARINTQWLLTSGTTEANAWKSTLVGHDTFTKVKPSAASIDAAKKAGVNNGNPLDAVQQ—CO2H 
 
Circular permutation (CpSav): 
Circular permutation of T7-core streptavidin at position P64/G68, using a GGGS linker184: 
H2N—ASMTGGQQMGG68SGTALGWTVAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFTKVKPSAAS139GGGSA13EAGITGTWYNQLGSTFIVTAGADGALTGTYESAVGNAESRYVLTGRYD 
SAP64—CO2H 
 
Circular permutated Sav with an additional helix-turn-helix motif (Cp1-4), designed by Dr. Christine Tinberg in the research group of Prof. David Baker (University of Washington, Seattle): 
Circular permutation of T7-core streptavidin at position P64/G68, using a GGGS linker.184 At the new C-terminus a 53 amino acid long helix-turn-helix motif is attached via different linkers: 
Cp1: H2N—ASMTGGQQMGG68SGTALGWTVAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFTKVKPSAAS139GGGSA13EAGITGTWYNQLGSTFIVTAGADGALTGTYESAVGNAESRYVLT 
        GRYDSAP64SSTDQEKTALNMARFIRSQTLTLLEKLNELDADEQADIAESLHDHADELYRSVLARF—CO2H 
Cp2: H2N—ASMTGGQQMGG68SGTALGWTVAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFTKVKPSAAS139GGGSA13EAGITGTWYNQLGSTFIVTAGADGALTGTYESAVGNAESRYVLT 
        GRYDSAP64PSMTTQEKTALNMARFIRSQTLTLLEKLNELDADEQADIAESLHDHADELYRSVLARF—CO2H 
Cp3: H2N—ASMTGGQQMGG68SGTALGWTVAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFTKVKPSAAS139GGGSA13EAGITGTWYNQLGSTFIVTAGADGALTGTYESAVGNAESRYVLT 
        GRYDSAP64GWNMTAQEKTALNMARFIRSQTLTLLEKLNELDADEQADIAESLHDHADELYRSVLARF—CO2H 
Cp4: H2N—ASMTGGQQMGG68SGTALGWTVAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFTKVKPSAAS139GGGSA13EAGITGTWYNQLGSTFIVTAGADGALTGTYESAVGNAESRYVLT 
        GRYDSAP64GGNMTAQEKTALNMARFIRSQTLTLLEKLNELDADEQADIAESLHDHADELYRSVLARF—CO2H 
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2.5.3 3D-model printing 
The 3D-printing market has made a big leap forward in the past years, both in terms of technical innovation 
and economy. Nowadays, a wide range of three dimensional models, from small molecules up to large 
protein complexes, can be rapidly and cost-effectively printed in full colors. Several guidelines describe the 
preparation process of such models, starting from crystal structures.194-198 These models can help to visualize 
extended three dimensional structures and are used for educational purposes.199-201  
Herein, we built a 3D-model of an artificial metalloenzyme to visualize its binding pocket and residues in close 
proximity of the metal cofactor, which could be considered for mutagenesis. The 3D-print model was 
prepared based on a crystal structure of homotetrameric Sav S112A bearing the biotinylated iridium cofactor 
[Cp*Ir(biot-p-L)Cl] (PDB ID 3PK2).60 The Cα-trace of the protein backbone was rendered in ball-and-stick style. 
The biotinylated iridium cofactor was displayed as van-der-Waals spheres. 28 residues in close proximity of 
the metal cofactor were highlighted as sticks.132 In order to increase the rigidity of the model, stabilizing 
artificial connections between the β-sheets within one monomer and between the four monomers were 
introduced. Additionally, the hydrogen bonds between the protein and the biotin moiety of the metal 
complex were included to attach the cofactor to the streptavidin. The complete model was prepared in VMD 
(version 1.9.1)202 and exported as an OBJ geometry definition file (Figure 29 a). Labels for selected residues 
(e.g. “48>”) were created in Blender (version 2.70) and combined with the protein model using Meshlab 
(version 1.3.4)203 (Figure 29 b). “Water tightness” of the fused structure was checked and the model was 
printed with the help of Dr. Stefan Imseng (Biozentrum, University of Basel) (Figure 29 c). The printed 3D-
structure was finally cleaned and chemically treated to obtain a smooth shiny surface (Figure 29 d). The 
overall production process, from the initial PDB file to the printed 3D-model, covered around one week of 
working time. This work can be divided into three phases: i) preparation of the model in VMD (~2.5 days), ii) 
finalize the model in Meshlab (~1 day) and iii) printing and refinement of the model (~1.5 days).  
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Figure 29: Printing of a 3D-model of streptavidin.  
a) Preparation of the 3D-model (crystal structure from PDB ID 3PK2)60 in VMD.202 Monomers of streptavidin highlighted as Cα-trace 
in blue, green, pink and red. Biotinylated iridium cofactor displayed as van-der-Waals spheres. Selected residues displayed as stick. 
Artificial stabilizing bonds displayed as grey cylinders. Hydrogen bonds between the protein and the cofactor displayed as white 
cylinders. b) Fusion of the protein structure and the residue numbering (e.g. “48>”) performed in Meshlab.203 Additionally, the model 
was checked for “water tightness”. c) Printing of the 3D-model in a full-color powder-printer. Printing was performed with the help 
of Dr. Stefan Imseng (Biozentrum, University of Basel). d) Finalized model after cleaning and chemical treatment of the surface.  
  
a) b) 
c) d) 
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3 Conclusion and Outlook 
In the course of this thesis, an artificial allylic deallocase based on the biotin-streptavidin technology was 
designed, engineered and applied in catalysis. The artificial metalloenzyme [CpRu(QA-Biot)(H2O)]PF6 (27) · 
Sav was formed by covalent attachment of a biotin anchor to the previously reported ruthenium complex 
[CpRu(QA-NMe2)(Allyl)]PF6 (7)94 with subsequent incorporation into streptavidin (Sav) isoforms. Different 
strategies for the synthesis of this biotinylated ruthenium complex were explored and the complex was 
analyzed by detailed NMR studies (chapters 2.1.1 and 2.1.2). An X-ray crystal structure of the artificial 
metalloenzyme [CpRu(QA-Biot)(H2O)]PF6 · Sav-S112M-K121A was solved (chapter 2.1.4). The designed 
artificial allylic deallocase was applied in catalysis towards the deprotection of a pro-fluorescent O-allyl-
carbamate caged coumarin derivative (1). 86 purified streptavidin mutants (point mutations and elongated 
loop constructs) were tested in vitro. High protein acceleration could be determined for some of them. 
Mutant S112M-K121R revealed a 7.1-fold higher activity than the wild-type and a 16.3-fold increased activity 
compared to the free biotinylated ruthenium cofactor (chapter 2.2).118  
In a next step, the artificial allylic deallocases were applied in an in vivo catalysis assay. Streptavidin isoforms 
were expressed and displayed on the surface of E. coli cells, using an ompA-Lpp outer-membrane anchoring 
system.131 The presence of streptavidin on the outer-membrane of E. coli was confirmed by selective labelling 
of the cells with a biotinylated fluorophore as well as by an assay applying a fluorescently labelled streptavidin 
antibody system (chapter 2.3.1). Performing catalysis on the surface of E. coli cells allows a faster screening 
of a streptavidin mutant library, since the extraction and purification of the proteins is not required. In this 
spirit, seven single site saturation mutagenesis libraries with a total of 140 mutants were investigated 
(chapter 2.3.2; in collaboration with Dr. Tillmann Heinisch and BSc Brett Garabedian, Ward group, University 
of Basel).118 Thereby, the activated double mutant S112M-K121R was selected as parent and the residues at 
the positions V47, N49, T114, N118, A119, S122 and L124 were separately saturated. The triple mutant 
S112M-K121R-S122N revealed a 30% higher activity in the in vivo catalysis than the respective parent S112M-
K121R. Screening of these seven libraries was performed in the 96-well plate format with a medium 
throughput rate. However, the developed assay can be adapted to an automated screening with robots, thus 
increasing the throughput rate to ~ 10’000 mutants per month.  
In order to further increase this number, a screening assay based on microfluidics was implemented (in 
collaboration with MSc Philipp Rottmann, Panke group, DBSSE ETH Zürich). E. coli cells displaying surface-
anchored streptavidin were loaded with biotinylated ruthenium cofactor and encapsulated in single 
emulsions (water-in-oil) together with the coumarin substrate (1). The fluorescence intensity of droplets 
containing either Sav-WT or mutant S112M-K121A was analyzed after overnight incubation. Unfortunately, 
the elevated activity of the double mutant compared to the wild-type dramatically decreased from 12.4-fold 
in the 96-well plate to 1.6-fold in the droplets (chapter 2.3.3).  
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However, libraries possessing only small differences in fluorescence intensity between their members can 
potentially be enriched for activated mutants applying several rounds of catalysis and sorting.204  
In a related project, caged small inducer molecules bearing an O-allyl-carbamate protective group were 
developed (chapter 2.4). This allowed us to control the expression of a GFP reporter protein by the action of 
the designed artificial allylic deallocases. First, the IPTG/lac-system was selected as biogenetic switch. 
Different caged IPTG derivatives, bearing self-immolative linkers, were synthesized and tested in catalysis. 
IPTG derivative 58 was selected as substrate for further experiments, due to its high stability against 
hydrolysis in the aqueous reaction medium. In the in vitro catalysis, [CpRu(QA-Biot)(H2O)]PF6 (27) · Sav-
S112M-K121A led to a 5.5-fold and a 10.8-fold higher conversion compared to the wild-type enzyme and the 
free cofactor, respectively (chapter 2.4.3). In the presence of GFP reporter cells (E. coli DH5α containing the 
pCD353 reporter plasmid), the purified artificial metalloenzyme [CpRu(QA-Biot)(H2O)]PF6 (27) · Sav-S112M-
K121A led to a 2.3-fold and a 3.6-fold higher GFP-fluorescence intensity compared to the wild-type enzyme 
and the free cofactor, respectively (chapter 2.4.4). It could be clearly demonstrated that the expression of a 
protein of interest in E. coli can be switched on by the action of an artificial metalloenzyme. In order to 
generalize the concept of the caged inducers, another system based on the DmpR regulator was investigated 
(in collaboration with Dr. Tsvetan Kardashliev, Panke group, DBSSE ETH Zürich; chapter 2.4.5). A caged 
hydroxyaniline derivative (72) was deprotected by our artificial allylic deallocase and subsequently 
successfully induced the expression of a GFP reporter protein.  
In parallel to these projects, the biotin binding vestibule of streptavidin was genetically engineered. It was 
tested for the construction of a lid-like structure on top of the binding site, which may partially shield the 
active ruthenium cofactor (chapter 2.5). In this way, the reaction environment (i.e. the second coordination 
sphere around the ruthenium cofactor6) may be influenced by genetic modification of the host protein. This 
potentially increases the activity and selectivity of the artificial metalloenzyme. Five positions, suitable for 
the introduction of lid structures, were identified. Small loops (Gly-Gly-Ser-Gly-Gly-Ser) were introduced at 
these positions. In total, 40 streptavidin (loop) mutants were designed, from which 28 could be expressed as 
soluble biotin binding tetramers (chapter 2.5.2). 19 variants were purified and from one (mutant S112M-
K121A) a crystal structure with the bound ruthenium cofactor [CpRu(QA-Biot)(H2O)]PF6 (27) could be 
determined (PDB ID 6FH8).118 Some of the loop mutants, especially the 66(GGS)2 and the 159TPR variants 
displayed promising catalytic activities. However, a streptavidin variant containing a lid-like structure, which 
spans the whole biotin binding vestibule, could not be successfully expressed.  
Finally, a three-dimensional model of the artificial metalloenzyme [Cp*Ir(biot-p-L)Cl] · Sav-S112A (PDB ID: 
3PK2)60 was prepared and printed (chapter 2.5.3).  
 
 
 
 68 
In summary, the initial aims of the thesis were (mostly) successfully fulfilled (chapter 1.6). An artificial allylic 
deallocase based on a ruthenium complex and the biotin-streptavidin technology was designed, synthesized 
and characterized. The new artificial metalloenzyme was evolved and applied in catalysis (in vitro as well as 
in vivo). Nevertheless, the designed artificial allylic deallocase can be further optimized, including: 
 
- Modification of the ruthenium cofactor and the host protein (e.g. ligand and mutant screening) 
- Expansion of the substrate scope (e.g. defined transfer of an allyl group) 
- Implementation of cascade reactions (e.g. combination of an ArM with a natural enzyme) 
- Expension of the reaction space (e.g. catalysis in the periplasm of E. coli) 
- Transfer of the ArM to other cells (e.g. mammalian cells or algae) 
 
Concerning the modification of the ruthenium cofactor, the biotin anchor could be attached to the 
cyclopentadienyl ligand instead of the 2-quinolinecarboxylate ligand (see Figure 3b). Biotinylated 
cyclopentadiene could be mixed with [(C6H6)RuCl2]2 and base, followed by treatment with acetonitrile and 
UV-light to form the complex [(Biot-Cp)Ru(MeCN)3]PF6.205 The weak acetonitrile ligands can be simply 
exchanged by other ligands in order to form more active complexes.95 A similar strategy was successfully 
applied in the formation of highly active artificial transfer hydrogenases.62 Beside the biotinylated ruthenium 
cofactor, also the host protein could be further engineered – by single point mutations as well as by 
introduction and modification of loops.206 Typically, large numbers of clones need to be tested in order to 
further evolve a variant which already shows an increased activity. Microfluidics in combination with droplet 
sorting provides the required ultrahigh-throughput capacity. Encapsulation of individual mutants in double 
emulsions (water-in-oil-in-water) combined with fluorescence activated cell sorting potentially allows to 
sceen up to 2000 mutants per second (see chapter 2.3.3).145 Thus, a library containing five simultaneously 
saturated single sites (205 = 3.2 million mutants) may be screened in reasonable times.148 At this point, the 
different proliferation rates of the cells and the expression levels of the mutants should be considered. 
Droplets containing mutants with a high expression level but a low activity will also show high fluorescence 
intensities. Thus, these droplets will be sorted too, leading to a higher number of false positives. Ideally, the 
expression level of a mutants and its activity would be determined simultaneously. This might be achieved 
by the split-GFP method207 or the split-HRP method.208  
Beside the biotinylated ruthenium cofactor and the streptavidin host, also the used substrates could be 
further engineered. The applied caged IPTG 58 revealed a certain level of unwanted background reaction, 
caused by hydrolysis of the ester function in the linker (chapters 2.4.2 and 2.4.3). Replacement of the ester 
by a carbamate would potentially increase the stability of the IPTG substrates. In this manner, an IPTG 
derivative (62) with a directly attached O-allyl carbamate protective group was designed (Figure 30). Since 
the sugar scaffold of this IPTG derivative was modified (the 2’-OH group was replaced by an NH2), the 
induction capacity of the uncaged product (63) would need to be evaluated first.  
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In addition, the preliminary test substrate 66 was designed. Possessing two carbamate groups, this substrate 
should be very stable towards hydrolysis. In order to increase the intramolecular cyclization rate after 
removal of the O-allyl carbamate caging group, an N,N’-dimethylethylenediamine core was selected.165 
Simultaneously with the formation of the urea (1,3-dimethyl-2-imidazolidinone), para-nitrophenol is 
released as a leaving group, which can be traced photospectrometrically. In a later stage, the para-
nitrophenol leaving group will be replaced by an IPTG molecule. The stability and the performance of these 
two substrates in catalysis will be tested.  
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Figure 30: Designed O-allyl carbamate protected substrates for an artificial allylic deallocase.  
 
In this thesis, we dealed with the deallylation of O-allyl carbamate protected substrates. The focus was set 
on the liberation of a fluorescent product (2) or inducer molecules (45, 67), rather than to which nucleophilic 
species the allyl fragment was transferred (see Scheme 3). The catalysis reactions were performed in complex 
medium, containing a variety of potential nucleophiles. A substrate, which contain itself a nucleophile, would 
potentially allow the transfer of an allyl group in an intramolecular fashion. The overall reaction rate might 
therefore be higher compared to an intermolecular reaction involving an external nucleophile. Furthermore, 
a substrate containing two O-allyl carbamates or a mixture of different substrates could be used in catalysis 
in order to evolve a regio- and substrate selectivity of the artificial allylic deallocase. The application of two 
caged coumarin derivatives, which possess different fluorescence spectra may be envisaged. The substrate 
selectivity of the artificial metalloenzyme could be determined by the ratio of the two fluorescence 
intensities.  
In addition, the developed artificial allylic deallocase could be applied in a cascade reaction. Based on the 
obtained results with the caged DmpR regulator system (chapter 2.4.5), we envisioned the combination of 
our artificial allylic deallocase with a cytochrome P450. The purified artificial metalloenzyme can deprotect 
an O-allyl carbamate-caged aniline. The generated aniline can be hydroxylated by a cytochrome P450209-210 
to generate a small molecule inducer (para-hydroxyaniline), which can switch on the expression of a GFP-
reporter protein (Scheme 10).  
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Scheme 10: Cascade reaction of an artificial allylic deallocase with a cytochrome P450 to activate a biogenetic switch.  
 
Artificial metalloenzymes are also functional in the periplasmic space of E. coli211, as shown by Ward et al. for 
an artificial metathase64 or by Tezcan et al. for a designed β-lactamses.23 Periplasmatic streptavidin was 
expressed in E. coli cell cultures at levels of up to 2 μM at an optical density of OD600 = 1 (unpublished data 
of the Ward group). These expression levels are up to 8-fold higher than the typical expression level of a 
surface-displayed streptavidin construct (chapter 2.3.1).127 Thus, higher conversions might be achieved with 
artificial metalloenzymes in the periplasm compared to their analogues on the surface of E. coli cells. 
Furthermore, an ultrahigh-throughput screening using FACS techniques could be performed without 
encapsulation of the cells in micro-droplets, assuming that the formed product (e.g. IPTG) does not difuse 
out of the cell. However, first the uptake of the biotinylated ruthenium cofactor and the substrate into the 
periplasmic space must be ensured. Installation of an engineered FhuA pore in the outer membrane212-214 or 
application of an osmotic shock215-216 might increase the uptake efficiency.  
Finally, the designed artificial allylic deallocase was applied in cell cultures other than E. coli. Dr. Yasunori 
Okamoto (Ward group, University of Basel) designed a gene switch in mammalian cells, which can be 
triggered with the artificial metalloenzyme.217 In combination with a biotinylated cell-penetrating peptide, 
the artificial allylic deallocase can enter the mammalian cell. In a cascade reaction with an esterase, an O-
allyl carbamate caged inducer is deprotected and can then switch on the gene of interest.  
MSc Mathieu Szponarski (Gademann group, University of Zürich) performed catalysis with our designed 
artificial allylic deallocases anchored to the surface of Chlamydomonas reinhardtii.218 The property, that the 
swimming direction of such algae can be controlled by light irradiation219 might be used to design a reaction 
set-up, in which the algae cells as a carrier of an active artificial metalloenzyme can be conducted to a desired 
place. In this way, the action of an artificial metalloenzyme could be spatially controlled.  
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4 Experimental part 
4.1 Instruments and material 
All commercially available chemicals were purchased from Sigma-Aldrich, ABCR, TCI Europe, Acros Organics, 
Alfa Aesar, Fluka, Fluorochem, Merck or Ukrorgsyntez Ltd. and used without further purification. 
FluoroSurfactant was purchased from RAN Biotechnologies. Deuterated solvents were purchased from 
Cambridge Isotope Laboratories Inc. or Armar Chemicals. Solvents for UPLC-MS measurements were 
purchased from Romil. The water was purified with a Milli-Q-system (Millipore). Antibiotics were purchased 
from Applichem GmbH, DNase I was from Roche Diagnostics AG, IPTG was from Apollo Scientific, biotin-4-
fluorescein was from ANAWA Trading SA, Atto-565-biotin was from Atto-Tec GmbH and Agarose/SDS-PAGE 
markers were from New England BioLab® Inc. Restriction enzymes, DNA ploymerases and ligases were 
purchased from New England BioLab® Inc. Primers were ordered from Microsynth AG. DNA string fragments 
(GeneArt® StringsTM DNA Fragments) were purchased from invitrogenTM by life technologiesTM. The mouse-
anti-streptavidin antibody (ab10020) was purchased from Abcam and the fluorescein isothiocyanate-tagged 
goat-anti-mouse antibody (f-2761)) was purchased from ThermoFisher. Thin layer chromatography (TLC) was 
performed on Merck TLC Silica gel 60 F254 plates, using a UV-detector (254 nm or 360 nm). Basic KMnO4 
solution or DACA solution (0.1% 4-(dimethylamino)-cinnamaldehyde and 1% H2SO4 in EtOH) was used for the 
staining. Column chromatography was performed using silica gel (Merck Silica gel 60 (0.040-0.063 mm)) or 
basic aluminium oxide (Fluka (0.05-0.15 mm)). NMR spectra were measured on a 400 MHz and 500 MHz 
Bruker Advance spectrometer at room temperature and evaluated with MestReNova. Chemical shifts (δ) are 
quoted in parts per million (ppm) and referenced to the residual solvent peaks. Scalar coupling (J) is reported 
in Hertz (Hz). HRMS analysis was performed by Dr. Heinz Nadig (University of Basel) on a Bruker maXis 4G. 
Mass-spectral analysis of the expressed streptavidin mutants was performed on a Bruker Daltonics, 
ESI/micrOTOF MS. UPLC-MS analysis was performed on a Water Acquity UPLC® equipped with an SQ Detector 
2 mass spectrometer. Details are given in the corresponding sections. Fluorescence/Absorption spectroscopy 
was performed on a TECAN infinite M1000 Pro. PCR reactions were performed with an Eppendorf 
Mastercycler Gradient. DNA sequencing (Sanger cycle sequencing/capillary electrophoresis) was performed 
by Microsynth AG. E. coli DH5α cells were purchased from ThermoFisher, E. coli NEB® Turbo cells were from 
New England BioLab® Inc., E. coli BL21(DE3) were from Stratagene (Agilent) and E. coli TOP10(DE3) cells were 
a gift from Dr. Markus Jeschek (Panke group, DBSSE ETH Zürich). Cells were chemically treated by Dipl.-Biol. 
Juliane Klehr (Ward group, University of Basel) according to the Hanahan method using RbCl. Affinity column 
chromatography (purification of the expressed streptavidin mutants) was performed on an Äktaprime Plus 
chromatography system, using 2-iminobiotin sepharose column. Flow cytometry analysis was performed on 
an Attune NxT acoustic focusing cytometer (life technologiesTM) with the help of Dr. Emeline Sautron.  
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4.2 Methods 
4.2.1 Protein-ligand docking 
All docking simulations were performed with GOLD (version 5.4), using the graphical interface Hermes 1.8.0 
with a method similar to that described by Robles et al.220 The method consists of (i) preparation of the 
catalyst structure file including the linker, (ii) preparation of the host structure file, and (iii) docking of the 
catalyst into a biotin-loaded streptavidin crystal structure by covalent linkage of the catalyst to the biotin 
anchor.  
The structure of the non-biotinylated ruthenium catalyst [CpRu(QA)(Allyl)]PF6 (5) was extracted from a crystal 
structure reported by Kitamura et al (Cambridge Structural Database Refcode: NAJLUG).85 Afterwards, where 
applicable, the allyl ligand was replaced by a water molecule giving to the oxygen atom the coordinates of 
the barycenter of the carbon atoms of the former allyl ligand. In order to preserve the structure of the 
ruthenium complex, the metal-ligand bonds were explicitly manually added to the structure file (text format), 
thereby constraining the ruthenium complex during the following docking. Using the building tool of UCSF 
Chimera221, the piperazine linker of [CpRu(QA-piperazine)(Allyl/H2O)]PF6 was constructed (the linker for the 
complex [(Biot-Cp)Ru(QA-NMe2)(Allyl)]PF6 (17) was constructed in the same way). The hydrogen atom of the 
secondary amine of the piperazine was then removed in order to allow later attachment of the biotin anchor.  
The structure of the receptor consisted of a dimer of streptavidin generated from a crystal structure reported 
by Dürrenberger et al. (PDB entry: 3PK2).60 In this homotetrameric structure, streptavidin contains the 
biotinylated iridium complex [Cp*Ir(Biot-p-L)Cl] (Figure 31). Using UCSF Chimera, two facing monomers, the 
solvent molecules and the salts were deleted. In the resulting dimer both [Cp*Ir(Biot-p-L)Cl] cofactors were 
deleted except for one biotin (including the NAm atom, Figure 31). Using the mutation tool of Chimera, the 
two monomers of streptavidin were mutated to yield a dimer of Sav S112M-K121A. As an initial starting 
point, the chains were set to adopt the conformation which is most frequently observed in crystal structures. 
During the docking procedure, a covalent restraint was set: the secondary amine N-atom of the piperazine 
linker of [CpRu(QA-piperazine)(Allyl/H2O)] was set to coincide with the NAm of the biotin in the streptavidin 
dimer (Figure 31). The 6 residues with the smallest distance to the catalyst, namely N118, S112M and L124 
of both streptavidin monomers, were kept flexible. Thus a library of rotamers was generated. The final 
rotamer having the highest ChemScore was selected and the coordinates of the atoms of both the biotin and 
the docked ruthenium cofactor were pooled in a single file to reconstruct the entire biotinylated ruthenium 
complex [CpRu(QA-Biot)(Allyl/H2O)] with the minimized docked conformation.  
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Figure 31: Covalent docking of a biotinylated ruthenium complex into a streptavidin dimer.  
The amide nitrogen (NAm) serves as anchoring atom. The part of the original biotinylated iridium complex [Cp*Ir(Biot-p-L)Cl], which 
was replaced during the docking process, is depicted in grey. 
 
4.2.2 HABA titration 
Stock solutions: 
- Phosphate buffer (20 mM NaH2PO4/Na2HPO4, pH 7.4) 
- Streptavidin wild-type (8 μM tetramer) in phosphate buffer 
- D-Biotin (0.96 mM) in phosphate buffer/DMF (80:20) 
- Ligand 26 (0.96 mM) in phosphate buffer/DMF (80:20) 
- Complex 27 (0.96 mM, prepared from a 1:1 mixture of [CpRu(MeCN)3]PF6 and Ligand 26 in DMF) in 
phosphate buffer/DMF (80:20) 
- HABA (9.6 mM) in phosphate buffer 
 
Titration: 
A blank sample (phosphate buffer only) was first determined. HABA stock solution (300 μl) was mixed with 
protein stock solution (2.4 ml) in a cuvette (d = 1 cm), incubated for 5 min at room temperature and 
absorption at 506 nm was determined. D-biotin, ligand or complex stock solution was titrated in steps of 5 
μl (= 0.25 eq. biotinylated compound vs. streptavidin tetramer) and absorption was determined.  
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4.2.3 Catalysis procedure for the coumarin substrate 
 
Catalysis reactions with coumarin substrate 1 and purified streptavidin: 
Stock solutions: 
- PBS buffer (1x, pH 7.4) containing 50 mM Na2HPO4/NaH2PO4 and 0.9% NaCl 
- Streptavidin (2 mM free biotin binding sites in water) 
- Ruthenium cofactors (1 mM in organic co-solvent) 
- Substrate 1 (10 mM in water) 
 
Catalysis reactions were performed in flat 96-well plates at a reaction volume of 200 μl and a substrate 
concentration of 500 μM. Other conditions are indicated in Table 4, Figure 11 or Figure 12. PBS buffer was 
filled into a 96-well plate followed by the addition of streptavidin and ruthenium cofactor. This solution was 
incubated at room temperature for 10 min (streptavidin can bind the biotinylated cofactor). Substrate was 
added and the plate was sealed with an aluminum cover and incubated at the given conditions. An aliquot of 
the reaction mixture (3 μl) was then diluted with water (147 μl) in a new flat black 96-well plate. Fluorescence 
of the product 2 was determined in a plate reader at λex. = 395 nm / λem. = 460 nm and compared with a 
standard curve of the product (Figure 32).  
 
 
Figure 32: Standard curve of coumarin product 2 in water.  
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4.2.4 Screening of E. coli surface Sav libraries 
Creation of libraries: 
PCR222 was performed applying the 22-codon trick144, in which a 12:9:1 mixture of primers containing the 
NDT, VHG or TGG codon, respectively, is used. The forward and reverse primers for the 7 mutagenesis 
positions are listed in Table 10.  
Table 10: Primers for site saturation mutagenesis at the positions V47, N49, T114, N118, A119, S122 and L124.  
Position Primer Sequence 
V47 NDT_fw GCGCAndtGGTAATGCAGAAAGC 
 VHG_rv GCGCAvhgGGTAATGCAGAAAGC 
 TGG_fw GCGCAtggGGTAATGCAGAAAGC 
 AHN_rv CTGCATTACCahnTGCGCTTTCATAC 
 CDB_rv CTGCATTACCcdbTGCGCTTTCATAC 
 CCA_rv CTGCATTACCccaTGCGCTTTCATAC 
N49 NDT_fw GGTndtGCAGAAAGCCGTTATGTTC 
 VHG_rv GGTvhgGCAGAAAGCCGTTATGTTC 
 TGG_fw GGTtggGCAGAAAGCCGTTATGTTC 
 AHN_rv CGGCTTTCTGCahnACCAACTGC 
 CDB_rv CGGCTTTCTGCcdbACCAACTGC 
 CCA_rv CGGCTTTCTGCccaACCAACTGC 
T114 NDT_fw GGGCndtACCGAAGCAAATGCCTGG 
 VHG_rv GGGCvhgACCGAAGCAAATGCCTGG 
 TGG_fw GGGCtggACCGAAGCAAATGCCTGG 
 AHN_rv CATTTGCTTCGGTahnGCCCATGGTCAG 
 CDB_rv CATTTGCTTCGGTcdbGCCCATGGTCAG 
 CCA_rv CATTTGCTTCGGTccaGCCCATGGTCAG 
N118 NDT_fw GCAndtGCCTGGCGCAGCACCCTGG 
 VHG_rv GCAvhgGCCTGGCGCAGCACCCTGG 
 TGG_fw GCAtggGCCTGGCGCAGCACCCTGG 
 AHN_rv GGTGCTGCGCCAGGCahnTGCTTCGGTG 
 CDB_rv GGTGCTGCGCCAGGCcdbTGCTTCGGTG 
 CCA_rv GGTGCTGCGCCAGGCccaTGCTTCGGTG 
A119 NDT_fw CAAATndtTGGCGCAGCACCCTGGTTG 
 VHG_rv CAAATvhgTGGCGCAGCACCCTGGTTG 
 TGG_fw CAAATtggTGGCGCAGCACCCTGGTTG 
 AHN_rv CAGGGTGCTGCGCCAahnATTTGCTTCG 
 CDB_rv CAGGGTGCTGCGCCAcdbATTTGCTTCG 
 CCA_rv CAGGGTGCTGCGCCAccaATTTGCTTCG 
S122 NDT_fw GCGCndtACCCTGGTTGGTCATGATAC 
 VHG_rv GCGCvhgACCCTGGTTGGTCATGATAC 
 TGG_fw GCGCtggACCCTGGTTGGTCATGATAC 
 AHN_rv CATGACCAACCAGGGTahnGCGCCAG 
 CDB_rv CATGACCAACCAGGGTcdbGCGCCAG 
 CCA_rv CATGACCAACCAGGGTccaGCGCCAG 
L124 NDT_fw CTGGAAAAGCACCndtGTTGGTCATG 
 VHG_rv CTGGAAAAGCACCvhgGTTGGTCATG 
 TGG_fw CTGGAAAAGCACCtggGTTGGTCATG 
 AHN_rv CAACahnGGTGCTGCGCCAGGCATTTGC 
 CDB_rv CAACcdbGGTGCTGCGCCAGGCATTTGC 
 CCA_rv CAACccaGGTGCTGCGCCAGGCATTTGC 
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PCR mixture: 
5 μl Q5-buffer (5x), 1 μl template DNA of Sav mutant S112M-K121R (25 ng/μl), 5 μl forward primers (1 μM; 
mixture of NDT/VHG/TGG = 12:9:1), 5 μl reverse primers (1 μM; mixture of AHN/CDB/CCA = 12:9:1), 0.5 μl 
dNTP`s (10 mM), 0.5 μl DMSO, 7.75 μl water, 0.25 μl Q5 Hot start HF DNA polymerase (2 U/μl).  
 
PCR program: 
95°C for 2 min; 95°C for 30 s, 70 °C for 15 s, 72°C for 5 min (14 cycles); 72°C for 10 min.  
 
PCR products were digested (DpnI, 37°C, 90 min) and transformed into chemically competent E. coli 
TOP10(DE3) cells (50 μl competent cells + 2 μl digested PCR product; heat-shock for 30 s at 42°C; incubation 
in LB-medium for 1 h at 37°C prior to plating). Colonies were grown on LB-agar plates containing 34 μg/ml 
chloramphenicol (37°C, overnight). 88 colonies per library were picked and overnight cultures were prepared 
(LB-medium with 34 μg/mL chloramphenicol, 37°C, 310 rpm). Cells were harvested, plasmids (13 clones per 
library) were isolated223 and analysed by Sanger DNA sequencing.224-225 Glycerol stocks (15% glycerol) were 
prepared.  
 
Catalysis activity assay: 
 
Stock solutions: 
- PBS-buffer (1x, pH 7.4) 
- L-arabinose (5% (wt/vol) in water) 
- Ruthenium cofactor stock (2 mM [CpRu(QA-Biot)(Sol.)] (27) in DMF) 
- Coumarin substrate stock (5 mM coumarin 1 in PBS-buffer) 
- Reaction-buffer: 22.5 ml PBS-buffer + 2.5 ml coumarin substrate stock + 25 μl ruthenium cofactor 
stock → final concentrations: 500 μM coumarin 1, 2 μM [CpRu(QA-Biot)(Sol.)] (27) 
 
Studier medium:  
1x M-stock (25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4) + MgSO4 (2 mM) + glycerol (0.5%) 
+ tryptone (15 g/L) + yeast extract (10 g/L).  
 
In a 96-deep well plate, LB-medium containing 34 μg/ml chloramphenicol (300 µl per well) was inoculated 
from glycerol stocks of the designed libraries (88 clones per library) or the corresponding controls (2x Sav-
WT and 2x Sav-S112M-K121R). The plate was incubated overnight (37°C, 200 rpm shaking). In a new 96-deep 
well plate, Studier-medium (34 μg/ml chloramphenicol, 240 µl per well) was inoculated with pre-culture (10 
μl) and incubated for 3.5 h (37°C, 310 rpm shaking). L-arabinose (10 μl) was added and the plate was 
incubated for 4 h (25°C, 280 rpm shaking).  
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Cells were centrifuged (3200 g, 8°C, 5 min), supernatant was discarded and the cells were resuspended in 
reaction-buffer (250 μl). The plate was then incubated for 16 h (30°C, 310 rpm shaking). Finally, the cell 
density (150 μl PBS-buffer + 50 μl reaction mixture, OD600) and the coumarin fluorescence (245 μl PBS-buffer 
+ 5 μl reaction mixture, λex. = 395 nm, λem. = 460 nm) were determined in a TECAN plate reader.  
 
4.2.5 Microfluidics and droplet production 
 
Stock solutions: 
- PBS-buffer (1x, pH 7.4) 
- Phosphate buffered LB-medium (50 mM Na2HPO4/NaH2PO4, pH 7.4) 
- L-arabinose (10% in water) 
- Ruthenium cofactor stock (2 mM [CpRu(QA-Biot)(Sol.)] (27) in DMF) 
- Coumarin substrate stock (0.75 mM coumarin 1 in buffered LB-medium (pH 7.4)) 
- Artificial metalloenzyme (200 μM Sav-S112M-K121A (free biotin binding sites) + 100 μM ruthenium 
cofactor) 
- Fluorinated oil: HFE-7500 3MTM NovecTM Engineered fluid (Fluorochem) +1% FluoroSurfactant (RAN 
Biotechnologies) 
 
Protein expression: 
A preculture of E. coli TOP10(DE3) cells containing the pBAD33-Lpp-ompA-T7-Sav plasmid was prepared in 
LB-medium (34 μg/ml chloramphenicol) and incubated overnight (37°C, 210 rpm shaking). Studier medium 
(see chapter 4.2.4) was inoculated with the preculture to a starting OD600 of 0.05. The main culture was 
incubated for 3 h (37°C, 210 rpm shaking). A part of the culture was induced with L-arabinose (final 
concentration: 0.2%) and incubated for 4 h (25°C, 210 rpm shaking). The remaining cells were kept on ice.  
 
Catalyst uptake: 
A defined amount of cells (2 ml culture at OD600 = 2.0) was transferred to an Eppendorf tube and centrifuged 
(11’000 g, 2 min, 8°C). The supernatant was discarded and the pellet resuspended in 2 ml PBS-buffer (1x, pH 
7.4). The sample was then centrifuged (11’000 g, 2 min, 8°C). The supernatant was discarded and the pellet 
resuspended in 2 ml PBS-buffer (1x, pH 7.4) containing 2 μM ruthenium cofactor. The sample was incubated 
for 30 min on ice. The sample was then centrifuged (11’000 g, 2 min, 8°C). The supernatant was discarded 
and the pellet resuspended in 2 ml PBS-buffer (1x, pH 7.4). 200 μl of the sample were transferred into a new 
Eppendorf tube. The sample was then centrifuged (11’000 g, 2 min, 8°C). The supernatant was discarded and 
the pellet resuspended in 2 ml phosphate buffered LB-medium (pH 7.4) → cells are now at a concentration 
of OD600 = 0.2.  
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Droplet production: 
Substrate mixture was prepared as follows: ruthenium cofactor stock (1.5 μl) + L-arabinose stock (30 μl) + 
substrate stock (750 μl) + phosphate buffered LB-medium (218.5 μl). This led to the following concentrations: 
ruthenium cofactor (3 μM), L-arabinose (0.3%), substrate (750 μM).  
 
The microfluidic chip was operated at the following flow rates: 
Cells: 60 μl/h; Substrate mixture: 120 μl/h; Fluorinated oil: 600 μl/h 
Droplets of each sample were produced for exactly 15 min. The droplets were then incubated in Eppendorf 
tubes for 19 h (25°C, gentle mixing).  
 
Droplet breaking and fluorescence determination: 
The oil at the bottom of the Eppendorf tube was carefully removed. 400 μl PBS-buffer (1x, pH 7.4) was added 
to the sample, followed by the addition of surfactant (1H,1H,2H,2H-perfluorooctan-1-ol, 100 μl). The sample 
was vortexed for 20 seconds and quickly centrifuged. 150 μl of the supernatant were transferred into a flat-
black 96-well plate and the fluorescence was determined in a plate reader (λex. = 395 nm, λem. = 460 nm).  
 
4.2.6 Catalysis procedure for caged IPTG substrates 
In vitro catalysis: 
General procedure for the in vitro catalysis with the IPTG substrates 58, 46, 50 and 54. Further details are 
given in the relevant sections and in Table 6, Table 7 and Figure 21.  
 
Stock solutions: 
- Phosphate buffer (50 mM Na2HPO4/NaH2PO4, various pH’s, containing 0.9% NaCl) 
- Streptavidin (2 mM free biotin binding sites in water) 
- Ruthenium cofactors (1 mM in organic co-solvent) 
- IPTG substrate (5 mM in water) 
 
Catalysis reactions were performed in flat 96-well plates in a reaction volume of 200 μl. Buffer (178 μl) was 
filled into a 96-well plate followed by the addition of streptavidin (1 μl) and ruthenium cofactor (1 μl). This 
solution was incubated at room temperature for 10 min (to allow streptavidin to bind to the biotinylated 
cofactor). Substrate (20 μl) was added and the plate was sealed with an aluminum cover and incubated at 
the given conditions. Aliquots of the reaction mixtures (50 μl) were then diluted with methanol (200 μl) and 
incubated at room temperature for 10 min (precipitation of the protein).  
Samples were then centrifuged (21’000 g, 20°C, 5 min). Supernatants (5 μl) were diluted with MilliQ-water 
(995 μl) and subjected to UPLC-MS analysis (Figure 33).  
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Figure 33: UPLC-MS chromatograms (single ion recording) of IPTG samples.  
Blank sample. b) Sample containing 0.5 μM IPTG. UPLC-MS conditions: Solvents: MilliQ-water + 0.1% HCOOH (Solvent C), MeCN + 
0.1% HCOOH (Solvent D); Column: ACQUITY UPLC® HSS T3 1.8 μm, 2.1x100 mm; Oven temperature: 40°C; Flow rate: 0.6 ml/min, Run 
time: 5.0 min; Gradient: 0 min (5% D), 1.0 min (5% D), 2.0 min (95% D), 3.0 min (5% D), 5.0 min (5% D); Injection volume: 5 μl; Cone 
voltage: 40 V; Single ion recording at 261 m/z (=[IPTG+Na]+); Retention time IPTG: 1.35 min.  
  
a) 
b) 
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4.2.7 Cloning of Sav loop mutants 
Sav gene constructs: 
The gene sequences for the streptavidin variants bearing an additional secondary structure element were 
ordered as double stranded DNA-string fragments (GeneArt® StringsTM DNA Fragments, invitrogenTM by life 
technologiesTM), containing a four-base pair overhang (ATAT, TATA) at both ends (Table 11).  
Table 11: DNA sequences of streptavidin variants with an additional secondary structure element.  
Entry Name Sequence (5` to 3`) 
1 48(GGS)2 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTGGC
GGCAGCGGCGGCAGCAATGCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGCAACCGATGGTAG
CGGTACCGCACTGGGTTGGACCGTTGCATGGAAAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCA
GTATGTTGGTGGTGCAGAAGCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGA
AAAGCACCCTGGTTGGTCATGATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAATTGATGCAGCAAAAAAAGCCG
GTGTGAATAATGGTAATCCGCTGGATGCAGTTCAGCAGTAATAGGGATCCTATA 
2 66(GGS)2 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAAT
GCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGCAACCGGCGGCAGCGGCGGCAGCGATGGTAG
CGGTACCGCACTGGGTTGGACCGTTGCATGGAAAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCA
GTATGTTGGTGGTGCAGAAGCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGA
AAAGCACCCTGGTTGGTCATGATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAATTGATGCAGCAAAAAAAGCCG
GTGTGAATAATGGTAATCCGCTGGATGCAGTTCAGCAGTAATAGGGATCCTATA 
3 84(GGS)2 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAAT
GCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGCAACCGATGGTAGCGGTACCGCACTGGGTTGG
ACCGTTGCATGGAAAAATAACTATCGTGGCGGCAGCGGCGGCAGCAATGCACATAGCGCAACCACGTGGTCAGGTCA
GTATGTTGGTGGTGCAGAAGCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGA
AAAGCACCCTGGTTGGTCATGATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAATTGATGCAGCAAAAAAAGCCG
GTGTGAATAATGGTAATCCGCTGGATGCAGTTCAGCAGTAATAGGGATCCTATA 
4 117(GGS)2 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAAT
GCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGCAACCGATGGTAGCGGTACCGCACTGGGTTGG
ACCGTTGCATGGAAAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAA
GCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAGGCGGCAGCGGCGGCAGCAATGCCTGGAA
AAGCACCCTGGTTGGTCATGATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAATTGATGCAGCAAAAAAAGCCGG
TGTGAATAATGGTAATCCGCTGGATGCAGTTCAGCAGTAATAGGGATCCTATA 
5 48TPR 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTGGC
GGCAGCGCGGAAGCGTGGTATAACCTGGGCAACGCGTATTATAAACAGGGCGATTATGATGAAGCGATTGAATATTA
TCAGAAAGCGCTGGAACTGAGCGGCGGCAATGCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGG
CAACCGATGGTAGCGGTACCGCACTGGGTTGGACCGTTGCATGGAAAAATAACTATCGTAATGCACATAGCGCAACCA
CGTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGAA
GCAAATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAATTGATGCA
GCAAAAAAAGCCGGTGTGAATAATGGTAATCCGCTGGATGCAGTTCAGCAGTAATAGGGATCCTATA 
6 66TPR 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAAT
GCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGCAACCGGCGGCAGCGCGGAAGCGTGGTATAA
CCTGGGCAACGCGTATTATAAACAGGGCGATTATGATGAAGCGATTGAATATTATCAGAAAGCGCTGGAACTGAGCG
GCGGCGATGGTAGCGGTACCGCACTGGGTTGGACCGTTGCATGGAAAAATAACTATCGTAATGCACATAGCGCAACC
ACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGA
AGCAAATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAATTGATGC
AGCAAAAAAAGCCGGTGTGAATAATGGTAATCCGCTGGATGCAGTTCAGCAGTAATAGGGATCCTATA 
7 84TPR 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAAT
GCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGCAACCGATGGTAGCGGTACCGCACTGGGTTGG
ACCGTTGCATGGAAAAATAACTATCGTGGCGGCAGCGCGGAAGCGTGGTATAACCTGGGCAACGCGTATTATAAACA
GGGCGATTATGATGAAGCGATTGAATATTATCAGAAAGCGCTGGAACTGAGCGGCGGCAATGCACATAGCGCAACCA
CGTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGAA
GCAAATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAATTGATGCA
GCAAAAAAAGCCGGTGTGAATAATGGTAATCCGCTGGATGCAGTTCAGCAGTAATAGGGATCCTATA 
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8 117TPR 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAAT
GCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGCAACCGATGGTAGCGGTACCGCACTGGGTTGG
ACCGTTGCATGGAAAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAA
GCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAGGCGGCAGCGCGGAAGCGTGGTATAACCT
GGGCAACGCGTATTATAAACAGGGCGATTATGATGAAGCGATTGAATATTATCAGAAAGCGCTGGAACTGAGCGGCG
GCAATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAATTGATGCAG
CAAAAAAAGCCGGTGTGAATAATGGTAATCCGCTGGATGCAGTTCAGCAGTAATAGGGATCCTATA 
9 139TPR 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAAT
GCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGCAACCGATGGTAGCGGTACCGCACTGGGTTGG
ACCGTTGCATGGAAAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAA
GCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGAAAAGCACCCTGGTTGGTCAT
GATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAGGCGGCAGCGCGGAAGCGTGGTATAACCTGGGCAACGCGTA
TTATAAACAGGGCGATTATGATGAAGCGATTGAATATTATCAGAAAGCGCTGGAACTGAGCGGCGGCTAATAGGGAT
CCTATA 
10 159TPR 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATTACCGGCACCTGGTATAATC
AGCTGGGTAGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAAT
GCAGAAAGCCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGCAACCGATGGTAGCGGTACCGCACTGGGTTGG
ACCGTTGCATGGAAAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAA
GCACGCATTAACACCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGAAAAGCACCCTGGTTGGTCAT
GATACCTTTACCAAAGTTAAACCGAGCGCAGCATCAATTGATGCAGCAAAAAAAGCCGGTGTGAATAATGGTAATCCG
CTGGATGCAGTTCAGCAGGGCGGCAGCGCGGAAGCGTGGTATAACCTGGGCAACGCGTATTATAAACAGGGCGATTA
TGATGAAGCGATTGAATATTATCAGAAAGCGCTGGAACTGAGCGGCGGCTAATAGGGATCCTATA 
11 CpSav 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTGGTAGCGGTACCGCACTGGGTTGGACCGTTGCATGGA
AAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAACA
CCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCA
AAGTTAAACCGAGCGCAGCATCAGGCGGCGGCAGCGCGGAAGCAGGTATTACCGGCACCTGGTATAATCAGCTGGGT
AGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAATGCAGAAAG
CCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGTAATAGGGATCCTATA 
12 Cp1 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTGGTAGCGGTACCGCACTGGGTTGGACCGTTGCATGGA
AAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAACA
CCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCA
AAGTTAAACCGAGCGCAGCATCAGGCGGCGGCAGCGCGGAAGCAGGTATTACCGGCACCTGGTATAATCAGCTGGGT
AGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAATGCAGAAAG
CCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGAGCAGCACCGATCAGGAAAAAACCGCGCTGAACATGGCGCG
TTTTATTCGTAGCCAGACCCTGACCCTGCTGGAAAAACTGAACGAACTGGATGCGGATGAACAGGCGGATATTGCGGA
AAGCCTGCATGATCATGCGGATGAACTGTATCGTAGCGTGCTGGCGCGTTTTTAATAGGGATCCTATA 
13 Cp2 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTGGTAGCGGTACCGCACTGGGTTGGACCGTTGCATGGA
AAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAACA
CCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCA
AAGTTAAACCGAGCGCAGCATCAGGCGGCGGCAGCGCGGAAGCAGGTATTACCGGCACCTGGTATAATCAGCTGGGT
AGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAATGCAGAAAG
CCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGCCGAGCATGACCACCCAGGAAAAAACCGCGCTGAACATGGC
GCGTTTTATTCGTAGCCAGACCCTGACCCTGCTGGAAAAACTGAACGAACTGGATGCGGATGAACAGGCGGATATTGC
GGAAAGCCTGCATGATCATGCGGATGAACTGTATCGTAGCGTGCTGGCGCGTTTTTAATAGGGATCCTATA 
14 Cp3 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTGGTAGCGGTACCGCACTGGGTTGGACCGTTGCATGGA
AAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAACA
CCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCA
AAGTTAAACCGAGCGCAGCATCAGGCGGCGGCAGCGCGGAAGCAGGTATTACCGGCACCTGGTATAATCAGCTGGGT
AGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAATGCAGAAAG
CCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGGCTGGAACATGACCGCGCAGGAAAAAACCGCGCTGAACAT
GGCGCGTTTTATTCGTAGCCAGACCCTGACCCTGCTGGAAAAACTGAACGAACTGGATGCGGATGAACAGGCGGATAT
TGCGGAAAGCCTGCATGATCATGCGGATGAACTGTATCGTAGCGTGCTGGCGCGTTTTTAATAGGGATCCTATA 
15 Cp4 
ATATCATATGGCAAGCATGACGGGTGGCCAGCAGATGGGTGGTAGCGGTACCGCACTGGGTTGGACCGTTGCATGGA
AAAATAACTATCGTAATGCACATAGCGCAACCACGTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAACA
CCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCA
AAGTTAAACCGAGCGCAGCATCAGGCGGCGGCAGCGCGGAAGCAGGTATTACCGGCACCTGGTATAATCAGCTGGGT
AGCACCTTTATTGTTACCGCGGGCGCAGATGGTGCACTGACCGGCACGTACGAAAGCGCAGTTGGTAATGCAGAAAG
CCGTTATGTTCTGACCGGTCGTTATGATAGCGCACCGGGCGGCAACATGACCGCGCAGGAAAAAACCGCGCTGAACAT
GGCGCGTTTTATTCGTAGCCAGACCCTGACCCTGCTGGAAAAACTGAACGAACTGGATGCGGATGAACAGGCGGATAT
TGCGGAAAGCCTGCATGATCATGCGGATGAACTGTATCGTAGCGTGCTGGCGCGTTTTTAATAGGGATCCTATA 
For the expression and purification of these constructs see also Table 9.  
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In case of the (GGS)2-constructs (Table 11, entries 1-4), new unique restriction sites were introduced into the 
gene sequences before and after each (GGS)2-motif (Figure 34). This allows a simple subsequent 
shuffling/combination of the loops (i.e. streptavidin mutants containing two (GGS)2-inserts at different 
positions; Table 9, entries 5-10).  
 
 
Figure 34: Designed streptavidin sequence containing unique restriction sites before and after the loops.  
Streptavidin sequence: double stranded DNA (upper line), amino acids (lower line). Streptavidin loops are displayed as orange arrows. 
Positions for (GGS)2-inserts are labelled in blue.  
General cloning procedure: 
PCR222 and site-directed mutagenesis performed in this thesis are based on the protocol of the QuikChangeTM 
site-directed mutagenesis kit from Stratagene226, modified by Zheng et al.227 Melting temperatures of primers 
were calculated according to the nearest neighbor method228 using the OligoCalc tool.229 The sequences in 
Table 11 were amplified by PCR applying the following conditions: 
 
 
G48...N49 
T66...D67 
A117...N118 
R84...N85 
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Forward primer (5‘ to 3‘): 
General:    ATATCATATGGCAAGCATGACGGGTGGCC  
 
Reverse primers (5’ to 3’): 
General:    TATAGGATCCCTATTACTGCTGAACTGCATCC 
Cp1-4:    TATAGGATCCCTATTAAAAACGCGCCAGCACG 
139/159TPR:  TATAGGATCCCTATTAGCCGCCGCTCAG 
CpSav:    TATAGGATCCCTATTACGGTGCGCTATCATAACG  
 
PCR mixture: 
20 μl Q5-buffer (5x), 0.5 μl template DNA (100 ng/μl), 2 μl primers (10 μM), 2 μl dNTP`s (10 mM), 4 μl DMSO, 
68 μl water, 1 μl Q5 Hot start HF DNA polymerase (2 U/μl).  
 
PCR program: 
98°C for 30 s; 98°C for 20 s, 70 °C for 30 s, 72°C for 30 s (30 cycles); 72°C for 8 min.  
 
Amplified DNA was purified by precipitation from ethanol:  
1) 1 ml ethanol (100 %) and 100 μl sodium acetate (3M, pH 4.8) were added to the PCR product.  
2) The sample was mixed, centrifuged (21’000 g, 4°C, 15 min) and the supernatant was carefully removed.  
3) The pellet was resuspended in 500ul cold ethanol (70%).  
4) The sample was centrifuged (21’000 g, 20°C, 5 min) and the supernatant was carefully removed.  
5) The pellet was resuspended in sterile MilliQ-water.  
 
The purified plasmids were digested with restriction enzymes (NdeI + BamHI-HF, 37°C, 60 min; removal of 
the ATAT/TATA overhangs). Simultaneously, an empty pET30a vector (Novagen)230 was digested applying the 
same conditions. All digested samples were loaded onto an agarose gel (1% agarose) and the desired bands 
were cut out and purified.223 The inserts were then ligated into the digested pET30a vector (T4-DNA Ligase, 
16°C, overnight, 10-fold molar excess of insert compared to vector). Ligated products were transformed into 
electro-competent TOP10 (DE3) E. coli cells (50 μl competent cells + 5 μl ligation product; electro-shock for 
5.6 ms at 1.8 kV; incubation in SOB-medium for 1 h at 37°C prior to plating) and plated onto LB-agar plates 
containing kanamycin (50 μg/ml). Colonies were picked and overnight cultures were prepared (LB-medium 
with 50 μg/ml kanamycin, 37°C, 210 rpm shaking). Cells were harvested, plasmids were isolated223 and 
analysed by Sanger DNA sequencing.224-225 Glycerol stocks (15% glycerol) were prepared from the correct 
clones. The plasmids were then, where applicable, transformed into chemically competent BL21(DE3) E. coli 
cells (50 μl competent cells + 1 μl purified plasmid; heat-shock for 30 s at 42°C; incubation in LB-medium for 
1 h at 37°C prior to plating).  
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Cloning of Sav variants containing two (GGS)2-motifs: 
In order to introduce two (GGS)2 loops into the same gene (Table 9, entries 5-10), the previously obtained 
single (GGS)2 loop mutants were digested applying different restriction enzymes (Figure 34, Table 12). The 
digested backbones and inserts were combined in the desired way followed by re-ligation. The ligation 
products were then transformed and sequenced as described for the single (GGS)2 mutants.  
Table 12: Digestion of streptavidin loop sequences applying different restriction enzymes.  
Entry (GGS)2 loop at position Restriction enzyme 1 Restriction enzyme 2 Used fragment 
1 G48…N49 AgeI BamHI backbone 
2 T66…D67 AgeI BamHI insert 
3 R84…N85 AgeI BamHI insert 
4 A117…N118 AgeI BamHI insert 
5 T66…D67 KpnI BamHI backbone 
6 R84…N85 KpnI BamHI insert 
7 A117…N118 KpnI BamHI insert 
8 A117…N118 Pm1I NdeI backbone 
9 R84…N85 Pm1I NdeI insert 
 
Cloning of Sav (GGX)n-constructs: 
In order to expand the diversity of the streptavidin (GGS)2 mutants, the first serine residue in the loop …G48-
G-G-S-G-G-S-N49… was selected for mutagenesis. A primer containing the degenerate “NDT” codon was used, 
which can encode for 12 different amino acids including aliphatic, aromatic, charged, small and large residues 
(Phe, Leu, Ile, Val, Tyr, His, Asn, Asp, Cys, Arg, Gly and Ser). PCR was performed applying the following 
conditions: 
 
Forward primer (5‘ to 3‘):  GGTGGCGGCNDTGGCGGCAG 
Reverse primer (5’ to 3’):   CTGCCGCCAHNACCGCCACC 
 
PCR mixture: 
5 μl Q5-buffer (5x), 0.25 μl template DNA (200 ng/μl), 1.25 μl primers (10 μM), 0.5 μl dNTP`s (10 mM), 0.75 
μl DMSO, 15.8 μl water, 0.25 μl Phusion Hot start HF DNA polymerase (2 U/μl).  
 
PCR program: 
98°C for 2 min; 98°C for 10 s, 68 °C for 20 s, 72°C for 3.5 min (30 cycles); 72°C for 8 min.  
 
PCR products were digested (DpnI, 37°C, 90 min) and mutants were analysed as described for the single 
(GGS)2 mutants. Due to the high GC-content of the streptavidin sequence and the similarity of the GGX and 
the GGS motif, primers likely annealed at a different position (3 amino acids shifted), leading to an elongation 
of the loop (Table 9, entries 11-18).  
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Cloning of Sav double mutants and Sav loop combinations: 
Various Sav double mutants and combinations of single mutants with loops (Table 9, entries 25-35) were 
produced, applying the following PCR conditions: 
 
Forward primers (5‘ to 3‘): 
S112M_fw:    GACCATGGGCACCACCGAAGCAAATGC 
K121A-L124G_fw:  CCTGGGCAAGCACCGGGGTTGGTCATGATACC 
K121R-L124G_fw:  CCTGGCGCAGCACCGGGGTTGGTCATGATACC 
K121R_fw:    CCTGGCGCAGCACCCTGGTTGGTCATGATACC 
 
Reverse primers (5’ to 3’): 
S112M_rv:  GTGCCCATGGTCAGCAGCCACTGG 
K121A_rv:  GTGCTTGCCCAGGCATTTGCTTCGGTGG 
K121R_rv:  GTGCTGCGCCAGGCATTTGCTTCGGTGG 
 
PCR mixture: 
5 μl Q5-buffer (5x), 0.5 μl template DNA (25 ng/μl), 0.5 μl primers (10 μM), 0.5 μl dNTP`s (10 mM), 1 μl DMSO, 
16.5 μl water, 0.5 μl Q5 Hot start HF DNA polymerase (2 U/μl).  
 
PCR program: 
95°C for 2 min; 95°C for 15 s, 60 °C for 20 s, 72°C for 5 min (17 cycles); 72°C for 10 min.  
 
PCR products were digested (DpnI, 37°C, 90 min) and mutants were analysed as described for the single 
(GGS)2 mutants. Mutants S112M-K121A, S112M-K121N and K121N-L124G were produced by other members 
of the Ward research group.  
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4.2.8 Expression and purification of Sav mutants 
The recombinant expression of streptavidin in E. coli cells used in this thesis relies on a pET expression 
system.230-231  
 
Expression in TOP10(DE3) E. coli cells: 
Pre-culture (10 mL LB-medium containing 50 μg/mL kanamycin) was inoculated from a glycerol stock and 
incubated overnight (37°C, 200 rpm shaking). The main culture (1 L LB-rich medium containing: 5.35 g/L yeast 
extract, 10.70 g/L bactotryptone, 1.77 g/L Na2HPO4, 1.70 g/L KH2PO4, 1.34 g/L NH4Cl, 0.36 g/L Na2SO4, 0.24 
g/L MgSO4, 0.5 g/L glucose, 6.31 g/L glycerol and 50 μg/mL kanamycin) was inoculated with pre-culture to a 
starting OD600 of 0.1 and incubated for 2.5 h (37°C, 200 rpm shaking). The temperature was set to 20°C and 
the culture was incubated for 1 h. At an OD600 of 1.0, the main culture was induced with IPTG (final 
concentration: 40 μM) and incubated for additional 20 h (20°C, 200 rpm shaking). The cell culture was 
centrifuged (3200 g, 8°C, 10 min). The cell pellet was resuspended in 50 ml lysis buffer (PBS buffer (1x, pH 
7.4) containing 0.5 mg/ml DNAse, 1.0 mg/ml Lysozyme and 1 mM PMSF) and incubated for 1 h (37°C, 200 
rpm shaking). Sample was freeze-thawed once and incubated for another 3 h (25°C, 180 rpm shaking).  
 
Expression in BL21(DE3) E. coli cells: 
The pre-culture (25 ml LB-medium containing 50 μg/mL kanamycin) was inoculated from a glycerol stock and 
incubated overnight (37°C, 200 rpm shaking). The main culture (1 L Auto-induction medium (ZYP-5052)232 
containing 50 μg/mL kanamycin) was inoculated with pre-culture (20 mL) and incubated for 24 h (30°C, 180 
rpm shaking). Cells were harvested and treated as described for the expression in E. coli TOP10(DE3).  
 
SDS-PAGE analysis: 
The solubility and oligomeric state of the expressed Sav loop mutants was analyzed by SDS-PAGE.233 200 μl 
cell lysate was centrifuged (21’000 g, 8°C, 10 min), the supernatant (= soluble fraction) was separated and 
the cell pellet (= insoluble fraction) was dissolved in 200 μl urea (8 M). Both fractions (19 μl each) were mixed 
with 1 μl B4F (0.04 mM in DMSO) and 10 μl loading buffer (3x) and applied to the polyacrylamide gel. The 
analysis of selected Sav loop mutants is displayed in Figure 35.  
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Soluble fraction (UV-light, B4F-stain)      Insoluble fraction (UV-light, B4F-stain) 
 
 
Soluble fraction (Vis-light, coomassie-stain)    Insoluble fraction (Vis-light, coomassie-stain) 
 
 
Figure 35: SDS-PAGE analysis of selected Sav loop mutants.  
 
Purification of cell lysate: 
The cell lysate was filled into dialysis bags (6-8 kDa MWCO) and dialyzed against guanidinium hydrochloride 
(6 M, pH set to 1.5 with HCl, 12 h), followed by dialysis in Tris-HCl (20 mM, pH 7.4, 12 h) and iminobiotin-
binding buffer (50 mM NaHCO3, 500 mM NaCl, pH 9.8, 12 h). The sample was centrifuged (3200 g, 10°C, 45 
min) and filtered (0.2 μm filter). The sample was purified by affinity column chromatography (AKTAprime 
Plus chromatography system equipped with a 2-iminobiotin sepharose column). The eluate was neutralized 
with Tris-HCl (pH 7.4, final concentration: 20 mM), followed by dialysis in MilliQ-water (4 x 12 h) and 
lyophilisation.  
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Refolding of streptavidin loop mutants: 
The refolding procedure for the streptavidin constructs 48TPR and 66TPR was adapted from methods 
reported by Howarth and Ting et al.187-188 Recently Ward et al. reported a detailed refolding procedure for 
chimeric streptavidin constructs.179  
 
Buffers: 
 
GuHCl (denaturing):  Guanidinium hydrochloride (45.84 g) in 80 ml MilliQ-water. pH set with HCl 
to 1.5. → final conc.: guanidinium hydrochloride (6 M).  
 
PBS-buffer (refolding): NaCl (32 g) + KCl (0.8 g) + Na2HPO4 · 12 H2O (14.32 g) + KH2PO4 (0.96 g) filled 
up with MilliQ-water to 4 L. pH set with HCl to 7.4. → final conc.: NaCl (137 
mM), KCl (2.7 mM), Na2HPO4 (10 mM), KH2PO4 (1.76 mM).  
 
The cell lysate was centrifuged (3200 g, 10°C, 45 min). The supernatant was discarded and the pellet was 
dissolved in GuHCl (80 ml) and heated to 95°C for 10min. The solution was then added dropwise to PBS-
buffer (4 L), whereupon a white precipitate was formed. The resulting mixture was stirred at 8°C overnight. 
The mixture was centrifuged (3200 g, 8°C, 10 min) and the supernatant, where applicable, was purified by 
affinity column chromatography (AKTAprime Plus chromatography system equipped with a 2-iminobiotin 
sepharose column). An SDS-PAGE analysis of the refolded streptavidin constructs is illustrated in Figure 36.  
 
        UV-light, B4F-stain      Vis-light, coomassie-stain 
 
 
Figure 36: SDS-PAGE analysis of the refolded streptavidin loop constructs 48TPR and 66TPR.  
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Free biotin binding sites: 
The number of free biotin binding sites per tetramer of the purified streptavidin loop mutants was 
determined by a B4F-test.55 BSA-buffer (5 mg BSA in 50 ml phosphate buffer (0.1 M NaH2PO4/Na2HPO4, pH 
7.0)) was prepared. Solutions of streptavidin (2 μM Sav-tetramer in BSA-buffer) and B4F (40 μM in BSA-
buffer) were prepared and mixed at different ratios. The samples were incubated for 5 min at 25°C and the 
fluorescence (λex. = 485 nm, λem. = 520 nm) was determined. The number of free biotin binding sites per 
streptavidin tetramer was determined at the intersection of the two linear segments in the titration profile. 
The titration profile of the Sav loop mutant Loop2-K121R (Table 9, entry 34) is displayed in Figure 37.  
 
 
Figure 37: B4F-test with the streptavidin mutant Loop2-K121R.  
At the intersection of the two linear segments obtained by linear regression (for the red and blue dots) the number of free biotin 
binding sites per streptavidin tetramer can be calculated. For the mutant Loop2-K121R displayed, a value of 3.5 was determined.  
 
MS-analysis: 
The mass of the expressed and purified Sav variants was determined by ESI-TOF mass spectrometry. Annex 
spectra on pages 210-213.  
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4.2.9 Preparation of a 3D-printing model 
Protocol for the preparation of a 3D-protein model: 
A crystal structure of [Cp*Ir(biot-p-L)Cl] · Sav-S112A (PDB ID 3PK2)60 was loaded into VMD (version 1.9.1).202 
Table 13 shows the list of “Representations” which were drawn in VMD. The material selection was set to AO 
Edgy. The resolution was set to 50.  
Table 13: Structure elements of the 3D-model drawn in VMD.  
Entry Selection Draw style Size (radius) Comment 
1 protein trace 0.8 Protein backbone 
2 type CA licorice 1.2 Cα-atoms of the backbone 
3 resid 400 CPK 3.0 Biotinylated ligand 
4 resid 48 50 53 84 85 86 87 98 110 111 
112 113 114 115 116 117 118 119 121 
122 123 124 and chain A and not type C 
N O and not altloc B 
licorice  0.6 Side chains of selected 
residues in monomer A 
5 resid 65 67 68 69 and chain D and not 
type C N O 
licorice 0.6 Side chains of selected 
residues in monomer A 
6 resid 64 and chain D and not type C O licorice 0.6 Pro64 of monomer D 
7 resid 23 27 43 45 90 128 and chain A and 
not type C N O 
licorice 0.6 Biotin binding residues  
(H-bonds) 
8 resid 49 and chain A and not sidechain licorice 0.6 Asn49 of monomer A 
 
2) In order to stabilize the protein structure, additional artificial bonds were inserted (grey cylinders). 
Residues to install these bonds were selected by visual inspection of the protein structure. A list of all 
stabilizing bonds is given in Table 14. In addition, the H-bonds between the protein and the biotinylated metal 
cofactor were drawn (white cylinders). The coordinates of the corresponding atoms were extracted from the 
pdb file using the TkConsole in VMD. The following commands were typed: 
 
set sel [atomselect 0 “resid 18 and name CA and chain A”]  //selects Cα of residue 18 of chain A 
set sel [atomselect 0 “index 84”]          //selects the atom with the index 84 
atomselect0 get {x y z}             //gets coordinates of the selected atoms 
atomselect0 writepdb test.pdb           //saves selection in pdb file named “test” 
 
A grey cylinder between two atoms with the coordinates (X1 Y1 Z1) and (X2 Y2 Z2) was drawn by typing the 
following commands into the VMD TkConsole: 
 
graphics top color 2                    //sets the color to grey 
graphics top cylinder {X1 Y1 Z1} {X2 Y2 Z2} radius 0.5 resolution 30 filled 1   //draws the cylinder 
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Table 14: Artificial bonds to stabilize the 3D-protein model.  
Chain Residue ↔ Chain Residue  Chain Residue ↔ Chain Residue 
A Tyr22  A Thr131  A Ala78  D Tyr60 
A Thr106  A Asp128  A Thr76  D Gly58 
A Arg103  A Thr131  A Gly58  D Thr57 
A Leu109  A Val125  A Ser88  D Ala72 
A Ala112  A Ser122  A Thr91  D Gly74 
A Gly98  A Ala102  A Gly74  D Thr76 
A Tyr96  A Ile104  A Tyr60  D Ala78 
A Ser93  A Gln107  A Thr71  D Gly113 
A Thr90  A Leu110  A Leu73  D Ala89 
A Ser88  A Ala112  A Gly94  D Thr111 
A Ala78  A Ala89  A Thr111  D Gly94 
A Thr76  A Thr91  A Thr91  D Thr91 
A Ala72  A Gln95       
A Asp61  A Ala72  B Leu124  D Leu124 
A Gly58  A Trp75  B Trp120  D Gly126 
A Thr42  A Val55  B Lys121  D Leu124 
A Leu39  A Gly58  B Thr123  D Val125 
A Ala33  A Leu39       
A Ile30  A Thr42  D Asn23:ND2  Ir400 O1 
A Thr28  A Glu44  D Ser27:OG  Ir400 O1 
A Trp21  A Phe29  D Ser45:OG  Ir400 N2 
A Thr18  A Thr32  D Tyr43:OH  Ir400 O1 
      D Thr90:OG1  Ir400 S1 
      D Asp128:OD2  Ir400 N1 
      D Asn49:N  Ir400 O2 
In green: Bonds within the same monomer (here shown for monomer A) were created in the other monomers (B-D) as well. In red: 
Bonds between two adjacent monomers (here shown for monomer A and D) were created for the other pair of monomers (B and C) 
as well. In blue: Bonds between two opposite monomers (here shown for monomer B and D) were created for the other pair of 
monomers (A and C) as well. In pink: Hydrogen bonds between the protein (here monomer D) and the biotinylated metal cofactor.  
3) The final structure in VMD was exported as an .OBJ file.  
 
4) The residue numbers (e.g. “48>”) were drawn in Blender (version 2.70) by adding a new object “Add object 
(Text)”. The text was modified in the “Edit Mode” using the following settings: Scale (X,Y,Z):  0.060; Extrude: 
0.200; Resolution: 30; Offset: 0.035; Spacing Letter: 1.50; Font Regular: MW-QUOIN. The labels were 
exported as .x3d files.  
 
5.) The protein structure from VMD and the residue labels from Blender were both imported into Meshlab 
(version 1.3.4). The labels were moved to the right place using the “Manipulators tool”. When required, the 
labels can be rescaled using the following command in the menu bar: 
 
Filters --> Normals, Curvatures and Orientation --> Transform: Scale 
If color got lost, then press: Render --> Color --> Color per Face 
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The labels and the protein structure were fused together: 
 
Filters --> Mesh layer --> Flatten visible layers (only select “Merge only visible layers”) 
If color got lost, then press: Filters --> Sampling --> Vertex Attribute Transfer (select “Transfer color”) 
Render --> Color --> Per Vertex 
 
The fused model was then checked for non-manifold edges and vertices: 
 
Render --> Show Non Manif Edges 
Render --> Show Non Manif Vertices 
 
The model was then checked for “water tightness”: 
 
View --> Show layer dialog 
Filters --> Quality, Measure and computation --> Compute Geometric Measures 
 
Finally, the model was exported as .x3d file (Vert=Color, Faces=Normal) 
 
6.) The model was printed on a ProJet 4500 printer from 3dsystems with the help of Dr. Stefan Imseng 
(Biozentrum, University of Basel).  
 
7.) The cleaned model was sprayed with a mixture of isopropanol/chloroform 1:1 to get a smooth and shiny 
surface.  
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4.3 Synthesis 
4.3.1 Biotinylated ruthenium cofactor: main synthesis route 
 
The synthesis of the biotinylated ligand 26 described in this chapter will be published elsewhere.118  
 
Compound 20: 
 
N
OH
O
O
1
23
4
567
8
9
10 11
20
 
 
The synthesis was performed similarly to Manfredini et al.234  
Kynurenic acid (19, 5.00 g, 26.4 mmol, 1.0 eq.) was dispersed in dry methanol (50 ml, 39.6 g, 1240 mmol, 47 
eq.). Concentrated sulfuric acid (3.0 ml, 5.5 g, 56.3 mmol, 2.1 eq.) was added, whereupon the mixture got 
clear. The solution was heated to reflux for 20 h under an N2 atmosphere. The solution was evaporated to 
dryness, yielding a yellow oil. Water (100 ml) and saturated aqueous NaHCO3 (100 ml) were added, 
whereupon an off-white solid precipitated. The solid was filtered, washed with diethyl ether (50 ml) and dried 
to yield the product as a white solid (20, 4.53 g, 22.3 mmol, 84% yield).  
 
Annex spectra on page 173.  
 
Appearance: White solid 
 
1H NMR (400 MHz, DMSO-d6, δ/ppm): 12.09 (s, 1H, OH), 8.08 (dd, J = 8.1, 1.5 Hz, 1H, 7), 7.94 (d, J = 8.4 Hz, 
1H, 10), 7.71 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H, 9), 7.38 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H, 8), 6.66 (s, 1H, 4), 3.96 (s, 3H, 
1). Solvents: Water (3.37), DMSO (2.50). Standard: TMS (0.01).  
 
13C NMR (101 MHz, DMSO-d6, δ/ppm): 162.85 (1C, 2), 140.45 (1C, 11, extrapolated from HMBC spectrum), 
132.48 (1C, 9), 125.80 (1C, 6), 124.59 (1C, 7), 124.10 (1C, 8), 120.00 (1C, 10), 109.90 (1C, 4), 53.46 (1C, 1). 
Solvents: DMSO (40.15, 39.94, 39.73, 39.52, 39.31, 39.10, 38.89). Standard: TMS (0.10). The signals for the 
quaternary carbons 3 and 5 could not be resolved.  
 
HRMS (ESI-MS, pos.) m/z: [M+H]+ calculated for C11H10NO3: 204.0655, found: 204.0655.  
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Compound 21: 
 
N
Br
O
O
1
23
4
567
8
9
10 11
21
 
 
The synthesis was performed similarly to Kato et al.235  
A mixture of methyl ester 20 (2.30 g, 11.3 mmol, 1.0 eq.), P2O5 (3.55 g, 24.9 mmol, 2.2 eq.) and Bu4NBr (4.02 
g, 12.4 mmol, 1.1 eq.) in toluene (80 ml) was heated at 90°C for 1 h with vigorous stirring. After cooling to 
room temperature, the resulting upper toluene layer was collected. The organic phase was washed with 
saturated NaHCO3 (150 ml), brine (150 ml) and water (150 ml), dried over Na2SO4 and concentrated under 
reduced pressure to yield a yellow solid (21, 1.10 g, 4.12 mmol, 36% yield). This crude product was used for 
the next synthesis step without further purification.  
 
Annex spectra on page 174.  
 
Appearance: Yellow solid 
 
1H NMR (400 MHz, DMSO-d6, δ/ppm): 8.38 (s, 1H, 4), 8.23 (s (broad), 1H, 7 or 10), 8.21 (s (broad), 1H, 7 or 
10), 8.01 – 7.94 (m, 1H, 8 or 9), 7.94 – 7.88 (m, 1H, 8 or 9), 3.97 (s, 3H, 1). Solvents: Toluene (7.24, 7.17, 2.29), 
Water (3.35), DMSO (2.50). 
 
13C NMR (101 MHz, DMSO-d6, δ/ppm): 164.17 (1C, 2), 147.52 (1C), 147.30 (1C), 134.29 (1C), 131.80 (1C), 
130.63 (1C), 130.60 (1C), 127.94 (1C), 126.31 (1C), 124.52 (1C), 52.90 (1C, 1). Solvents: Toluene (137.32, 
128.87, 128.18, 125.29, 21.03), DMSO (40.15, 39.94, 39.73, 39.52, 39.31, 39.10, 38.89). Impurities: 29.04, 
23.37.  
 
UPLC-MS (ESI-MS, pos.) m/z: [M+H]+ calculated for C12H879BrNO2: 265.98, found: 266.02; calculated for 
C12H881BrNO2: 267.98, found: 267.97.  
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Compound 22: 
 
N
N
O
O
1
23
4
567
8
9
10 11
N
OO
12
13
14
15
16
22
 
 
Under an N2 atmosphere, methyl 4-bromoquinoline-2-carboxylate (21, 1.00 g, 3.76 mmol, 1.0 eq.), tert-butyl 
piperazine-1-carboxylate (707 mg, 3.76 mmol, 1.0 eq.), Pd2(dba)3 (196 mg, 0.23 mmol, 0.06 eq.), rac. BINAP 
(135 mg, 0.23 mmol, 0.06 eq.) and CsCO3 (2.74 g, 8.41 mmol, 2.2 eq.) were mixed in dry 1,4-dioxane (30 ml) 
and heated to reflux for 15 h. The red mixture was filtered and the clear solution evaporated to dryness. The 
resulting red oil was taken up in ethyl acetate and purified by flash column chromatography (SiO2, ethyl 
acetate/cyclohexane 1:2 → 1:1). The fractions were concentrated and dried under reduced pressure to yield 
the product as a yellow-orange solid (22, 409 mg, 1.10 mmol, 29% yield).  
 
Annex spectra on page 175.  
 
Appearance: Yellow-orange solid 
 
TLC: Ethyl acetate/cyclohexane 2:3; Rf = 0.30 
 
1H NMR (400 MHz, CDCl3 δ/ppm): 8.26 (ddd, J = 8.5, 1.3, 0.6 Hz, 1H, 10), 8.04 (ddd, J = 8.4, 1.5, 0.6 Hz, 1H, 7), 
7.73 (ddd, J = 8.5, 6.8, 1.4 Hz, 1H, 9), 7.67 (s, 1H, 4), 7.59 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H, 8), 4.06 (s, 3H, 1), 3.78 
– 3.69 (m, 4H, 13), 3.30 – 3.19 (m, 4H, 12), 1.50 (s, 9H, 16). Solvents: Chloroform (7.26), DCM (5.29). Standard: 
TMS (0.00).  
 
13C NMR (101 MHz, CDCl3 δ/ppm): 166.49 (1C, 2), 158.01 (1C, 5), 154.86 (1C, 14), 149.14 (1C, 11), 148.59 (1C, 
3), 131.60 (1C, 10), 130.04 (1C, 9), 127.61 (1C, 8), 124.47 (1C, 6), 123.49 (1C, 7), 109.14 (1C, 4), 80.37 (1C, 15), 
53.38 (1C, 1), 52.26 (2C, 12), 43.63 (2C, 13, extrapolated from HMQC spectrum), 28.57 (3C, 16). Solvents: 
Chloroform (77.48, 77.16, 76.84). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+H]+ calculated for C20H26N3O4: 372.1918, found: 372.1923.  
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Compound 24: 
 
O
NH
O
H
HN
H S
O
F
F
F
F
F24
1
23456
7
8
9
10
11
12
13
14
15
16
 
 
The synthesis was performed according to Thompson et al.236  
To a dispersion of D-biotin (23, 1.00 g, 4.08 mmol, 1.0 eq.) in DMF (25 ml), triethylamine (1.00 ml, 0.73 g, 
7.17 mmol, 1.8 eq.) was added at 0°C. Pentafluorophenyl trifluoroacetate (1.00 ml, 1.63 g, 5.81 mmol, 1.4 
eq.) was slowly added, which led to the formation of a pink solution. The reaction mixture was allowed to 
warm up to room temperature and was further stirred for 2 h, whereupon a white precipitate formed. Diethyl 
ether (80 ml) was added, the precipitate was filtered, washed with diethyl ether (80 ml) and dried at reduced 
pressure to yield the product as a white solid (24, 998 mg, 2.43 mmol, 60% yield).  
 
Annex spectra on page 176.  
 
Appearance: White solid 
 
1H NMR (400 MHz, DMSO-d6 δ/ppm): 6.45 (s, 1H, 15), 6.37 (s, 1H, 13), 4.36 – 4.27 (m, 1H, 12), 4.19 – 4.11 (m, 
1H, 16), 3.17 – 3.08 (m, 1H, 10), 2.87 – 2.81 (m, 1H, 11), 2.79 (t, J = 7.6 Hz, 2H, 6), 2.58 (d, J = 12.4 Hz, 1H, 11), 
1.78 – 1.34 (m, 6H, 7 + 8 + 9). Solvents: Water (3.32), DMSO (2.50).  
 
13C NMR (101 MHz, DMSO-d6 δ/ppm): 169.51 (1C, 5), 162.67 (1C, 14), 61.02 (1C, 16), 59.17 (1C, 12), 55.25 
(1C, 10), 39.78 (1C, 11, extrapolated from HMQC spectrum), 32.30 (1C, 6), 27.92 (1C, 9), 27.68 (1C, 8), 24.30 
(1C, 7). Solvents: DMSO (40.15, 39.94, 39.73, 39.52, 39.31, 39.10, 38.89). The signals for the quaternary 
carbons 1 – 4 could not be resolved. 
 
19F NMR (376 MHz, DMSO-d6 δ/ppm): -153.59 (d, J = 19.1 Hz, 2F, 3), -158.12 (t, J = 23.1 Hz, 1F, 1), -162.63 
(dd, J = 23.3, 19.1 Hz, 2F, 2). 
 
NMR spectra are in good accordance with the results from Neier et al.237  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C16H15N2O3SF5Na: 433.0616, found: 433.0616.  
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Compound 25: 
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The synthesis was performed similarly to Kajetanowicz et al.238  
Methyl 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)quinoline-2-carboxylate (22, 0.40 g, 1.09 mmol, 1.0 eq.) and 
triisopropylsilane (0.44 ml, 0.35 g, 2.18 mmol, 2.0 eq., scavenger for carbocations) were dissolved in DCM (2 
ml) and treated with concentrated trifluoroacetic acid (2 ml). The red solution was stirred for 1 h at room 
temperature and then evaporated to dryness. The orange oil was dissolved in DCM (2 ml). Addition of diethyl 
ether (20 ml) led to the formation of a yellow precipitate which was filtered, washed with diethyl ether (2 x 
10 ml) and dried under reduced pressure to afford an off-white solid (0.52 g). This solid was dissolved in DMF 
(5 ml), followed by the addition of N,N-diisopropylethylamine (0.95 ml, 0.70 g, 5.44 mmol, 5.0 eq.) and D-
biotin pentafluorophenyl ester (24, 0.44 g, 1.09 mmol, 1.0 eq.). The reaction mixture was stirred for 24 h at 
room temperature (until no more D-biotin pentafluorophenyl ester was detectable on TLC (DCM/MeOH 10:1, 
DACA-stain) and evaporated to dryness to obtain a brown oil. Addition of diethyl ether (20 ml) led to the 
precipitation of an off-white solid, which was filtered and washed with diethyl ether (4 x 50 ml). The solid 
was then dissolved in DCM (20 ml), washed with saturated NaHCO3 (20 ml) and water (20 ml). The organic 
fraction was dried over Na2SO4. The solvent was evaporated under reduced pressure to yield the product as 
a pale yellow solid (25, 224 mg, 0.85 mmol, 78% yield).  
 
Annex spectra on page 177.  
 
Appearance: Pale yellow solid 
 
1H NMR (400 MHz, Methanol-d4 δ/ppm): 8.18 (dd, J = 5.6, 0.8 Hz, 1H, 7), 8.16 (dd, J = 5.4, 0.6 Hz, 1H, 10), 
7.79 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H, 9), 7.68 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H, 8), 7.67 (s, 1H, 4), 4.50 (ddd, J = 7.9, 
5.0, 1.0 Hz, 1H, 23), 4.32 (dd, J = 7.9, 4.4 Hz, 1H, 27), 4.03 (s, 3H, 1), 3.92 (t, J = 4.8 Hz, 2H, 13 or 15), 3.88 (t, J 
= 5.0 Hz, 2H, 13 or 15), 3.39 – 3.33 (m, 2H, 12 or 14), 3.30 – 3.27 (m, 2H, 12 or 14), 3.23 (ddd, J = 8.8, 5.9, 4.4 
Hz, 1H, 21), 2.93 (dd, J = 12.8, 5.0 Hz, 1H, 22), 2.71 (d, J = 12.6 Hz, 1H, 22), 2.51 (t, J = 7.4 Hz, 2H, 17), 1.83 – 
1.59 (m, 4H, 18 + 20), 1.56 – 1.45 (m, 2H, 19). Solvents: DCM (5.49), Water (4.86), DMF (7.97, 2.99, 2.86). 
Standard: TMS (0.00). Acidic protons 24 and 26 are due to proton-deuterium exchange with the solvent 
methanol-d4 not visible in the 1H spectrum.  
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13C NMR (101 MHz, Methanol-d4 δ/ppm): 174.24 (1C, 16), 167.04 (1C, 2), 166.14 (1C, 25), 159.64 (1C, 5), 
149.97 (1C, 11), 149.48 (1C, 3), 131.56 (1C, 9), 131.15 (1C, 10), 128.86 (1C, 8), 125.46 (1C, 6), 125.03 (1C, 7), 
109.78 (1C, 4), 63.41 (1C, 27), 61.68 (1C, 23), 57.08 (1C, 21), 53.48 (1C, 1), 53.41 (1C, 12 or 14), 53.15 (1C, 12 
or 14), 46.88 (1C, 13 or 15), 42.83 (1C, 13 or 15), 41.09 (1C, 22), 33.75 (1C, 17), 29.94 (1C, 19), 29.60 (1C, 20), 
26.41 (1C, 18). Solvents: Methanol (49.68, 49.46, 49.25, 49.04, 48.82, 48.61, 48.40). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+H]+ calculated for C25H32N5O4S: 498.2170, found: 498.2178.  
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The methyl ester 25 (100 mg, 0.20 mmol, 1.0 eq.) was dissolved in MeOH (2 ml) and treated with LiOH·H2O 
(16 mg, 0.40 mmol, 2.0 eq.). The reaction mixture was stirred for 22 h at room temperature (until no more 
starting material was detected on TLC (DCM/MeOH 10:1). The mixture was filtered to remove the excess of 
insoluble LiOH. Addition of diethyl ether (5 ml) led to the formation of an off-white precipitate, which was 
washed with diethyl ether (3 x 5 ml) and dried under reduced pressure to obtain the product as an off-white 
solid (26, 80.9 mg, 0.17 mmol, 83% yield).  
 
Annex spectra on page 178.  
 
Appearance: Off-white solid 
 
1H NMR (400 MHz, Methanol-d4 δ/ppm): 8.14 (dd, J = 8.4, 0.8 Hz, 1H, 6), 8.07 (dd, J = 8.6, 0.9 Hz, 1H, 9), 7.72 
(ddd, J = 8.4, 6.8, 1.4 Hz, 1H, 8), 7.66 (s, 1H, 3), 7.59 (ddd, J = 8.3, 6.8, 1.2 Hz, 1H, 7), 4.50 (ddd, J = 7.9, 5.0, 
0.9 Hz, 1H, 22), 4.32 (dd, J = 7.9, 4.4 Hz, 1H, 26), 3.91 (t, J = 5.4 Hz, 2H, 12 or 14), 3.88 (t, J = 4.7 Hz, 2H, 12 or 
14), 3.39 – 3.32 (m, 2H, 11 or 13), 3.30 – 3.23 (m, 2H, 11 or 13), 3.27 – 3.18 (m, 1H, 20), 2.93 (dd, J = 12.7, 5.0 
Hz, 1H, 21), 2.71 (d, J = 12.7 Hz, 1H, 21), 2.52 (t, J = 7.4 Hz, 2H, 16), 1.84 – 1.58 (m, 4H, 17 + 19), 1.57 – 1.45 
(m, 2H, 18). Solvents: Water (4.87), diethyl ether (3.49 + 1.17). Standard: TMS (0.00). Acidic protons 23 and 
25 are due to proton-deuterium exchange with the solvent methanol-d4 not visible in the 1H spectrum.  
 
13C NMR (101 MHz, Methanol-d4 δ/ppm): 174.24 (1C, 15), 173.04 (1C, 1), 166.15 (1C, 24), 159.12 (1C, 4), 
157.23 (1C, 2), 149.54 (1C, 10), 130.78 (1C, 8), 130.66 (1C, 9), 127.53 (1C, 7), 124.80 (1C, 5 or 6), 124.79 (1C, 
5 or 6), 109.87 (1C, 3), 63.41 (1C, 26), 61.69 (1C, 22), 57.05 (1C, 20), 53.37 (1C, 11 or 13), 53.35 (1C, 11 or 13), 
46.99 (1C, 12 or 14), 42.93 (1C, 12 or 14), 41.08 (1C, 21), 33.76 (1C, 16), 29.92 (1C, 18), 29.58 (1C, 19), 26.42 
(1C, 17). Solvents: Methanol (49.68, 49.46, 49.25, 49.04, 48.82, 48.61, 48.40). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+H2]+ calculated for C24H30N5O4S: 484.2013, found: 484.2014.  
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4.3.2 Biotinylated ruthenium cofactor: alternative synthesis routes 
 
Compound 28: 
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The synthesis was performed similarly to Meggers et al.94  
The methyl ester 22 (100 mg, 0.27 mmol, 1.0 eq.) was dissolved in MeOH (5 ml) and treated with LiOH·H2O 
(22.4 mg, 0.54 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 48 h (until no more 
methyl ester 22 was detected on TLC (cyclohexane/ethyl acetate 1:1)). The mixture was filtered to remove 
the excess of insoluble LiOH·H2O. The solvent was evaporated and the residue dried under reduced pressure 
to yield a yellow-orange solid (94 mg, lithium salt of the carboxylic acid). This solid and sodium bicarbonate 
(36 mg, 0.44 mmol, 1.7 eq.) were dispersed in dry DMF (10 ml) and treated with allyl bromide (48 μl, 67 mg, 
0.54 mmol, 2.0 eq.). The mixture was stirred at 50°C for 18 h. Water (25 ml) was added and the reaction 
mixture was extracted with DCM (3 x 25 ml). The organic phase was dried over Na2SO4 and the solvent 
evaporated to obtain a yellow oil. This oil was purified by flash column chromatography (SiO2, 
cyclohexane/ethyl acetate 5:2). The fractions were concentrated and dried under reduced pressure to yield 
the product as a yellow solid (28, 66 mg, 0.17 mmol, 64% yield).  
 
Annex spectra on page 179.  
 
Appearance: Yellow solid 
 
TLC: Ethyl acetate/cyclohexane 1:2; Rf = 0.45 
 
1H NMR (500 MHz, Chloroform-d δ/ppm): 8.27 (ddd, J = 8.6, 1.3, 0.6 Hz, 1H, 12), 8.04 (ddd, J = 8.4, 1.5, 0.6 
Hz, 1H, 9), 7.73 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H, 11), 7.66 (s, 1H, 6), 7.59 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H, 10), 6.12 
(ddt, J = 17.1, 10.4, 5.9 Hz, 1H, 2), 5.47 (dq, J = 17.2, 1.5 Hz, 1H, 1), 5.34 (dq, J = 10.4, 1.2 Hz, 1H, 1), 4.98 (dt, 
J = 6.0, 1.3 Hz, 2H, 3), 3.78 – 3.69 (m, 4H, 15 + 17), 3.30 – 3.21 (m, 4H, 14 + 16), 1.51 (s, 9H, 20). Solvents: 
DMF (8.02, 2.95, 2.88), chloroform (7.27), ethyl acetate (4.12, 2.05, 1.26), water (1.72), cyclohexane (1.43). 
Standard: TMS (0.00).  
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13C NMR (126 MHz, Chloroform-d δ/ppm): 165.51 (1C, 4), 157.82 (1C, 7), 154.72 (1C, 18), 149.06 (1C, 13), 
148.54 (1C, 5), 131.90 (1C, 2), 131.56 (1C, 12), 129.83 (1C, 11), 127.46 (1C, 10), 124.32 (1C, 8), 123.30 (1C, 9), 
119.25 (1C, 1), 109.02 (1C, 6), 80.23 (1C, 19), 66.84 (1C, 3), 52.09 (2C, 14 + 16), 43.65 (2C, 15 + 17, extrapolated 
from HMQC spectrum), 28.43 (3C, 20). Solvents: Chloroform (77.28, 77.03, 76.77). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+H]+ calculated for C22H28N3O4: 398.2074, found: 398.2080.  
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Compound 30: 
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The synthesis was performed similarly to Meggers et al.94  
Under a nitrogen atmosphere, [CpRu(MeCN)3]PF6 (12.8 mg, 0.03 mmol, 1.0 eq.) was dissolved in dry acetone 
(1 ml), yielding a yellow solution. A solution of ligand 28 (12.0 mg, 0.03 mmol, 1.0 eq.) in dry acetone (1 ml) 
was added. The resulting orange solution was stirred at room temperature for 45 min. The solvent was 
evaporated under a stream of nitrogen, yielding an orange-brown residue. This residue was washed with dry 
cold acetone (1 ml) to obtain the product as a yellow solid (30, 4.1 mg, 5.8 μmol, 20% yield).  
 
Annex spectrum on page 180.  
 
Appearance: Yellow solid 
 
1H NMR (400 MHz, Acetonitrile-d3 δ/ppm): 8.17 (dd, J = 8.5, 1.3 Hz, 1H, 10 or 13), 7.96 (ddd, J = 8.6, 6.9, 1.5 
Hz, 1H, 11 or 12), 7.76 (ddd, J = 8.3, 6.9, 1.1 Hz, 1H, 11 or 12), 7.72 (d, J = 8.8 Hz, 1H, 10 or 13), 7.47 (s, 1H, 
7), 6.12 (s, 5H, 1), 4.64 – 4.49 (m, 2H, 2 or 3 or 4), 4.37 (d, J = 10.1 Hz, 1H, 2 or 3 or 4), 4.29 (dd, J = 6.0, 2.7 
Hz, 1H, 2 or 3 or 4), 4.08 (dd, J = 5.8, 2.9 Hz, 1H, 2 or 3 or 4), 3.77 – 3.60 (m, 4H, 15 + 17 or 16 + 18), 3.57 – 
3.38 (m, 4H, 15 + 17 or 16 +18), 1.47 (s, 9H, 21). Solvents: Water (2.16), acetone (2.09), acetonitrile (1.94).  
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Compound 29: 
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Allyl ester 28 (25 mg, 63 μmol, 1.0 eq.) was dissolved in dry 1,4-dioxane (2 ml) and treated with HCl (4 M in 
1,4-dioxane, 157 μl, 630 μmol, 10.0 eq.). The resulting yellow solution was stirred at room temperature for 
2.5 h, whereby a yellow precipitate formed. The precipitate was filtered, washed with diethyl ether (3 x 5 ml) 
and dried to yield the crude product as a yellow solid (29, 15.7 mg, 47 μmol, 75% yield). UPLC-MS analysis 
stated the presence of a small fraction of the educt (28). However, the obtained crude product was used for 
the next synthesis step without further purification.  
 
Annex spectra on page 181.  
 
Appearance: Yellow solid 
 
1H NMR (400 MHz, Methanol-d4 δ/ppm): 8.33 – 8.25 (m, 2H, 9 – 12), 8.05 (t, J = 7.7 Hz, 1H, 9 – 12), 7.88 – 
7.82 (m, 1H, 9 – 12), 7.81 (s, 1H, 6), 6.16 (ddt, J = 16.5, 11.1, 5.8 Hz, 1H, 2), 5.53 (d, J = 17.2 Hz, 1H, 1), 5.40 
(d, J = 10.4 Hz, 1H, 1), 5.05 (d, J = 6.0 Hz, 2H, 3), 4.07 (t, J = 4.8 Hz, 4H, 14 + 16 or 15 + 17), 3.62 (t, J = 5.0 Hz, 
4H, 14 + 16 or 15 + 17). Solvents: Water (4.88), methanol (3.31). Impurities: 3.79, 2.03, 1.51.  
 
UPLC-MS (ESI-MS, pos.) m/z: Product 29: [M-Cl]+ calculated for C17H20N3O2: 298.16, found: 298.15.  
Educt 28: [M-H]+ calculated for C22H28N3O4: 398.21, found: 398.14.  
 
Solubility: Product 29 is soluble in DMSO, MeOH and insoluble in acetone, MeCN, DCM, THF.  
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Compound 32: 
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The synthesis was performed similarly to Thompson et al.236  
To a solution of desthiobiotin (31, 0.20 g, 0.93 mmol, 1.0 eq.) in DMF (4 ml), triethylamine (0.23 ml, 0.17 g, 
1.68 mmol, 1.8 eq.) was added at room temperature. Pentafluorophenyl trifluoroacetate (0.22 ml, 0.36 g, 
1.30 mmol, 1.4 eq.) was slowly added. The reaction mixture was stirred at room temperature for 2 h. The 
solvent was evaporated and the resulting residue was washed with diethyl ether (3 x 5 ml) and dried under 
reduced pressure to obtain the product as a white solid (32, 100 mg, 0.26 mmol, 28% yield).  
 
Annex spectra on page 182.  
 
Appearance: White solid 
 
1H NMR (400 MHz, DMSO-d6 δ/ppm): 6.31 (s, 1H, 12 or 14), 6.12 (s, 1H, 12 or 14), 3.67 – 3.56 (m, 1H, 11 or 
16), 3.49 (td, J = 7.7, 4.8 Hz, 1H, 11 or 16), 2.78 (t, J = 7.3 Hz, 2H, 6), 1.67 (p, J = 7.2 Hz, 2H, 10), 1.47 – 1.15 
(m, 6H, 7 – 9), 0.96 (d, J = 6.4 Hz, 3H, 16). Solvents: Water (3.33), DMSO (2.50).  
 
19F NMR (376 MHz, DMSO-d6 δ/ppm): -153.68 (d, J = 19.3 Hz, 2F, 3), -158.14 (t, J = 23.2 Hz, 1F, 1), -162.64 
(dd, J = 23.2, 19.0 Hz, 2F, 2).  
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Compound 33: 
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The synthesis was performed similarly to Kajetanowicz et al.238  
Methyl 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)quinoline-2-carboxylate (22, 74 mg, 0.20 mmol, 1.0 eq.) and 
triisopropylsilane (82 μl, 64 mg, 0.40 mmol, 2.0 eq., scavenger for carbocations) were dissolved in DCM (2 
ml) and treated with concentrated trifluoroacetic acid (2 ml). The resulting red solution was stirred at room 
temperature for 2 h. The solvent was evaporated and the yellow residue was dissolved in DMF (3 ml), 
followed by the addition of N,N-diisopropylethylamine (0.35 ml, 0.26 g, 2.00 mmol, 10.0 eq.) and 
desthiobiotin pentafluorophenyl ester (32, 76 mg, 0.20 mmol, 1.0 eq.). The reaction mixture was stirred at 
room temperature for 24 h (until no more desthiobiotin pentafluorophenyl ester was visible on TLC 
(DCM/MeOH 10:1, DACA-stain) and then evaporated to dryness. The resulting red-brown oil was taken up in 
DCM (10 ml), washed with saturated NaHCO3 (10 ml) and water (10 ml) and dried over Na2SO4. The solvent 
was evaporated under reduced pressure to afford the crude product as a yellow-orange solid (33, 85.5 mg, 
0.18 mmol, 92% yield). This crude product was used for the next synthesis step without further purification.  
 
Annex spectra on page 183.  
 
Appearance: Yellow-orange solid 
 
1H NMR (400 MHz, Methanol-d4 δ/ppm): 8.16 – 8.08 (m, 2H, 7 + 10), 7.77 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H, 8 or 
9), 7.65 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H, 8 or 9), 7.59 (s, 1H, 4), 4.02 (s, 3H, 1), 3.93 – 3.77 (m, 5H, 13 + 15 + 22 
or 26), 3.75 – 3.65 (m, 1H, 22 or 26), 3.31 – 3.17 (m, 4H, 12 + 14), 2.48 (t, J = 7.5 Hz, 2H, 17), 1.74 – 1.60 (m, 
2H, 21), 1.55 – 1.24 (m, 6H, 18 – 20), 1.11 (d, J = 6.5 Hz, 3H, 27). Solvents: DMF (7.98, 2.99, 2.86), DCM (5.50), 
Water (4.87), Methanol (3.32). Impurities: 4.12, 1.15, 1.13, 1.04. Acidic protons 23 and 25 are due to proton-
deuterium exchange with the solvent methanol-d4 not visible in the 1H spectrum.  
 
UPLC-MS (ESI-MS, pos.) m/z: [M+H]+ calculated for C25H34N5O4: 468.26, found: 468.2; [M+Na]+ calculated for 
C25H33N5O4Na: 490.24, found: 490.2.  
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The synthesis was performed similarly to Meggers et al.94  
The methyl ester 33 (85 mg, 0.18 mmol, 1.0 eq.) was dissolved in MeOH (2 ml) and treated with LiOH·H2O 
(15 mg, 0.36 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 24 h (until no more 
methyl ester 33 was detected on TLC (DCM/MeOH 20:1, DACA-stain)). The mixture was filtered to remove 
the excess of insoluble LiOH·H2O. The obtained yellow solution was evaporated to dryness to yield a yellow-
orange solid (83 mg, lithium salt of the carboxylic acid). This solid and sodium bicarbonate (25 mg, 0.30 mmol, 
1.7 eq.) were dispersed in dry DMF (2 ml) and treated with allyl bromide (31 μl, 43 mg, 0.36 mmol, 2.0 eq.). 
The mixture was stirred at 50°C for 18 h. Water (10 ml) was added and the reaction mixture was extracted 
with DCM (3 x 10 ml). The organic phase was dried over Na2SO4 and concentrated to obtain a yellow oil. This 
oil was purified by flash column chromatography (SiO2, DCM/MeOH 25:1 → 15:1, product spot on TLC stained 
with DACA-stain). The fractions were concentrated and dried under reduced pressure to yield the crude 
product as a yellow solid (34, 5.0 mg, 0.01 mmol, 6% yield). According to NMR and UPLC-MS analysis the 
obtained product also contained parts (~15%) of the initial methyl ester 33. However, the obtained crude 
product was used for the next synthesis step without further purification.  
 
Annex spectra on page 184.  
 
Appearance: Yellow solid 
 
TLC: DCM/MeOH 15:1; Rf = 0.40 
 
1H NMR (400 MHz, Acetone-d6 δ/ppm): 8.26 – 8.19 (m, 1H, 9 or 12), 8.16 – 8.08 (m, 1H, 9 or 12), 7.80 (ddd, J 
= 8.4, 6.9, 1.4 Hz, 1H, 10 or 11), 7.68 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H, 10 or 11), 7.64 (s, 1H, 6), 6.13 (ddt, J = 17.2, 
10.5, 5.6 Hz, 1H, 2), 5.54 – 5.44 (m, 1H, 1), 5.35 – 5.27 (m, 1H, 1), 4.91 (dt, J = 5.6, 1.5 Hz, 2H, 3), 3.92 – 3.85 
(m, 4H, 15 + 17), 3.83 – 3.73 (m, 1H, 24 or 28), 3.71 – 3.63 (m, 1H, 24 or 28), 3.40 – 3.23 (m, 4H, 14 + 16), 2.47 
(t, J = 7.4 Hz, 2H, 19), 1.73 – 1.47 (m, 8H, 20 – 23), 1.10 (d, J = 6.4 Hz, 3H, 29). Solvents: DCM (5.62), water 
(2.82), acetone (2.05), “grease” (1.29, 0.87).  
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UPLC-MS (ESI-MS, pos.) m/z: Product 34: [M+H]+ calculated for C27H36N5O4: 494.28, found: 494.2; [M+Na]+ 
calculated for C27H35N5O4Na: 516.26, found: 516.2. Impurity (methyl ester 33) [M+H]+ calculated for 
C25H34N5O4: 468.26, found: 468.3.  
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Compound 36: 
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The synthesis was performed as described by Alves et al.239  
D-Biotin (23, 1.00 g, 4.10 mmol, 1.0 eq.) was suspended in glacial acetic acid (12 ml) and treated with aq. 
H2O2 (30% v/v, 4.30 ml, 41.00 mmol, 10.0 eq.). The mixture was stirred at room temperature for 24 h, 
whereupon a white precipitate formed. The precipitate was filtered, washed with diethyl ether (3 x 10 ml) 
and dried at reduced pressure to yield the product as a white solid (36, 932 mg, 3.37 mmol, 82% yield).  
 
Annex spectra on page 185.  
 
Appearance: White solid 
 
1H NMR (500 MHz, DMSO-d6 δ/ppm): 12.02 (s, 1H, COOH), 6.70 (s, 1H, 11), 6.60 (s, 1H, 9), 4.46 – 4.39 (m, 1H, 
8), 4.39 – 4.35 (m, 1H, 12), 3.32 – 3.27 (m, 1H, 7), 3.21 – 3.13 (m, 1H, 6), 3.02 (d, J = 13.8 Hz, 1H, 7), 2.24 – 
2.20 (m, 2H, 2), 1.72 – 1.59 (m, 2H, 5), 1.58 – 1.49 (m, 2H, 3), 1.46 – 1.37 (m, 2H, 4). Solvents: DMSO (2.50).  
 
13C NMR (126 MHz, DMSO-d6 δ/ppm): 174.37 (1C, 1), 161.60 (1C, 10), 60.25 (1C, 6), 54.19 (1C, 7), 53.47 (1C, 
12), 48.96 (1C, 8), 33.37 (1C, 2), 25.55 (1C, 4), 24.40 (1C, 3), 21.14 (1C, 5). Solvents: DMSO (40.02, 39.85, 
39.69, 39.52, 39.35, 39.19, 39.02).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C10H16N2O5SNa: 299.0672, found: 299.0675.  
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Compound 37: 
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The synthesis was performed similarly to Thompson et al.236  
To a dispersion of D-biotin sulfone (36, 0.50 g, 1.81 mmol, 1.0 eq.) in DMF (8 ml), triethylamine (0.44 ml, 0.32 
g, 3.19 mmol, 1.76 eq.) was slowly added at 0°C. Pentafluorophenyl trifluoroacetate (0.45 ml, 0.73 g, 2.56 
mmol, 1.43 eq.) was then added dropwise. The pink mixture was stirred at 0°C for 1 h and then at room 
temperature for 4 h. Diethyl ether (100 ml) was added, which led to the formation of a white precipitate. The 
white solid was filtered, washed with diethyl ether (4 x 20 ml) and dried under reduced pressure to yield the 
product as a white solid (37, 587 mg, 1.33 mmol, 73% yield).  
 
Annex spectra on page 186.  
 
Appearance: White solid 
 
1H NMR (400 MHz, DMSO-d6 δ/ppm): 6.73 (s, 1H, 12 or 14), 6.62 (s, 1H, 12 or 14), 4.59 – 4.19 (m, 2H, 11 + 
15), 3.41 – 3.28 (m, 1H, 16), 3.27 – 3.15 (m, 1H, 10), 3.15 – 3.01 (m, 1H, 16), 2.93 – 2.73 (m, 2H, 6), 1.93 – 
1.61 (m, 4H, 7 + 9), 1.61 – 1.43 (m, 2H, 8). Solvents: DMSO (2.50). Standard: TMS (0.00).  
 
13C NMR (101 MHz, DMSO-d6 δ/ppm): 169.46 (1C, 5), 161.58 (1C, 13), 60.16 (1C, 10), 54.19 (1C, 16), 53.43 
(1C, 11 or 15), 48.96 (1C, 11 or 15), 32.19 (1C, 6), 25.20 (1C, 7 or 8), 24.14 (1C, 7 or 8), 21.00 (1C, 9). Solvents: 
DMSO (40.15, 39.94, 39.73, 39.52, 39.31, 39.10, 38.90). The signals for the quaternary carbons 1 – 4 could 
not be resolved.  
 
19F NMR (376 MHz, DMSO-d6 δ/ppm): -153.37 – -153.65 (m, 2F, 3), -157.95 – -158.27 (m, 1F, 1), -162.48 – -
162.84 (m, 2F, 2).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C16H15N2O5F5SNa: 465.0514, found: 465.0518.  
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Compound 38: 
 
38
N
O
O
N
N
O
1
23
4
567
8
9
10 11
12
13
16
17
18 19
20
14
15
HN
O
H
NH
H
S21 22
23
25
27
2426
O O
 
 
The synthesis was performed similarly to Kajetanowicz et al.238  
Methyl 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)quinoline-2-carboxylate (22, 0.13 g, 0.35 mmol, 1.0 eq.) and 
triisopropylsilane (0.14 ml, 0.11 g, 0.70 mmol, 2.0 eq., scavenger for carbocations) were dissolved in DCM 
(3.5 ml) and treated with concentrated trifluoroacetic acid (3.5 ml). The resulting orange solution was stirred 
at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure. The obtained 
residue was dissolved in DMF (5 ml), followed by the addition of N,N-diisopropylethylamine (0.61 ml, 0.46 g, 
3.50 mmol, 10.0 eq.) and D-biotin sulfone pentafluorophenyl ester (37, 0.15 g, 0.35 mmol, 1.0 eq.). The 
reaction mixture was stirred at room temperature for 20 h, whereupon a white precipitate was formed. The 
solvent was evaporated and the white residue was mixed with DCM (50 ml). This mixture was washed with 
saturated NaHCO3 (50 ml) and water (50 ml). The organic phase was concentrated under reduced pressure. 
The obtained white solid was washed with methanol (2 x 10 ml) and diethyl ether (2 x 10 ml) and dried under 
reduced pressure to yield the product as a white solid (38, 156 mg, 0.29 mmol, 84% yield).  
 
Annex spectra on page 187.  
 
Appearance: White solid 
 
1H NMR (400 MHz, DMSO-d6 δ/ppm): 8.14 (dd, J = 8.4, 1.3 Hz, 1H, 7), 8.10 (dd, J = 8.5, 1.2 Hz, 1H, 10), 7.82 
(ddd, J = 8.3, 6.8, 1.4 Hz, 1H, 9), 7.70 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H, 8), 7.54 (s, 1H, 4), 6.72 (s, 1H, 26), 6.61 (s, 
1H, 24), 4.46 – 4.41 (m, 1H, 23), 4.41 – 4.35 (m, 1H, 27), 3.94 (s, 3H, 1), 3.77 (t, J = 5.0 Hz, 4H, 13 + 15), 3.36 
– 3.29 (m, 1H, 22), 3.29 – 3.20 (m, 4H, 12 + 14), 3.20 – 3.15 (m, 1H, 21), 3.03 (d, J = 14.2 Hz, 1H, 22), 2.41 (t, J 
= 7.4 Hz, 2H, 17), 1.78 – 1.63 (m, 2H, 20), 1.63 – 1.54 (m, 2H, 18), 1.51 – 1.41 (m, 2H, 19). Solvents: DMF (7.95, 
2.89, 2.73), DCM (5.76), water (3.33), DMSO (2.50).  
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13C NMR (Peaks assigned from HMQC and HMBC spectra, DMSO-d6 δ/ppm): 170.65 (1C, 16), 165.58 (1C, 2), 
161.45 (1C, 25), 157.11 (1C, 5), 148.23 (1C, 11), 130.33 (1C, 10), 130.01 (1C, 9), 127.37 (1C, 8), 123.64 (1C, 7), 
123.28 (1C, 6), 108.16 (1C, 4), 60.16 (1C, 21), 54.05 (1C, 22), 53.33 (1C, 27), 52.42 (1C, 1), 51.56 (2C, 12 + 14), 
48.80 (1C, 23), 44.70 (1C, 13 or 15), 40.81 (1C, 13 or 15), 31.93 (1C, 17), 25.59 (1C, 19), 24.53 (1C, 18), 21.04 
(1C, 20). The signal for the quaternary carbon 3 could not be resolved. A proper 13C NMR spectrum could not 
be measured due to limited solubility of the compound in DMSO.  
 
HRMS (ESI-MS, pos.) m/z: [M+H]+ calculated for C25H32N5O6S: 530.2068, found: 530.2076.  
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Compound 39: 
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The synthesis was performed similarly to Meggers et al.94  
The lithium salt of biotinylated acid 26 (75 mg, 0.15 mmol, 1.0 eq.) and sodium bicarbonate (22 mg, 0.26 
mmol, 1.7 eq.) were suspended in dry DMF (2 ml) and treated with allyl bromide (20 μl, 28 mg, 0.23 mmol, 
1.5 eq.). The mixture was stirred at 50°C for 15 h. Water (10 ml) was added and the reaction mixture was 
extracted with DCM (3 x 10 ml). The organic phase was dried over Na2SO4 and concentrated to obtain a yellow 
oil. This oil was purified by flash column chromatography (SiO2, pure acetone, product spot on TLC stained 
with DACA-stain). The fractions were concentrated and dried under reduced pressure to yield the product as 
a light yellow solid (39, 66.9 mg, 0.12 mmol, 83% yield).  
 
Annex spectra on page 188.  
 
Appearance: Light yellow solid 
 
TLC: Pure acetone; Rf = 0.20 
 
1H NMR (500 MHz, Chloroform-d δ/ppm): 8.28 (ddd, J = 8.5, 1.3, 0.6 Hz, 1H, 12), 8.05 (ddd, J = 8.5, 1.5, 0.6 
Hz, 1H, 9), 7.74 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H, 11), 7.67 (s, 1H, 6), 7.61 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H, 10), 6.12 
(ddt, J = 17.2, 10.4, 5.9 Hz, 1H, 2), 5.99 (s, 1H, 25), 5.47 (dq, J = 17.2, 1.5 Hz, 1H, 1), 5.36 (s, 1H, 27), 5.34 (dq, 
J = 10.4, 1.2 Hz, 1H, 1), 4.98 (dt, J = 5.9, 1.4 Hz, 2H, 3), 4.52 (ddt, J = 7.5, 5.0, 1.1 Hz, 1H, 28), 4.33 (ddd, J = 7.8, 
4.6, 1.5 Hz, 1H, 24), 4.00 – 3.85 (m, 2H, 15 or 17), 3.85 – 3.73 (m, 2H, 15 or 17), 3.35 – 3.29 (m, 2H, 14 or 16), 
3.29 – 3.23 (m, 2H, 14 or 16), 3.19 (ddd, J = 8.1, 6.8, 4.6 Hz, 1H, 23), 2.92 (dd, J = 12.8, 5.0 Hz, 1H, 29), 2.75 
(d, J = 12.7 Hz, 1H, 29), 2.44 (td, J = 7.7, 2.4 Hz, 2H, 19), 1.82 – 1.66 (m, 4H, 20 + 22), 1.55 – 1.46 (m, 2H, 21). 
Solvents: Chloroform (7.27), water (1.94), “grease” (1.26, 0.88). Standard: TMS (0.00).  
 
13C NMR (126 MHz, Chloroform-d δ/ppm): 171.72 (1C, 18), 165.49 (1C, 4), 163.58 (1C, 26), 157.45 (1C, 7), 
149.04 (1C, 13), 148.53 (1C, 5), 131.85 (1C, 2), 131.59 (1C, 12), 129.96 (1C, 11), 127.65 (1C, 10), 124.26 (1C, 
8), 123.20 (1C, 9), 119.33 (1C, 1), 109.13 (1C, 6), 66.89 (1C, 3), 61.89 (1C, 24), 60.16 (1C, 28), 55.41 (1C, 23), 
52.32 (1C, 14 or 16), 52.10 (1C, 14 or 16), 45.62 (1C, 15 or 17), 41.58 (1C, 15 or 17), 40.56 (1C, 29), 32.62 (1C, 
19), 28.35 (1C, 21), 28.30 (1C, 20 or 22), 25.06 (1C, 20 or 22). Solvents: Chloroform (77.29, 77.03, 76.78). 
Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+H]+ calculated for C27H34N5O4S: 524.2326, found: 524.2333.   
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Compound 18: 
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The synthesis was performed similarly to Meggers et al.94  
The synthesis was carried out in the glove-box with oven dried glass equipment. Ligand (39, 6.1 mg, 11.5 
μmol, 1.0 eq.) was dissolved in dry DCM (2.0 ml), yielding a yellow solution. A solution of [CpRu(MeCN)3]PF6 
(5.0 mg, 11.5 μmmol, 1.0 eq.) in dry DCM (2.0 ml) was added dropwise over a time period of 15 min, with a 
simultaneous color change from yellow to orange and the formation of an orange precipitate. This residue 
was filtered, washed with dry DCM (3 x 1 ml) and dried to obtain a yellow-orange solid.  
 
Annex spectra on page 189.  
 
Appearance: Yellow-orange solid 
 
1H NMR (600 MHz, Acetonitrile-d3 δ/ppm): Assignment of signals: see chapter 2.1.2 
 
19F NMR (565 MHz, Acetonitrile-d3 δ/ppm): -72.95 (d, J = 706.4 Hz, PF6).  
 
HRMS (ESI-MS, pos.) m/z: [M-PF6]+ calculated for C32H38N5O4Sru: 690.1690, found: 690.1697.  
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4.3.3 Non-biotinylated ruthenium complex 
 
Compound 7: 
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The synthesis of allyl 4-(dimethylamino)quinoline-2-carboxylate (42) was performed as described by Meggers 
et al.94 The starting material used, 4-(dimethylamino)quinoline-2-carboxylic acid (41), was purchased from 
Ukrorgsyntez Ltd. The synthesis of [CpRu(QA-NMe2)(Allyl)]PF6 (7)was performed as described by Meggers et 
al.94  
 
Annex spectra on page 190.  
 
Appearance: Yellow solid 
 
1H NMR (400 MHz, Acetone-d6 δ/ppm): 8.38 – 8.31 (m, 1H, 10), 8.01 – 7.89 (m, 2H, 12 + 13), 7.72 (ddd, J = 
8.3, 5.9, 2.1 Hz, 1H, 11), 7.32 (s, 1H, 7), 6.46 (s, 5H, 1), 4.83 (d, J = 10.7 Hz, 1H, 2 or 4), 4.73 (tt, J = 10.7, 6.2 
Hz, 1H, 3), 4.60 (d, J = 10.9 Hz, 1H, 2 or 4), 4.32 (dd, J = 6.2, 2.9 Hz, 1H, 2 or 4), 4.23 (dd, J = 6.2, 2.9 Hz, 1H, 2 
or 4), 3.41 (s, 6H, 15). Solvents: Water (2.81), acetone (2.05). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M-PF6]+ calculated for C20H21N2O2Ru: 423.0646, found: 423.0651.  
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4.3.4 Caged coumarin substrate 
The caged coumarin substrate 1 was synthesized following literature procedures from Kanaoka et al.119, 
Griffiths and Ryckelynck et al.120 and Meggers et al.94 3-Aminophenol (67) was treated with ethyl 
chloroformate to afford carbamate 68, which was converted to coumarin 69 using a Pechmann condensation. 
In the next step, sulfonate 70 was formed. The ethyl carbamate group was then cleaved by treatment with a 
mixture of boiling sulfuric/acetic acid. Amine 71 was then converted into the O-allyl carbamate protected 
coumarin substrate 1 by treatment with allyl chloroformate in triethylammonium bicarbonate buffer. An 
overview of the synthesis is given in Scheme 11.  
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O
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67 68 69 70
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Scheme 11: Synthesis procedure of an allyl carbamate protected coumarin substrate (1).  
Reaction conditions: a) Ethyl chloroformate (2.0 eq.), diethyl ether/THF 5:1 (dry), r.t., 2 h; b) 1.) Ethyl 4-chloroacetoacetate (1.1 eq.), 
aq. H2SO4 (70%), 0°C to r.t., 16 h. 2.) Water, 0°C, 30 min; c) Na2SO3 (5.0 eq.), acetone/water (3:2), reflux, 24 h; d) H2SO4/acetic acid 
1:1, 100°C, 16 h; e) Allyl chloroformate (5.0 eq.), triethylammonium bicarbonate buffer (1 M, pH 8.5), 0°C to r.t., 3.5 h.  
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The synthesis of 7-aminocoumarin-4-methansulfonic acid (71, Scheme 11) was performed as described by 
Kanaoka et al.119 and Griffiths and Ryckelynck et al.120  
 
The synthesis of compound 1 was performed as described by Meggers et al.94  
7-aminocoumarin-4-methansulfonic acid (71, 102 mg, 0.40 mmol, 1.0 eq.) was dispersed in 
triethylammonium bicarbonate buffer (1 M, pH 8.5, 4.0 ml, 4.0 mmol, 10.0 eq.). Allyl chloroformate (215 μl, 
244 mg, 1.96 mmol, 5.0 eq.) was added dropwise at 0°C. The mixture was stirred for 1.5 h at 0°C and then for 
2 h at room temperature. The resulting brownish solution was acidified with glacial acetic acid (0.5 ml) to pH 
4 and then filtered. The filtrate was purified by preparative reverse phase HPLC (XSELECTTM CSHTM Prep C18 
5 μm OBDTM 19 x 150 mm, water/acetonitrile containing 5 mM triethylamine and 5 mM acetic acid). The 
resulting fractions were finally lyophilized to obtain the product as a white solid (1, 46.8 mg, 0.11 mmol, 53% 
yield).  
 
Annex spectra on page 191.  
 
Appearance: White solid 
 
1H NMR (400 MHz, DMSO-d6 δ/ppm): 10.21 (s, 1H, 5), 7.85 (d, J = 8.8 Hz, 1H, 13), 7.54 (d, J = 2.1 Hz, 1H, 7), 
7.33 (dd, J = 8.8, 2.1 Hz, 1H, 14), 6.24 (s, 1H, 10), 6.00 (ddt, J = 17.2, 10.9, 5.5 Hz, 1H, 2), 5.39 (dq, J = 17.2, 1.6 
Hz, 1H, 1), 5.26 (dq, J = 10.5, 1.3 Hz, 1H, 1), 4.65 (dt, J = 5.5, 1.4 Hz, 2H, 3), 3.99 (s, 2H, 15), 3.08 (q, J = 7.3 Hz, 
6H, 17), 1.17 (t, J = 7.3 Hz, 9H, 18). Solvents: Water (3.32), DMSO (2.50). Standard: TMS (0.00).  
 
13C NMR (101 MHz, DMSO-d6 δ/ppm): 160.25 (1C, 9), 154.08 (1C, 8), 153.01 (1C, 4), 149.99 (1C, 11), 142.30 
(1C, 6), 132.97 (1C, 2), 127.74 (1C, 13), 117.94 (1C, 1), 113.96 (1C, 10 or 12 or 14), 113.91 (1C, 10 or 12 or 14), 
113.78 (1C, 10 or 12 or 14), 104.19 (1C, 7), 65.09 (1C, 3), 53.14 (1C, 15), 45.71 (3C, 17), 8.62 (3C, 18). Solvents: 
DMSO (40.15, 39.94, 39.73, 39.52, 39.31, 39.10, 38.89).  
 
HRMS (ESI-MS, neg.) m/z: [M-HNEt3]- calculated for C14H12NO7S: 338.0340, found: 338.0342.  
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Compound 2: 
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The synthesis of compound 2 was performed as described by Meggers et al.94  
7-aminocoumarin-4-methansulfonic acid (71, 100 mg, 0.40 mmol, 1.0 eq.) was dispersed in 
triethylammonium bicarbonate buffer (1 M, pH 8.5, 4.0 ml, 4.0 mmol, 10.0 eq.). The resulting yellowish 
solution was acidified with glacial acetic acid (0.5 ml) to pH 4 and then filtered. The filtrate was purified by 
preparative reverse phase HPLC (XSELECTTM CSHTM Prep C18 5 μm OBDTM 19 x 150 mm, water/acetonitrile 
containing 5 mM triethylamine and 5 mM acetic acid). The obtained fractions were then lyophilized to obtain 
the product as a light yellow solid (2, 39.0 mg, 0.11 mmol, 28% yield).  
 
Annex spectra on page 192.  
 
Appearance: Light yellow solid 
 
1H NMR (500 MHz, DMSO-d6 δ/ppm): 8.86 (s, 1H, 11), 7.55 (d, J = 8.7 Hz, 1H, 8), 6.51 (dd, J = 8.7, 2.2 Hz, 1H, 
9), 6.38 (d, J = 2.2 Hz, 1H, 2), 6.04 (s, 2H, NH2), 5.92 (s, 1H, 5), 3.86 (s, 2H, 10), 3.08 (q, J = 7.2 Hz, 6H, 12), 1.17 
(t, J = 7.3 Hz, 9H, 13). Solvents: Water (3.32), DMSO (2.50).  
 
13C NMR (126 MHz, DMSO-d6 δ/ppm): 160.95 (1C, 4), 155.75 (1C, 1 or 3), 152.66 (1C, 1 or 3), 150.51 (1C, 6), 
127.88 (1C, 8), 110.84 (1C, 9), 109.24 (1C, 5), 108.60 (1C, 7), 98.26 (1C, 2), 53.32 (1C, 10), 45.75 (1C, 12), 8.66 
(1C, 13). Solvents: DMSO (40.02, 39.85, 39.69, 39.52, 39.35, 39.19, 39.02).  
 
HRMS (ESI-MS, neg.) m/z: [M]- calculated for C10H8NO5S: 254.0129, found: 254.0132.  
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4.3.5 Caged IPTG substrates 
 
Compound 44: 
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The synthesis was performed as described by Craig et al.240  
Under an N2 atmosphere, p-nitrophenyl chloroformate (43, 2.00 g, 9.92 mmol, 1.1 eq.) was dissolved in dry 
DCM (10 ml) and the solution was cooled to -10°C. Allyl alcohol (0.62 ml, 0.53 g, 9.02 mmol, 1.0 eq.) was 
slowly added, followed by the dropwise addition of triethylamine (5.0 ml, 3.63 g, 36.08 mmol, 4.0 eq.). The 
resulting yellow mixture was stirred for 30 min at -10°C and then allowed to warm up to room temperature 
with further stirring for 16 h. The residue was mixed with ethyl acetate (40 ml) and washed with sat. aq. 
NH4Cl (4 x 40 ml) and water (40 ml). The organic phase was dried over Na2SO4, the solvent was evaporated 
and the residue purified by flash column chromatography (SiO2, cyclohexane/ethyl acetate 9:1). The fractions 
were concentrated and dried under reduced pressure to yield the product as a white crystalline solid (44, 
938 mg, 4.20 mmol, 47% yield).  
 
Annex spectra on page 193.  
 
Appearance: White crystalline solid 
 
TLC: Ethyl acetate/cyclohexane 1:9; Rf = 0.40 
 
1H NMR (400 MHz, Chloroform-d δ/ppm): 8.32 – 8.25 (m, 2H, 2), 7.43 – 7.36 (m, 2H, 3), 6.01 (ddt, J = 17.2, 
10.4, 5.9 Hz, 1H, 7), 5.46 (dq, J = 17.2, 1.4 Hz, 1H, 8), 5.37 (dq, J = 10.4, 1.1 Hz, 1H, 8), 4.78 (dt, J = 5.9, 1.3 Hz, 
2H, 6). Solvents: Chloroform (7.26), water (1.55). Standard: TMS (0.00).  
 
13C NMR (101 MHz, Chloroform-d δ/ppm): 155.52 (1C, 4), 152.30 (1C, 5), 145.42 (1C, 1), 130.58 (1C, 7), 125.31 
(2C, 2), 121.78 (2C, 3), 120.19 (1C, 8), 69.76 (1C, 6). Solvents: Chloroform (77.33, 77.02, 76.70). Standard: 
TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C10H9NO5Na: 246.0373, found: 246.0374.  
  
 119 
Compound 46: 
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The synthesis was performed similarly to Ito and Abe et al.112  
Isopropyl β-D-1-thiogalactopyranoside (45, 210 mg, 0.90 mmol, 1.0 eq), 4-dimethylaminopyridine (110 mg, 
0.90 mmol, 1.0 eq) and para-nitrophenyl allyl carbonate (44, 200 mg, 0.90 mmol, 1.0 eq.) were dissolved in 
pyridine (10 ml). The yellow solution was stirred at room temperature for 18 h. The solvent was evaporated 
and the residue purified by flash column chromatography (SiO2, DCM/MeOH 50:1 → 25:1). The fractions 
were concentrated and dried under reduced pressure to yield the product as a white solid (46, 34.2 mg, 0.11 
mmol, 12% yield).  
 
Annex spectra on page 194.  
 
Appearance: White solid 
 
TLC: DCM/MeOH 50:1; Rf = 0.20 
 
1H NMR (400 MHz, Chloroform-d δ/ppm): 5.93 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H, 2), 5.36 (dq, J = 17.2, 1.5 Hz, 
1H, 1), 5.28 (dq, J = 10.4, 1.2 Hz, 1H, 1), 4.63 (dt, J = 5.8, 1.4 Hz, 2H, 3), 4.43 – 4.40 (m, 1H, 5), 4.40 – 4.37 (m, 
1H, 10), 4.37 – 4.32 (m, 1H, 5), 4.00 (s (broad), 1H, 7), 3.76 (ddd, J = 6.9, 5.7, 1.2 Hz, 1H, 6), 3.69 – 3.60 (m, 
2H, 8 + 9), 3.30 (s (broad), 1H, OH), 3.21 (p, J = 6.8 Hz, 1H, 11), 2.95 (s (broad), 1H, OH), 2.89 (s (broad), 1H, 
OH), 1.34 (d, J = 6.1 Hz, 3H, 12 or 13), 1.33 (d, J = 5.8 Hz, 3H, 12 or 13). Solvents: Chloroform (7.26), water 
(1.71). Standard: TMS (0.00).  
 
13C NMR (101 MHz, Chloroform-d δ/ppm): 154.97 (1C, 4), 131.32 (1C, 2), 119.17 (1C, 1), 85.91 (1C, 10), 75.85 
(1C, 6), 74.39 (1C, 8 or 9), 70.40 (1C, 8 or 9), 68.78 (1C, 3), 68.48 (1C, 7), 66.31 (1C, 5), 35.91 (1C, 11), 24.20 
(1C, 12 or 13), 23.98 (1C, 12 or 13). Solvents: Chloroform (77.33, 77.02, 76.70). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C13H22O7SNa: 345.0978, found: 345.0985.  
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4-Aminobenzyl alcohol (47, 2.00 g, 16.24 mmol, 1.0 eq.) was dissolved in a mixture of pyridine (20 ml) and 
DCM (30 ml). Allyl chloroformate (1.90 ml, 2.15 g, 17.82 mmol, 1.1 eq.) in DCM (8 ml) was added dropwise 
and the resulting orange mixture was stirred for 3 h at room temperature. The mixture was diluted with DCM 
(100 ml) and washed with water (3 x 100 ml). The organic phase was dried over Na2SO4 and the solvent was 
evaporated. The residue was purified by flash column chromatography (SiO2, cyclohexane/ethyl acetate 2:1). 
The fractions were concentrated and dried under reduced pressure to yield the product as a light yellow 
crystalline solid (48, 1.97 g, 9.51 mmol, 59% yield).  
 
Annex spectra on page 195.  
 
Appearance: Light yellow crystalline solid 
 
TLC: Ethyl acetate/cyclohexane 1:2; Rf = 0.30 
 
1H NMR (500 MHz, Chloroform-d δ/ppm): 7.35 (d, J = 8.2 Hz, 2H, 6), 7.30 – 7.26 (m, 2H, 7), 6.84 (s (broad), 
1H, NH), 5.96 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H, 2), 5.36 (dq, J = 17.2, 1.5 Hz, 1H, 1), 5.26 (dq, J = 10.4, 1.3 Hz, 
1H, 1), 4.66 (dt, J = 5.7, 1.4 Hz, 2H, 3), 4.61 (s, 2H, 9), 2.00 (s (broad), 1H, OH). Solvents: Chloroform (7.26). 
Standard: TMS (0.00).  
 
13C NMR (126 MHz, Chloroform-d δ/ppm): 153.32 (1C, 4), 137.25 (1C, 5), 136.04 (1C, 8), 132.39 (1C, 2), 127.93 
(2C, 7), 118.85 (2C, 6), 118.29 (1C, 1), 65.89 (1C, 3), 64.86 (1C, 9). Solvents: Chloroform (77.29, 77.04, 76.79). 
Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C11H13NO3Na: 230.0788, found: 230.0787.  
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The synthesis was performed similarly to Hay et al.241  
The benzyl alcohol derivative 48 (1.50 g, 7.24 mmol, 1.0 eq.) was dissolved in THF (80 ml) followed by the 
dropwise addition of N,N-diisopropylethylamine (1.60 ml, 1.22 g, 9.41 mmol, 1.3 eq.). A solution of 4-
nitrophenyl chloroformate (2.19 g, 10.86 mmol, 1.5 eq.) in THF (20 ml) was then slowly added and the 
resulting yellow mixture was stirred at room temperature for 16 h. The solvent was evaporated and the 
residue was taken up in ethyl acetate (100 ml). The organic fraction was washed with water (2 x 50 ml) and 
brine (50 ml), dried over Na2SO4 and evaporated to dryness. The residue was purified by flash column 
chromatography (SiO2, DCM/cyclohexane 3:1 → pure DCM). The fractions were concentrated and dried 
under reduced pressure to yield the crude product as a light yellow crystalline solid (49, 586 mg, 22% yield). 
NMR analysis stated the presence of para-nitrophenol as an impurity. However, the isolated sample was used 
for the next synthesis step without further purification.  
 
Annex spectra on page 196.  
 
Appearance: Light yellow crystalline solid 
 
TLC: DCM/cyclohexane 3:1; Rf = 0.20 
 
1H NMR (500 MHz, Chloroform-d δ/ppm): 8.29 – 8.24 (m, 2H, 13), 7.46 – 7.41 (m, 2H, 6), 7.41 – 7.38 (m, 2H, 
7), 7.38 – 7.35 (m, 2H, 12), 6.78 (s (broad), 1H, NH), 5.97 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H, 2), 5.37 (dq, J = 17.2, 
1.5 Hz, 1H, 1), 5.28 (dq, J = 10.4, 1.3 Hz, 1H, 1), 5.25 (s, 2H, 9), 4.68 (dt, J = 5.7, 1.4 Hz, 2H, 3). Impurity: Para-
nitrophenol (8.17 – 8.12 (m, 2H, HAryl), 6.92 – 6.87 (m, 2H, HAryl), 6.68 (s (broad), 1H, OH)). Solvents: 
Chloroform (7.26), Water (1.73). Standard: TMS (0.00).  
 
13C NMR (126 MHz, Chloroform-d δ/ppm): 155.52 (1C, 11), 153.23 (1C, 4), 152.46 (1C, 10), 145.38 (1C, 14), 
138.55 (1C, 5), 132.16 (1C, 2), 129.95 (2C, 7), 129.21 (1C, 8), 125.30 (2C, 13), 121.79 (2C, 12), 118.83 (2C, 6), 
118.52 (1C, 1), 70.67 (1C, 9), 66.10 (1C, 3). Impurity: Para-nitrophenol (161.64 (1C), 141.48 (1C, extrapolated 
from HMBC spectrum), 126.19 (2C), 115.63 (2C)). Solvents: Chloroform (77.28, 77.03, 76.78). Standard: TMS 
(0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C18H16N2O7Na: 395.0850, found: 395.0852.  
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The synthesis was performed similarly to Ito and Abe et al.112  
Isopropyl β-D-1-thiogalactopyranoside (45, 320 mg, 1.34 mmol, 1.0 eq.), 4-dimethylaminopyridine (166 mg, 
1.34 mmol, 1.0 eq.) and para-nitrophenyl carbonate 49 (500 mg, 1.34 mmol, 1.0 eq.) were dissolved in 
pyridine (10 ml). The resulting yellow solution was stirred at room temperature for 16 h. The solvent was 
evaporated and the residue was purified by flash column chromatography (SiO2, DCM/MeOH 20:1 → 15:1). 
The fractions were concentrated and dried under reduced pressure to yield the product as a white solid (50, 
118 mg, 0.17 mmol, 19% yield).  
 
Annex spectra on page 197.  
 
Appearance: White solid 
 
TLC: DCM/MeOH 15:1; Rf = 0.35 
 
1H NMR (400 MHz, Methanol-d4 δ/ppm): 7.45 (d, J = 8.6 Hz, 2H, 6), 7.31 (d, J = 8.6 Hz, 2H, 7), 6.00 (ddt, J = 
17.2, 10.8, 5.5 Hz, 1H, 2), 5.36 (dq, J = 17.2, 1.6 Hz, 1H, 1), 5.23 (dq, J = 10.5, 1.4 Hz, 1H, 1), 5.09 (s, 2H, 9), 
4.63 (dt, J = 5.4, 1.5 Hz, 2H, 3), 4.42 – 4.38 (m, 1H, 16), 4.38 – 4.33 (m, 1H, 11), 4.22 (dd, J = 11.3, 4.3 Hz, 1H, 
11), 3.84 (dd, J = 3.0, 1.1 Hz, 1H, 13), 3.78 – 3.73 (m, 1H, 12), 3.58 – 3.49 (m, 1H, 14 or 15), 3.47 (d, J = 3.2 Hz, 
1H, 14 or 15), 3.14 (p, J = 6.7 Hz, 1H, 17), 1.28 (d, J = 1.5 Hz, 3H, 18 or 19), 1.26 (d, J = 1.6 Hz, 3H, 18 or 19). 
Solvents: Water (4.86), methanol (3.31). Alcohol groups of the sugar frame are most likely due to proton-
deuterium exchange with the solvent methanol-d4 not visible in the 1H spectrum.  
 
13C NMR (101 MHz, Methanol-d4 δ/ppm): 156.55 (1C, 10), 155.56 (1C, 4), 140.62 (1C, 5), 134.20 (1C, 2), 131.37 
(1C, 8), 130.32 (1C, 7), 119.63 (1C, 6), 117.87 (1C, 1), 87.05 (1C, 16), 77.51 (1C, 12), 75.97 (1C, 14 or 15), 71.43 
(1C, 14 or 15), 70.42 (1C, 9 or 13), 70.39 (1C, 9 or 13), 68.45 (1C, 11), 66.45 (1C, 3), 36.20 (1C, 17), 24.55 (1C, 
18 or 19), 24.20 (1C, 18 or 19). Solvents: Methanol (49.64, 49.43, 49.21, 49.00, 48.79, 48.57, 48.36).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C21H29NO9SNa: 494.1455, found: 494.1464.  
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The synthesis was performed similarly to Taylor et al.242  
5-aminovaleric acid (51, 2.00 g, 17.07 mmol, 1.0 eq.) and NaOH (2.46 g, 61.46 mmol, 3.6 eq.) were dissolved 
in water (150 ml) and cooled to 0°C. Allyl chloroformate (2.72 ml, 3.09 g, 25.61 mmol, 1.5 eq.) was slowly 
added and the resulting mixture was stirred at 0°C for 5 h. The mixture was washed with diethyl ether (100 
ml). The aqueous phase was acidified with HCl (1M, 20 ml) to pH 2 and extracted with ethyl acetate (3 x 80 
ml). The organic phase was dried over Na2SO4 and evaporated under reduced pressure to obtain the product 
as a white solid (52, 2.63 g, 13.08 mmol, 77% yield).  
 
Annex spectra on page 198.  
 
Appearance: White solid 
 
1H NMR (500 MHz, Chloroform-d δ/ppm): 5.91 (ddt, J = 16.4, 10.9, 5.6 Hz, 1H, 2), 5.30 (d, J = 17.3 Hz, 1H, 1), 
5.21 (d, J = 10.4 Hz, 1H, 1), 4.88 (s (broad), 1H, NH), 4.56 (d, J = 5.6 Hz, 2H, 3), 3.26 – 3.14 (m, 2H, 5), 2.38 (t, 
J = 7.2 Hz, 2H, 8), 1.73 – 1.63 (m, 2H, 7), 1.62 – 1.51 (m, 2H, 6). Solvents: Chloroform (7.27). Standard: TMS 
(0.00).  
 
13C NMR (126 MHz, Chloroform-d δ/ppm): 178.85 (1C, 9), 156.39 (1C, 4), 132.89 (1C, 2), 117.70 (1C, 1), 65.56 
(1C, 3), 40.56 (1C, 5), 33.49 (1C, 8), 29.33 (1C, 6), 21.75 (1C, 7). Solvents: Chloroform (77.30, 77.04, 76.79). 
Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C9H15NO4Na: 224.0893, found: 224.0892.  
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The synthesis was performed similarly to Thompson et al.236  
Acid 52 (1.00 g, 4.97 mmol, 1.0 eq.) was dissolved in DMF (20 ml) and cooled to 0°C. Triethylamine (1.24 ml, 
0.90 g, 8.95 mmol, 1.8 eq.) was added dropwise, followed by the addition of pentafluorophenyl 
trifluoroacetate (1.28 ml, 2.09 g, 7.45 mmol, 1.5 eq). The resulting pink solution was allowed to warm up to 
room temperature, followed by further stirring for 3 h. The solvent was evaporated and the residue was 
purified by flash column chromatography (SiO2, cyclohexane/ethyl acetate 5:1). The fractions were 
concentrated and dried under reduced pressure to yield the product as a light yellow solid (53, 1.67 g, 92% 
yield). Due to instability of the activated pentafluorophenyl ester, a small fraction of pentaflourophenol was 
detected in the obtained product. However, the sample was used for the next synthesis step without further 
purification.  
 
Annex spectra on page 199.  
 
Appearance: Light yellow solid 
 
TLC: Ethyl acetate/cyclohexane 1:5; Rf = 0.30 
 
1H NMR (400 MHz, Chloroform-d δ/ppm): 5.92 (ddt, J = 16.4, 10.9, 5.7 Hz, 1H, 2), 5.30 (dq, J = 17.2, 1.6 Hz, 
1H, 1), 5.21 (dq, J = 10.4, 1.4 Hz, 1H, 1), 4.80 (s (broad), 1H, NH), 4.56 (d, J = 5.7 Hz, 2H, 3), 3.25 (q, J = 6.7 Hz, 
2H, 5), 2.71 (t, J = 7.3 Hz, 2H, 8), 1.86 – 1.76 (m, 2H, 7), 1.69 – 1.59 (m, 2H, 6). Solvents: Chloroform (7.26). 
Standard: TMS (0.00).  
 
13C NMR (126 MHz, Chloroform-d δ/ppm): 169.25 (1C, 9), 156.42 (1C, 4), 132.84 (1C, 2), 117.75 (1C, 1), 65.63 
(1C, 3), 40.41 (1C, 5), 32.84 (1C, 8), 29.22 (1C, 6), 21.82 (1C, 7). Solvents: Chloroform (77.30, 77.04, 76.79). 
Standard: TMS (0.00). The signals for the quaternary carbons 10 – 13 could not be resolved.  
 
19F NMR (376 MHz, Chloroform-d δ/ppm): -152.84 (d, J = 17.8 Hz, 2F, 11), -158.00 (t, J = 21.6 Hz, 1F, 13), -
162.32 (dd, J = 22.6, 18.0 Hz, 2F, 12). Byproduct: Pentafluorophenol (-163.15 (dd, J = 17.5, 5.7 Hz), -164.00 – 
-164.37 (m), -169.15 (tt, J = 22.0, 5.8 Hz)).  
 
NMR spectra are in good accordance with the results from Withers et al.243  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C15H14NO4F5Na: 390.0735, found: 390.0739.  
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The synthesis was performed similarly to Ito and Abe et al.112  
Isopropyl β-D-1-thiogalactopyranoside (45, 0.65 g, 2.72 mmol, 1.0 eq.), 4-dimethylaminopyridine (0.33 g, 
2.72 mmol, 1.0 eq.) and activated pentafluorophenyl ester 53 (1.00 g, 2.72 mmol, 1.0 eq.) were dissolved in 
pyridine (10 ml). The resulting light-yellow solution was stirred at room temperature for 16 h. The solvent 
was evaporated and the residue was purified by flash column chromatography (SiO2, DCM/MeOH 20:1 → 
15:1). The fractions were concentrated and dried under reduced pressure to yield the product as an off-white 
solid (54, 451 mg, 1.07 mmol, 39% yield).  
 
Annex spectra on page 200.  
 
Appearance: Off-white solid 
 
TLC: DCM/MeOH 10:1; Rf = 0.55 
 
1H NMR (400 MHz, Chloroform-d δ/ppm): 5.91 (ddt, J = 16.4, 10.9, 5.6 Hz, 1H, 2), 5.30 (dd, J = 17.2, 1.5 Hz, 
1H, 1), 5.21 (dd, J = 10.4, 1.4 Hz, 1H, 1), 4.96 (s, 1H, NH), 4.55 (d, J = 5.7 Hz, 2H, 3), 4.40 (d, J = 9.1 Hz, 1H, 15), 
4.37 – 4.26 (m, 2H, 10), 3.96 (dd, J = 3.0, 1.2 Hz, 1H, 12), 3.75 – 3.70 (m, 1H, 11), 3.70 – 3.65 (m, 1H, 14), 3.65 
– 3.63 (m, 1H, 13), 3.63 – 3.60 (m, 1H, OH), 3.27 – 3.21 (m, 1H, OH), 3.21 – 3.19 (m, 1H, 16), 3.19 – 3.11 (m, 
2H, 5), 2.36 (t, J = 7.2 Hz, 2H, 8), 1.74 – 1.60 (m, 2H, 7), 1.60 – 1.48 (m, 2H, 6), 1.35 (d, J = 6.6 Hz, 3H, 17 or 
18), 1.32 (d, J = 6.5 Hz, 3H, 17 or 18). Solvents: Pyridine (8.60, 7.77, 7.37), chloroform (7.27), methanol (3.49). 
Standard: TMS (0.00).  
 
13C NMR (126 MHz, Chloroform-d δ/ppm): 173.37 (1C, 9), 156.44 (1C, 4), 132.88 (1C, 2), 117.71 (1C, 1), 85.88 
(1C, 15), 75.93 (1C, 11), 74.55 (1C, 13), 70.37 (1C, 14), 68.63 (1C, 12), 65.57 (1C, 3), 62.99 (1C, 10), 40.54 (1C, 
5), 35.85 (1C, 16), 33.59 (1C, 8), 29.34 (1C, 6), 24.20 (1C, 17 or 18), 23.91 (1C, 17 or 18), 21.89 (1C, 7). Solvents: 
Pyridine (148.82, 137.01, 124.18), Chloroform (77.29, 77.03, 76.78), methanol (50.83). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C18H31NO8SNa: 444.1663, found: 444.1666.  
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The synthesis was performed similarly to Taylor et al.242  
2-aminophenylacetic acid (55, 2.50 g, 16.54 mmol, 1.0 eq.) and NaOH (2.38 g, 59.54 mmol, 3.6 eq.) were 
dissolved in water (150 ml) and cooled to 0°C in an ice bath. Allyl chloroformate (2.64 ml, 2.99 g, 24.81 mmol, 
1.5 eq.) was slowly added and the resulting yellow solution was stirred for 2.5 h at 0°C and then for 1.5 h. at 
room temperature. The reaction mixture was washed with diethyl ether (2 x 50 ml). The aqueous phase was 
acidified with HCl (1 M, 20 ml) to pH 2 and extracted with ethyl acetate (3 x 80 ml). The organic phase was 
dried over Na2SO4 and the solvent was evaporated to obtain the crude product as an orange-brown solid (56, 
2.19 g, 9.30 mmol, 56% yield). This crude product was used for the next synthesis step without further 
purification.  
 
Annex spectra on page 179.  
 
Appearance: Orange-brown solid 
 
1H NMR (400 MHz, Chloroform-d δ/ppm): 10.49 (s (broad), 1H, 14), 7.63 (s (broad), 2H, 5 + 7), 7.29 (td (broad), 
J = 7.7, 1.6 Hz, 1H, 8), 7.21 (dd (broad), J = 7.7, 1.7 Hz, 1H, 10), 7.12 (t (broad), J = 7.4 Hz, 1H, 9), 6.10 – 5.80 
(m, 1H, 2), 5.32 (d (broad), J = 17.5 Hz, 1H, 1), 5.23 (d (broad), J = 10.7 Hz, 1H, 1), 4.66 (dt, J = 5.7, 1.4 Hz, 2H, 
3), 3.65 (s, 2H, 12). Solvents: Chloroform (7.26), ethyl acetate (4.13, 2.04, 1.26). Standard: TMS (0.00).  
 
13C NMR (101 MHz, Chloroform-d δ/ppm): 176.63 (1C, 13), 136.23 (1C, 6), 132.31 (1C, 2), 130.83 (1C, 10), 
128.54 (1C, 8), 125.50 (1C, 9, extrapolated from HMQC spectrum), 124.39 (1C, 7, extrapolated from HMQC 
spectrum), 118.29 (1C, 1), 66.27 (1C, 3), 38.05 (1C, 12). Solvents: Ethyl acetate (171.40, 60.50, 21.05, 14.18), 
chloroform (77.35, 77.03, 76.71). Standard: TMS (0.00). The signals for the quaternary carbons 4 and 11 could 
not be resolved.  
 
HRMS (ESI-MS, pos.) m/z: [M+H]+ calculated for C12H14NO4: 236.0917, found: 236.0915.  
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The synthesis was performed similarly to Thompson et al.236  
To a solution of acid 56 (2.00 g, 8.50 mmol, 1.0 eq.) in DCM (50 ml), triethylamine (2.13 ml, 1.55 g, 15.30 
mmol, 1.8 eq.) was slowly added at 0°C, accompanied by the appearance of a red color. Pentafluorophenyl 
trifluoroacetate (1.24 ml, 2.02 g, 7.23 mmol, 0.85 eq.) was slowly added. The dark yellow solution was 
allowed to warm up to room temperature, followed by further stirring for 4 h. DCM was removed under 
reduced pressure and the residue was purified by flash column chromatography (SiO2, ethyl 
acetate/cyclohexane 1:5 → 1:4). The fractions were concentrated and dried under reduced pressure to yield 
the product as a white crystalline solid (57, 1.25 g, 3.12 mmol, 43% yield).  
 
Annex spectra on page 202.  
 
Appearance: White crystalline solid 
 
TLC: Ethyl acetate/cyclohexane 1:5; Rf = 0.35 
 
1H NMR (400 MHz, Chloroform-d δ/ppm): 7.88 (d, J = 8.2 Hz, 1H, 7), 7.37 – 7.27 (m, 1H, 8), 7.30 – 7.23 (m, 
1H, 10), 7.17 (td, J = 7.5, 1.1 Hz, 1H, 9), 6.05 (ddt, J = 17.2, 10.5, 5.6 Hz, 1H, 2), 5.52 (dq, J = 17.1, 1.5 Hz, 1H, 
1), 5.35 (dq, J = 10.5, 1.3 Hz, 1H, 1), 4.90 (dt, J = 5.6, 1.4 Hz, 2H, 3), 3.70 (s, 2H, 12). Solvents: Chloroform 
(7.26). Standard: TMS (0.00).  
 
13C NMR (101 MHz, Chloroform-d δ/ppm): 172.83 (1C, 13), 150.66 (1C, 4), 140.57 (1C, 6), 131.03 (1C, 2), 
128.25 (1C, 8), 124.61 (1C, 9), 124.24 (1C, 10), 123.25 (1C, 11), 119.45 (1C, 1), 115.26 (1C, 7), 67.58 (1C, 3), 
36.50 (1C, 12). Solvents: Chloroform (77.36, 77.04, 76.72). Standard: TMS (0.00). The signals for the 
quaternary carbons 14 – 17 could not be resolved.  
 
19F NMR (376 MHz, Chloroform-d δ/ppm): -163.00 (dd, J = 17.4, 5.7 Hz, 2F, 15 or 16), -164.04 – -164.21 (m, 
2F, 15 or 16), -169.06 (tt, J = 22.1, 5.7 Hz, 1F, 17). 
 
HRMS (ESI-MS, pos.) m/z: [M-OC6F5+OCH3+H]+ calculated for C13H16NO4: 250.1074, found: 250.1073.  
Trans-esterification of the activated pentafluorophenyl ester to the corresponding methyl ester has most 
likely taken place in methanol as ESI solvent.  
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The synthesis was performed similarly to Ito and Abe et al.112  
Isopropyl β-D-1-thiogalactopyranoside (45, 0.60 g, 2.49 mmol, 1.0 eq.), 4-dimethylaminopyridine (0.31 g, 
2.49 mmol, 1.0 eq. and activated pentafluorophenyl ester 57 (1.00 g, 2.49 mmol, 1.0 eq.) were dissolved in 
pyridine (10 ml). The resulting yellow solution was stirred at room temperature for 18 h. The solvent was 
evaporated and the residue was purified by flash column chromatography (SiO2, DCM/MeOH 30:1 → 20:1). 
The fractions were concentrated and dried under reduced pressure to yield the crude product as a brown 
solid. This solid was washed with cyclohexane (5 x 5 ml) to yield the product as an off-white solid (58, 236 
mg, 0.52 mmol, 21% yield).  
 
Annex spectra on page 203.  
 
Appearance: Off-white solid 
 
TLC: DCM/MeOH 25:1; Rf = 0.20 
 
1H NMR (400 MHz, Chloroform-d δ/ppm): 7.70 (s (broad), 2H, NH + 6), 7.30 (td, J = 7.8, 1.7 Hz, 1H, 7), 7.18 
(dd, J = 7.6, 1.6 Hz, 1H, 9), 7.10 (td, J = 7.4, 1.3 Hz, 1H, 8), 5.98 (ddt, J = 17.4, 10.4, 5.8 Hz, 1H, 2), 5.36 (dq, J = 
17.3, 1.5 Hz, 1H, 1), 5.26 (dq, J = 10.5, 1.3 Hz, 1H, 1), 4.67 (dt, J = 5.8, 1.4 Hz, 2H, 3), 4.40 – 4.34 (m, 1H, 18), 
4.34 – 4.29 (m, 2H, 13), 3.91 – 3.84 (m, 1H, 14 or 15 or 16 or 17), 3.71 – 3.66 (m, 1H, 14 or 15 or 16 or 17), 
3.65 (s, 2H, 11), 3.63 – 3.59 (m, 1H, 14 or 15 or 16 or 17), 3.59 – 3.54 (m, 1H, 14 or 15 or 16 or 17), 3.25 – 
3.17 (m, 1H, OH), 3.17 – 3.09 (m, 1H, 19), 3.00 – 2.84 (m, 1H, OH), 2.80 – 2.75 (m, 1H, OH), 1.32 (d, J = 7.0 Hz, 
3H, 20 or 21), 1.29 (d, J = 6.8 Hz, 3H, 20 or 21). Solvents: Chloroform (7.26), water (1.70), cyclohexane (1.43). 
Standard: TMS (0.00).  
 
13C NMR (101 MHz, Chloroform-d δ/ppm): 171.81 (1C, 12), 154.24 (1C, 4), 136.48 (1C, 5), 132.52 (1C, 2), 
130.78 (1C, 9), 128.57 (1C, 7), 125.83 (1C, 10, extrapolated from HMBC spectrum), 125.23 (1C, 8), 124.33 (1C, 
6, extrapolated from HMQC spectrum), 118.28 (1C, 1), 85.84 (1C, 18), 75.65 (1C, 14 or 15 or 16 or 17), 74.35 
(1C, 14 or 15 or 16 or 17), 70.30 (1C, 14 or 15 or 16 or 17), 68.55 (1C, 14 or 15 or 16 or 17), 66.09 (1C, 3), 
64.00 (1C, 13), 38.45 (1C, 11), 35.80 (1C, 19), 24.19 (1C, 20 or 21), 23.96 (1C, 20 or 21). Solvents: Chloroform 
(77.33, 77.02, 76.70). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C21H29NO8SNa: 478.1506, found: 478.1511.  
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4.3.6 Caged 2`-Amino-IPTG substrate 
The synthesis of the 2’-amino modified IPTG substrate (62, Scheme 12) started from D-(+)-galactosamine 
hydrochloride (59). First, the O-allyl carbamate group was introduced by treatment with allyl chloroformate, 
followed by protection of the alcohols with acetic anhydride (60). Next, the isopropyl thioether was 
introduced using 2-propanethiol and BF3·Et2O as a Lewis acid (61). Finally, the acetyl protecting groups were 
removed with NaOMe to yield the desired product (62).  
 
12%
a
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60 61
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Scheme 12: Synthesis procedure of a caged 2’-O-allyl carbamate-IPTG substrate (62).  
Reaction conditions: a) 1.) Allyl chloroformate (1.7 eq.), NaHCO3, H2O, 0°C to r.t., 16 h. 2.) Acetic anhydride (8.0 eq.), pyridine, r.t., 48 
h; b) 2-propanethiol (1.5 eq.), BF3·Et2O (2.6 eq.), DCM (dry), r.t., 3 h; c) NaOMe (4.5 eq.), MeOH, r.t., 2 h.  
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Compound 60: 
 
60
OO
H
H
O
H
NH
H
O
O
O
O
O
O OO
 
 
The synthesis was performed similarly to Spaink et al.244  
D-(+)-Galactosamine hydrochloride (59, 1.00 g, 4.64 mmol, 1.00 eq.) and NaHCO3 (0.97 g, 11.6 mmol, 2.50 
eq.) were dissolved in water (100 ml) and cooled to 0°C. Allyl chloroformate (0.84 ml, 0.95 g, 7.89 mmol, 1.70 
eq.) was added dropwise and the resulting colorless solution was stirred at room temperature for 16 h. The 
solution was concentrated under reduced pressure and co-evaporated with toluene (3 x 50 ml). The obtained 
off-white solid was dissolved in pyridine (15 ml) followed by the slow addition of acetic anhydride (3.51 ml, 
3.80 g, 37.12 mmol, 8.0 eq.). The resulting light-yellow mixture was stirred at room temperature for 48 h. 
The solution was concentrated under reduced pressure and co-evaporated with toluene (3 x 30 ml). The 
residue was taken up in ethyl acetate (50 ml) and washed with HCl (1 M, 40 ml), water (40 ml) and saturated 
NaHCO3 (40 ml). The organic phase was dried over Na2SO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (SiO2, cyclohexane/ethyl acetate 2:1, product spot on 
TLC stained with KMnO4). The fractions were concentrated and dried under reduced pressure to yield the 
product as a white crystalline solid (60, 235 mg, 0.55 mmol, 12% yield). The product was obtained as an 
anomeric mixture of the sugar. Separation of the required β-anomer was performed at a later step of the 
synthesis procedure (after introduction of the thioether).  
 
Annex spectra on page 204.  
 
Appearance: White crystalline solid 
 
TLC: Ethyl acetate/cyclohexane 1:2; Rf = 0.30 
 
1H NMR (400 MHz, Chloroform-d δ/ppm): 6.30 – 6.12 (m, 1H), 5.90 (ddt, J = 16.2, 10.8, 5.5 Hz, 1H), 5.71 (d, J 
= 8.8 Hz), 5.41 (ddd, J = 16.4, 3.4, 1.2 Hz, 1H), 5.37 – 5.06 (m, 3H), 4.77 – 4.65 (m, 1H), 4.63 – 4.49 (m, 2H), 
4.49 – 4.29 (m, 1H), 4.27 – 4.12 (m, 2H), 4.09 – 4.00 (m, 1H), 2.20 – 2.00 (m, 12H, HAcetyl). Solvents: Chloroform 
(7.26), ethyl acetate (4.11, 2.05, 1.26), water (1.59). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C18H25NO11Na: 454.1320, found: 454.1322.  
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Compound 61: 
 
OO
H
H
O
H
H
NH
H
S
O
1
2
34
56
7
8
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OO
O
O
O
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17
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61  
 
The synthesis was performed similarly to Kong et al.245  
The allyl carbamate/acetyl-protected sugar 60 (0.23 g, 0.53 mmol, 1.0 eq.) was dissolved in dry DCM (10 ml) 
under an N2 atmosphere. BF3·Et2O (48%, 175 μl, 0.20 g, 1.39 mmol, 2.6 eq.) was added dropwise followed by 
the addition of 2-propanethiol (72 μl, 0.06 g, 0.78 mmol, 1.5 eq.). The obtained orange solution was stirred 
at room temperature for 3 h. Na2CO3 was added to neutralize the reaction mixture, which was then filtered. 
The remaining filter cake was extracted with DCM (3 x 20 ml). The combined filtrates were concentrated 
under reduced pressure and the residue was purified by flash column chromatography (SiO2, 
cyclohexane/ethyl acetate 3:1, product spot on TLC stained with KMnO4). The fractions were concentrated 
and dried under reduced pressure to yield the desired β-anomer of the product as a white solid (61, 53 mg, 
0.12 mmol, 22% yield). Cross-peaks in the NOESY spectrum between the axial protons 6 – 12, 6 – 16 and 12 
– 16 as well as their non-existence in the spectrum of the α-anomer (the corresponding proton 16’ has only 
one strong NOE cross-peak to proton 13’) highlighted the correct spatial geometry of the isolated product. 
Furthermore, the signal of proton 5 showed a pseudo-quartet splitting in the 1H NMR spectrum, arising from 
couplings to protons 6, 16 and the NH group. The determined coupling constants, all ~10 Hz, are typical for 
a bi-axial substitution at the sugar scaffold.  
 
Annex spectra on page 205.  
 
Appearance: White solid 
 
TLC: Ethyl acetate/cyclohexane 1:2; Rf (α-anomer) = 0.41, Rf (β-anomer) = 0.27 
 
1H NMR (500 MHz, Chloroform-d δ/ppm): 5.90 (ddt, J = 16.2, 10.6, 5.5 Hz, 1H, 2), 5.40 (dd, J = 3.5, 0.7 Hz, 1H, 
9), 5.29 (d (broad), J = 17.2 Hz, 1H, 1), 5.21 (dd, J = 10.5, 1.4 Hz, 1H, 1), 5.18 (s (broad), 1H, 6), 4.87 – 4.70 (m 
(broad), 2H, 16 + NH), 4.63 – 4.51 (m, 2H, 3), 4.17 (dd, J = 11.3, 6.9 Hz, 1H, 13), 4.10 (dd, J = 11.3, 6.3 Hz, 1H, 
13), 3.92 (td, J = 6.6, 1.1 Hz, 1H, 12), 3.90 – 3.83 (m, 1H, 5), 3.20 (hept, J = 6.7 Hz, 1H, 17), 2.15 (s, 3H, 11), 
2.04 (s, 3H, 8 or 15), 2.01 (s, 3H, 8 or 15), 1.32 (d, J = 2.0 Hz, 3H, 18 or 19), 1.31 (d, J = 1.8 Hz, 3H, 18 or 19). 
Solvents: Chloroform (7.27), water (1.65). Standard: TMS (0.00).  
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13C NMR (Peaks assigned from HMQC+HMBC spectra, Chloroform-d δ/ppm): 170.42 (1C, 7 or 14), 170.41 (1C, 
7 or 14), 170.30 (1C, 10), 155.54 (1C, 4), 132.70 (1C, 2), 117.64 (1C, 1), 84.62 (1C, 16), 74.37 (1C, 12), 71.19 
(1C, 6), 67.13 (1C, 9), 65.86 (1C, 3), 61.85 (1C, 13), 51.62 (1C, 5), 35.49 (1C, 17), 23.79 (1C, 18 or 19), 23.77 
(1C, 18 or 19), 20.76 (1C, 11), 20.71 (1C, 8 or 15), 20.68 (1C, 8 or 15). Solvents: Chloroform (77.32). Standard: 
TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C19H29NO9SNa: 470.1455, found: 470.1463.  
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Compound 62: 
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The synthesis was performed similarly to Kong et al.245  
Protected IPTG derivative 61 (50 mg, 0.11 mmol, 1.0 eq.) was dissolved in MeOH (2 ml). NaOMe (30 mg, 0.50 
mmol, 4.5 eq.) in MeOH (1 ml) was slowly added and the mixture was stirred at room temperature for 2 h. 
The mixture was neutralized with 10% acetic acid in MeOH (1 ml) and concentrated. The residue was purified 
by flash column chromatography (SiO2, DCM/MeOH 10:1, product spot on TLC stained with KMnO4). The 
fractions were concentrated and dried under reduced pressure to yield the product as a white solid (62, 31.0 
mg, 0.10 mmol, 86% yield).  
 
Annex spectra on page 206.  
 
Appearance: White solid 
 
TLC: DCM/MeOH 10:1; Rf = 0.30 
 
1H NMR (400 MHz, Methanol-d4 δ/ppm): 5.94 (ddt, J = 17.2, 10.5, 5.3 Hz, 1H, 2), 5.33 (dq, J = 17.3, 1.8 Hz, 1H, 
1), 5.17 (dq, J = 10.5, 1.5 Hz, 1H, 1), 4.62 – 4.55 (m, 1H, 10), 4.55 – 4.46 (m, 2H, 3), 3.88 (dd, J = 3.3, 1.1 Hz, 
1H, 6), 3.78 – 3.69 (m, 2H, 9), 3.69 – 3.63 (m, 1H, 5), 3.57 (dd, J = 10.2, 3.2 Hz, 1H, 7), 3.48 (ddd, J = 6.7, 5.4, 
1.1 Hz, 1H, 8), 3.20 (p, J = 6.8 Hz, 1H, 11), 1.29 (d, J = 6.6 Hz, 3H, 12 or 13), 1.26 (d, J = 6.9 Hz, 3H, 12 or 13). 
Solvents: Water (4.86), methanol (3.31).  
 
13C NMR (126 MHz, Methanol-d4 δ/ppm): 158.81 (1C, 4), 134.51 (1C, 2), 117.20 (1C, 1), 85.94 (1C, 10), 80.57 
(1C, 8), 74.13 (1C, 7), 69.85 (1C, 6), 66.35 (1C, 3), 62.64 (1C, 9), 54.72 (1C, 5), 35.76 (1C, 11), 24.40 (1C, 12 or 
13), 24.21 (1C, 12 or 13). Solvents: Methanol (49.51, 49.34, 49.17, 49.00, 48.83, 48.66, 48.49).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C13H23NO6SNa: 344.1138, found: 344.1143.  
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4.3.7 Caged aniline substrate 
 
Compound 72: 
 
HO N
H
O
O
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The synthesis was performed similarly to Griffiths and Ryckelynck et al.120 
At 0°C, allyl chloroformate (3.90 ml, 4.42 g, 36.7 mmol, 2.0 eq.) was added dropwise to a stirred suspension 
of 3-aminophenol (67, 2.00 g, 18.3 mmol, 1.0 eq.) in a mixture of dry diethyl ether (100 ml) and dry THF (20 
ml). A white precipitate (the amine hydrochloride) formed immediately. The reaction mixture was stirred an 
additional 2 h at room temperature. The hydrochloride was removed by filtration. The filtrate was 
evaporated under reduced pressure. The obtained brown oil was solubilized in diethyl ether (20 ml) and the 
resulting organic phase was washed with solutions of HCl (1 M, 20 ml), saturated NaHCO3 (20 ml) and water 
(20 ml). The organic phase was dried over Na2SO4 and the solvent was evaporated to yield a brown oil. The 
residue was purified by flash column chromatography (SiO2, ethyl acetate/cyclohexane 1:3) to yield the 
product as a white crystalline solid (72, 792 mg, 4.1 mmol, 22% yield).  
 
Annex spectra on page 207.  
 
Appearance: White solid 
 
TLC: Ethyl acetate/cyclohexane 1:3; Rf = 0.30 
 
1H NMR (500 MHz, Chloroform-d δ/ppm): 7.30 (s (broad), 1H, 10), 7.13 (t, J = 8.1 Hz, 1H, 7), 6.81 (s (broad), 
1H, NH), 6.68 (ddd, J = 8.0, 2.1, 0.9 Hz, 1H, 6), 6.58 (ddd, J = 8.1, 2.4, 0.9 Hz, 1H, 8), 6.52 (s (broad), 1H, OH), 
5.95 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H, 2), 5.36 (dq, J = 17.2, 1.5 Hz, 1H, 1), 5.26 (dq, J = 10.4, 1.3 Hz, 1H, 1), 4.67 
(dt, J = 5.7, 1.4 Hz, 2H, 3). Solvents: Chloroform (7.26), cyclohexane (1.43). Standard: TMS (0.00).  
 
13C NMR (126 MHz, Chloroform-d δ/ppm): 156.77 (1C, 9), 153.62 (1C, 4), 138.69 (1C, 5), 132.07 (1C, 2), 129.98 
(1C, 7), 118.54 (1C, 1), 110.86 (1C, 8), 110.58 (1C, 6), 106.03 (1C, 10), 66.17 (1C, 3). Solvents: Chloroform 
(77.28, 77.03, 76.77). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M + H]+ calculated for C10H12NO3: 194.0812, found: 194.0811.  
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4.3.8 Urea test substrate 
Compound 65: 
 
N
N O
O
O
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The synthesis was performed similarly to Baures et al.246  
N,N‘-Dimethylethylenediamine (64, 7.40 ml, 6.06 g, 68.8 mmol, 1.0 eq.) was dissolved in dry THF (60 ml) and 
cooled to 0°C. A solution of di-tert-butyl dicarbonate (5.00 g, 22.9 mmol, 0.33 eq.) in dry THF (40 ml) was 
slowly added, whereupon a white precipitate was formed. The reaction mixture was allowed to warm to 
room temperature and was further stirred for 19 h. The reaction mixture was filtered and the filtrate was 
concentrated under reduced pressure. The residue was dissolved in ethyl acetate (50 ml) and washed with 
brine (3 x 50 ml). The organic phase was dried over Na2SO4 and concentrated under reduced pressure to yield 
a colorless oil (2.938 g, single Boc protected N,N‘-dimethylethylenediamine = tert-butyl methyl(2-
(methylamino)ethyl)carbamate). This oil was dissolved in dry THF (30 ml) and cooled to 0°C. Triethylamine 
(2.17 ml, 1.57 g, 15.6 mmol, 1.1 eq. with respect to the obtained colorless oil) was added. Allyl chloroformate 
(1.90 ml, 2.15 g, 17.88 mmol, 1.2 eq. with respect to the obtained colorless oil) was added dropwise over 10 
min, whereupon a white precipitate formed. The mixture was allowed to warm to room temperature and 
was further stirred for 3 h. The reaction mixture was concentrated under reduced pressure. The residue was 
suspended in ethyl acetate (100 ml) and washed with brine (3 x 30 ml). The organic phase was dried over 
Na2SO4 and concentrated under reduced pressure to yield a slightly yellow oil. The residue was purified by 
flash column chromatography (SiO2, ethyl acetate/cyclohexane 1:3) to yield the product as a colorless oil (65, 
1920 mg, 7.0 mmol, 33% yield).  
 
Annex spectra on page 208.   
 
Appearance: Colorless oil 
 
TLC: Ethyl acetate/cyclohexane 1:3; Rf = 0.30 
 
1H NMR (500 MHz, Chloroform-d δ/ppm): 5.94 (ddt, J = 17.3, 10.8, 5.5 Hz, 1H, 2), 5.30 (dq, J = 17.3, 1.7 Hz, 
1H, 1), 5.25 – 5.15 (m, 1H, 1), 4.62 – 4.55 (m, 2H, 3), 3.48 – 3.30 (m, 4H, 6 + 7), 2.95 (s, 3H, 5), 2.92 – 2.83 (m, 
3H, 8), 1.46 (s, 9H, 11). Solvents: Chloroform (7.28), water (1.82). Standard: TMS (0.00).  
 
13C NMR (126 MHz, Chloroform-d δ/ppm): 155.95 (1C, 4), 155.54 (1C, 9), 133.12 (1C, 2), 117.59 (1C, 1), 79.56 
(1C, 10), 66.13 (1C, 3), 46.71 (2C, 6 + 7), 35.19 (1C, 5), 34.53 (1C, 8), 28.41 (1C, 11). Solvents: Chloroform 
(77.31, 77.05, 76.80). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C13H24N2O4Na: 295.1628, found: 295.1632.   
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Compound 66: 
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The synthesis was performed similarly to Hay et al.241  
Boc-protected allyl carbamate 65 (0.91 g, 3.3 mmol, 1.0 eq.) was dissolved in DCM (5 ml) and cooled to 0°C. 
Triisopropylsilane (1.5 ml, 6.6 mmol, 2.0 eq., scavenger for carbocations) and trifluoroacetic acid (5 ml) were 
added and the mixture was stirred 30 min at 0°C and then 1.5 h at room temperature. The solvent was 
evaporated and the residue was dissolved in ethyl acetate (10 ml) and washed with brine (3 x 10 ml). The 
organic phase was dried over Na2SO4 and concentrated under reduced pressure to yield a yellow oil (0.65 g). 
This oil was dissolved in dry THF (5 ml). At 0°C, triethylamine (5.30 ml, 3.85 g, 38 mmol, 12 eq.) and para-
nitrophenyl chloroformate (0.77 g, 3.8 mmol, 1.2 eq.) in dry THF (5 ml) were added dropwise. The mixture 
was stirred for 30 min at 0°C and then for 2.5 h at room temperature. The solvent was evaporated and the 
residue taken up in ethyl acetate (20 ml) and washed with brine (3 x 10 ml). The organic phase was dried over 
Na2SO4 and evaporated under reduced pressure. The crude product was purified by flash column 
chromatography (aluminum oxide, ethyl acetate/cyclohexane 2:5) to yield the product as a light yellow oil 
(66, 339 mg, 1.00 mmol, 30% yield).  
 
Annex spectra on page 209.   
 
Appearance: Light yellow oil 
 
TLC: Ethyl acetate/cyclohexane 2:5; Rf = 0.30 
 
1H NMR (500 MHz, Chloroform-d δ/ppm): 8.24 (dd, J = 9.3, 2.8 Hz, 2H, 12), 7.33 – 7.28 (m, 2H, 11), 6.00 – 
5.84 (m, 1H, 2), 5.37 – 5.25 (m, 1H, 1), 5.25 – 5.15 (m, 1H, 1), 4.64 – 4.55 (m, 2H, 3), 3.61 (dd (broad), J = 10.6, 
5.7 Hz, 5-8), 3.55 (s (broad), 5-8), 3.14 (d (broad), J = 14.9 Hz, 5-8), 3.06 (d (broad), J = 14.1 Hz, 5-8), 2.99 (s 
(broad), 5-8). Solvents: Chloroform (7.28), ethyl acetate (4.13, 2.05, 1.26), water (1.74), “grease” (1.26, 0.88). 
Standard: TMS (0.00).  
 
13C NMR (126 MHz, Chloroform-d δ/ppm): 156.34 (1C, 4 or 10), 155.99 (1C, 4 or 10), 153.30 (1C, 9), 144.85 
(1C, 13), 132.82 (1C, 2), 125.11 (2C, 12), 122.23 (2C, 11), 117.60 (1C, 1), 66.24 (1C, 3), 46.93 (5-8), 46.29 (5-
8), 35.22 (5-8), 34.41 (5-8). Solvents: Chloroform (77.32, 77.07, 76.81). Standard: TMS (0.00).  
 
HRMS (ESI-MS, pos.) m/z: [M+Na]+ calculated for C15H19N3O6Na: 360.1166, found: 360.1171.  
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4.4 Table of compounds 
Number Structure Name 
1 
ON
H
O
S
O
O O-
O
O
HNEt3+
 
Triethylammonium (7-
(((allyloxy)carbonyl)amino)-2-oxo-2H-
chromen-4-yl)methanesulfonate 
2 
OH2N O
S
O
O O-HNEt3+
 
Triethylammonium (7-amino-2-oxo-2H-
chromen-4-yl)methanesulfonate 
3 
N
O
O
Ru
PF6
 
[CpRu(PA)(Allyl)]PF6 
4 
N
O
O
Ru
PF6
 
[Cp*Ru(PA)(Allyl)]PF6 
5 
N
O
O
Ru
PF6
 
[CpRu(QA)(Allyl)]PF6 
6 
N
O
O
Ru
PF6
O
 
[CpRu(QA-Ome)(Allyl)]PF6 
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7 
N
N
O
O
Ru
PF6
 
[CpRu(QA-NMe2)(Allyl)]PF6 
8 
N
O
O
Ru
PF6
 
[Cp*Ru(QA)(Allyl)]PF6 
9 
N
Ru
PF6
O
 
[CpRu(HQ)(Allyl)]PF6 
10 
N
Ru
PF6
O
Cl  
[CpRu(HQ-Cl)(Allyl)]PF6 
11 
N
Ru
PF6
O
O2N  
[CpRu(HQ-NO2)(Allyl)]PF6 
12 N
Ru
PF6
O
O
O  
[CpRu(HQ-CO2Me)(Allyl)]PF6 
 139 
13 
Ru
Cl
 
[Cp*Ru(cod)Cl] 
14 
O
H
N O
O
H
NO
O
O
O  
O-allyl-carbamate caged rhodamine 110 
15 
O
H
N
O
N N
H
O
O
Br  
O-allyl-carbamate caged DNA binding 
agent 
16 
O
H
N
O N
S
N
S
OH
O  
O-allyl-carbamate caged D-aminoluciferin 
17 
N
N
O
O
Ru
PF6NH
NH
O
H
HN
H S
O
 
[(Cp-Biot)Ru(QA-NMe2)(Allyl)]PF6 
18 N
N
O
O
Ru
PF6
N
NH
O
H
HN
H
O
S
 
[CpRu(QA-Biot)(Allyl)]PF6 
19 
N
OH
OH
O
 
Kynurenic acid 
20 
N
OH
O
O
 
Methyl 4-hydroxyquinoline-2-carboxylate 
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21 
N
Br
O
O
 
Methyl 4-bromoquinoline-2-carboxylate 
22 
N
O
O
N
N
OO
 
Methyl 4-(4-(tert-
butoxycarbonyl)piperazin-1-yl)quinoline-
2-carboxylate 
23 OH
NH
O
H
HN
H S
O
 
D-Biotin 
24 
O
NH
O
H
HN
H S
O
F
F
F
F
F  
D-Biotin pentafluorophenyl ester 
25 
N
O
O
N
N
O
HN
O
H
NH
H
S
 
Methyl 4-(4-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanoyl)piperazin-1-yl)quinoline-
2-carboxylate 
26 
N
O
O
N
N
O
HN
O
H
NH
H
S
Li
 
Lithium 4-(4-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanoyl)piperazin-1-yl)quinoline-
2-carboxylate 
 141 
27 N
N
O
O
Ru
Sol.
PF6
N
NH
O
H
HN
H S
O  
[CpRu(QA-Biot)(Sol.)]PF6 
28 
N
O
O
N
N
OO
 
Allyl 4-(4-(tert-butoxycarbonyl)piperazin-
1-yl)quinoline-2-carboxylate 
29 
N
O
O
N
N
H2 Cl  
4-(2-((allyloxy)carbonyl)quinolin-4-
yl)piperazin-1-ium chloride 
30 
N
O
O
Ru
PF6
N
N
O
O
 
[CpRu(QA-Boc)(Allyl)] PF6 
31 OH
NH
O
H
HN
H
O
 
Desthiobiotin 
32 
O
NH
O
H
HN
H
O
F
F
F
F
F  
Desthiobiotin pentafluorophenyl ester 
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33 
N
O
O
N
N
O
HN
O
H
NH
H
 
Methyl 4-(4-(6-((4R,5S)-5-methyl-2-
oxoimidazolidin-4-yl)hexanoyl)piperazin-
1-yl)quinoline-2-carboxylate 
34 
N
O
O
N
N
O
HN
O
H
NH
H
 
Allyl 4-(4-(6-((4R,5S)-5-methyl-2-
oxoimidazolidin-4-yl)hexanoyl)piperazin-
1-yl)quinoline-2-carboxylate 
35 N
N
O
O
Ru
PF6
N
NH
O
H
HN
H
O  
[CpRu(QA-Desthiobiot)(Allyl)]PF6 
36 OH
NH
O
H
HN
H S
O
O
O  
D-Biotin sulfone 
37 
O
NH
O
H
HN
H S
O
O
O
F
F
F
F
F
 
D-Biotin sulfone pentafluorophenyl ester 
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38 
N
O
O
N
N
O
HN
O
H
NH
H
S
O O
 
Methyl 4-(4-(5-((3aS,4S,6aR)-5,5-dioxido-
2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanoyl)piperazin-1-
yl)quinoline-2-carboxylate 
39 
N
O
O
N
N
O
HN
O
H
NH
H
S
 
Allyl 4-(4-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanoyl)piperazin-1-yl)quinoline-
2-carboxylate 
40 
N
N
O
O
Ru
PF6
DMSO
 
[CpRu(Allyl-QA-NMe2)(DMSO)]PF6 
41 
N
OH
O
N  
4-(dimethylamino)quinoline-2-carboxylic 
acid 
42 
N
O
O
N  
Allyl 4-(dimethylamino)quinoline-2-
carboxylate 
43 
O Cl
O
O2N  
4-nitrophenyl carbonochloridate 
44 
O O
O
O2N  
Allyl (4-nitrophenyl) carbonate 
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45 
OHO
H
H
HO
H
H
OH
H
S
OH
 
Isopropyl-β-D-thiogalactopyranosid 
(IPTG) 
46 OHO
H
H
HO
H
H
OH
H
S
O
O
O
 
Allyl (((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-
6-(isopropylthio)tetrahydro-2H-pyran-2-
yl)methyl) carbonate 
47 
H2N
OH
 
(4-aminophenyl)methanol 
48 
N
H
OH
O
O
 
Allyl (4-
(hydroxymethyl)phenyl)carbamate 
49 
O N
H
O O O
O
NO2
 
Allyl (4-((((4-
nitrophenoxy)carbonyl)oxy)methyl)phen
yl)carbamate 
50 
OHO
H
H
HO
H
H
OH
H
S
O
O
O
NH
O
O
 
Allyl (4-((((((2R,3R,4S,5R,6S)-3,4,5-
trihydroxy-6-(isopropylthio)tetrahydro-
2H-pyran-2-
yl)methoxy)carbonyl)oxy)methyl)phenyl)
carbamate 
51 
H2N OH
O
 
5-aminopentanoic acid 
52 
N
H
OH
O
O
O
 
5-(((allyloxy)carbonyl)amino)pentanoic 
acid 
53 
N
H
O
O
O
O
F
F
F
F
F  
Perfluorophenyl 5-
(((allyloxy)carbonyl)amino)pentanoate 
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54 
OHO
H
H
HO
H
H
OH
H
S
OO
N
H
O
O
 
((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-
(isopropylthio)tetrahydro-2H-pyran-2-
yl)methyl 5-
(((allyloxy)carbonyl)amino)pentanoate 
55 
NH2
OH
O  
2-(2-aminophenyl)acetic acid 
56 
NH
OH
O
O
O
 
2-(2-
(((allyloxy)carbonyl)amino)phenyl)acetic 
acid 
57 
NH
O
O
O
O
F
F
F
F
F
 
Perfluorophenyl 2-(2-
(((allyloxy)carbonyl)amino)phenyl) 
acetate 
58 
OHO
H
H
HO
H
H
OH
H
S
OO
H
NO
O
 
((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-
(isopropylthio)tetrahydro-2H-pyran-2-
yl)methyl 2-(2-
(((allyloxy)carbonyl)amino)phenyl) 
acetate 
59 
OHO
H
H
HO
H
NH3
H
OH
OH
Cl
 
D-(+)-Galactosamine hydrochloride 
60 
OO
H
H
O
H
NH
H
O
O
O
O
O
O OO  
(3R,4R,5R,6R)-6-(acetoxymethyl)-3-
(((allyloxy)carbonyl)amino)tetrahydro-
2H-pyran-2,4,5-triyl triacetate 
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61 
OO
H
H
O
H
H
NH
H
S
O
OO
O
O
O  
(2R,3R,4R,5R,6S)-2-(acetoxymethyl)-5-
(((allyloxy)carbonyl)amino)-6-
(isopropylthio)tetrahydro-2H-pyran-3,4-
diyl diacetate 
62 
OHO
H
H
HO
H
H
NH
H
S
OH
OO  
Allyl ((2S,3R,4R,5R,6R)-4,5-dihydroxy-6-
(hydroxymethyl)-2-
(isopropylthio)tetrahydro-2H-pyran-3-
yl)carbamate 
63 
OHO
H
H
HO
H
H
NH2
H
S
OH
 
2-Amino-IPTG 
64 
H
N
N
H  
N,N‘-Dimethylethylenediamine 
65 N
N O
O
O
O  
Allyl tert-butyl ethane-1,2-
diylbis(methylcarbamate) 
66 N
N
O
O
O
O
NO2
 
Allyl (4-nitrophenyl) ethane-1,2-
diylbis(methylcarbamate) 
67 
HO NH2  
3-Aminophenol 
68 
HO N
H
O
O
 
Ethyl (3-hydroxyphenyl)carbamate 
69 
O ON
H
O
O
Cl
 
Ethyl (4-(chloromethyl)-2-oxo-2H-
chromen-7-yl)carbamate 
70 
Na+
O O
S
O
O O-
N
H
O
O
 
Sodium (7-((ethoxycarbonyl)amino)-2-
oxo-2H-chromen-4-yl)methanesulfonate 
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71 
OH2N O
S
O
O OH
 
7-Aminocoumarin-4-methansulfonic acid 
72 
HO N
H
O
O
 
Allyl (3-hydroxyphenyl)carbamate 
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5 Abbreviations 
Abbreviation Name 
AIDA Adhesin involved in diffuse adherence 
ArM Artificial metalloenzyme 
B4F Biotin-4-fluorescein 
BINAP 2,2‘-bis(diphenylphosphino)-1,1‘-binaphthyl 
Biot D-biotin 
Boc tert-butyloxycarbonyl 
bpy 2,2’-bipyridine 
Bpy-Ala (2,2’-bipyridin-5-yl) alanine 
BSA Bovine serum albumin 
CAP Catabolite activator protein 
CFE Cell free extract 
cod η4-1,5-cyclooctadiene 
COSY Correlation spectroscopy 
Cp η5-cyclopentadienyl 
Cp* η5-1,2,3,4,5-pentamethyl-cyclopentadienyl 
DACA 4-(dimethylamino)-cinnamaldehyde 
DCM Dichloromethane 
DIPEA N,N-Diisopropylethylamine (Hünig’s base) 
DMAP 4-Dimethylaminopyridine 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
DOSY Diffusion ordered nuclear magnetic resonance spectroscopy 
ESI-TOF MS Electrospray ionization time of flight mass spectrometry 
FACS Fluorescence activated cell sorting 
FADS Fluorescence activated droplet sorting 
FBBS Free biotin-binding sites 
FRET Förster resonance energy transfer 
GFP Green fluorescent protein 
GSH Glutathione 
HABA 2-(4’-hydroxybenzeneazo)benzoic acid 
HMBC Heteronuclear multiple-bond correlation spectroscopy 
HMQC Heteronuclear single-quantum correlation spectroscopy 
HPLC High performance liquid chromatography 
HQ 8-hydroxyquinolinate 
HRMS High-resolution mass spectrometry 
HRP Horse radish peroxidase 
ICP-MS Inductively coupled plasma mass spectrometry 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
L-ara L-arabinose 
LB-medium Lysogeny Broth-medium 
MS Mass spectrometry 
MW Molecular weight 
MWCO Molecular weight cut-off 
NMR Nuclear magnetic resonance spectroscopy 
NOESY Nuclear overhauser enhancement and exchange spectroscopy 
OD600 Optical density at 600 nm 
PA 2-pyridinecarboxylate 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
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Abbreviation Name 
Pd2(dba)3 Tris(dibenzylideneacetone)dipalladium(0) 
PDB Protein data base 
PFP Pentafluorophenyl ester 
PMSF Phenylmethylsulfonylfluorid 
ppm Parts per million 
QA 2-quinolinecarboxylate 
rac Racemic 
RFU Relative fluorescence units 
Sav Streptavidin 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SOB-medium Super Optimal Broth-medium 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TIS Triisopropylsilane 
TLC Thin-layer chromatography 
TMS Tetramethylsilane 
TPR Tetratricopeptide repeat 
Tris-HCl Tris(hydroxymethyl)aminomethane hydrochloride 
UPLC-MS Ultra performance liquid chromatography coupled to mass spectrometry 
WT Wild-type 
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7 Annexes 
7.1 Additional screening results 
Table 15: Screening of streptavidin mutants for the uncaging of coumarin 1 using [CpRu(QA-Biot)(Sol.)]PF6·Sav. 
Mutant Fluorescence [RFU]  Mutant Fluorescence [RFU] 
Substrate only 2335  L124H 2018 
Free cofactor 1921  L124K 1321 
WT 3247  L124N 1786 
N49A 3206  L124V 1474 
N49Y 4657  L124Y 407 
P64G 2903  H127A 3034 
A65F 3437  D128A 1219 
H87A 3004  S112A-K121A 14491 
T114G 1600  S112A-K121G 8031 
S112A 6010  S112A-K121L 14771 
S112C 1531  S112A-K121N 8960 
S112D 1890  S112A-K121T 8497 
S112E 840  S112C-K121H 1082 
S112F 5099  S112H-K121H 1722 
S112G 2646  S112K-L124E 982 
S112H 6024  S112M-K121A 26435 
S112K 3453  S112M-K121E 12460 
S112L 7965  S112M-K121N 15600 
S112M 10770  S112M-K121R 35527 
S112N 3752  S112N-K121E 1727 
S112P 1657  S112Q-K121E 3731 
S112Q 3977  S112R-K121E 4345 
S112R 4053  S112V-K121E 1664 
S112T 4996  S112W-K121E 2599 
S112V 8555  S112Y-K121E 10359 
S112W 4717  S112Y-K121R 17264 
S112Y 6285  N118E-K121E 1384 
K121A 10318  N118K-K121E 866 
K121C 479  N118L-K121E 2659 
K121D 2057  N118S-K121E 1201 
K121E 2293  K121N-L124G 1507 
K121F 7102  K121R-L124G 3641 
K121H 1792  D67V-S112A-K121L 12369 
K121L 10423  R84A-S112A-K121A 4931 
K121M 4358  48(GGS)2 1280 
K121N 5638  66(GGS)2 4175 
K121P 1667  66(GGS)2-S112M 13787 
K121Q 5412  66(GGS)2-K121R 19529 
K121R 15224  84(GGS)2 2136 
K121S 5587  Loop2 1642 
K121V 7387  Loop2-S112M 2700 
K121W 5844  Loop2-K121R 2780 
K121Y 5401  159TPR 1587 
L124F 3820  159TPR-K121R 11046 
L124G 10154    
Equation: see Scheme 6. Conditions: see Figure 11. 
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Table 16: Screening of streptavidin mutants for the uncaging of IPTG substrate 54 using [CpRu(QA-Biot)(Sol.)]PF6·Sav.a 
Entry Sav Yield [%] 
1b - 6 
2 - 10 
3 WT 11 
4 S112A 10 
5 S112D 11 
6 S112H 11 
7 S112K 11 
8 S112M 12 
9 S112L 11 
10 S112N 9 
11 S112Y 11 
12 K121A 26 
13 K121E 12 
14 K121F 32 
15 K121H 7 
16 K121M 20 
17 K121R 26 
18 K121Y 19 
19 K121Q 28 
20 L124F 9 
21 L124G 27 
22 L124H 7 
23 L124K 5 
24 L124Y 6 
aReaction conditions: Phosphate-buffer (50 mM NaH2PO4/Na2HPO4, pH 7.4), 0.9% NaCl, 500 μM IPTG substrate 54, 5 μM ruthenium 
cofactor [CpRu(QA-Biot)(Sol.)]PF6 (27), 10 μM Sav (free biotin binding sites), 0.5% DMF, 25°C, shaking (1000 rpm), 22 h. Yields 
(concentration of liberated IPTG) were determined by UPLC-MS (see chapter 4.2.6). bNo ruthenium cofactor was added.  
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7.2 NMR and mass spectra 
Annex 1: Compound 20 
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Annex 2: Compound 21 
 
UPLC – trace: 
 
 
Mass – trace: 
 
  
Total ion count (TIC): 
 
 
Absorption at 254 nm: 
 
 
Diode array: 
Mass at 2.74 min: 
 
 
 
 
Mass at 2.37 min: 
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Annex 3: Compound 22 
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Annex 4: Compound 24 
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Annex 5: Compound 25 
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Annex 6: Compound 26 
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Annex 7: Compound 28 
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Annex 8: Compound 30 
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Annex 9: Compound 29 
 
UPLC – trace: 
 
 
 
MS – trace: 
 
 
 
 
  
Absorption at 254 nm: 
 
 
Absorption at 210 nm: 
 
 
Total ion count (TIC): 
Mass at 2.35 min: 
 
 
 
 
Mass at 1.24 min: 
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Annex 10: Compound 32 
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Annex 11: Compound 33 
 
UPLC – trace: 
 
 
Mass – trace: 
 
 
 
 
 
  
Total ion count (TIC): 
 
 
Absorption at 254 nm: 
 
 
Absorption at 210 nm: 
Mass at 1.75 min: 
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Annex 12: Compound 34 
 
UPLC – trace:  
 
 
Mass – trace: 
 
 
 
 
 
  
Total ion count (TIC): 
 
 
Absorption at 254 nm: 
 
 
Absorption at 210 nm: 
Mass at 1.90 min: 
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Annex 13: Compound 36 
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Annex 14: Compound 37 
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Annex 15: Compound 38 
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Annex 16: Compound 39 
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Annex 17: Compound 18 
 
 
 
 
  
1H-NMR: 
19F-NMR: 
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Annex 18: Compound 7 
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Annex 19: Compound 1 
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Annex 20: Compound 2 
 
 
  
 193 
Annex 21: Compound 44 
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Annex 22: Compound 46 
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Annex 23: Compound 48 
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Annex 24: Compound 49 
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Annex 25: Compound 50 
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Annex 26: Compound 52 
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Annex 27: Compound 53 
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Annex 28: Compound 54 
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Annex 29: Compound 56 
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Annex 30: Compound 57 
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Annex 31: Compound 58 
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Annex 32: Compound 60 
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Annex 33: Compound 61 
 
   
NOESY spectrum of the β-anomer 
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Annex 34: Compound 62 
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Annex 35: Compound 72 
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Annex 36: Compound 65 
 
  
 209 
Annex 37: Compound 66 
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Annex 38: ESI-TOF MS analysis of expressed and purified Sav variants after deconvolution 
 
 
 
 
 
  
48(GGS)2 
66(GGS)2 
84(GGS)2 
Loop2 
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Annex 39: ESI-TOF MS analysis of expressed and purified Sav variants after deconvolution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
159TPR 
66(GGS)2-S112M 
66(GGS)2-K121R 
S112M-K121N 
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Annex 40: ESI-TOF MS analysis of expressed and purified Sav variants after deconvolution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
S112M-K121R 
159TPR-K121R 
Loop2-K121R 
S112M-K121A 
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Annex 41: ESI-TOF MS analysis of expressed and purified Sav variants after deconvolution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loop2-S112M 
K121A-L124G 
K121R-L124G 
K121N-L124G 
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